Section |
Name |
Details |
03.04.02 |
Omalizumab Xolair® |
75mg/0.5mL solution for injection pre-filled syringes 150mg/1mL solution for injection pre-filled syringes
Restriction: In line with NICE Guidance only and NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for Asthma
This is a Specialised Drug which is commissioned by the North Staffs and Stoke CCGs ONLY for Chronic Spontaneous Urticaria.
Blueteq form NICE TA339 - CCG |
13.05.02 |
5-Methoxypsoralen 20mg tablets |
Unlicensed preparation
Restriction: To be initiated by a dermatology consultant |
13.05.02 |
8-Methoxypsoralen 10mg tablets, capsules |
Unlicensed preparation
Restriction: To be initiated by a dermatology consultant |
13.05.02 |
8-Methoxypsoralen |
Unlicensed preparation
Restriction: To be initiated by a dermatology consultant |
10.01.03 |
Abatacept Orencia® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies |
02.09 |
Abciximab ReoPro® |
IV Infusion
Restriction: Cardiology only
DISCONTINUED |
08.01.05 |
Abemaciclib Verzenios® |
Restriction: In line with NICE guidance only |
08.03.04.02 |
Abiraterone acetate Zytiga® |
Zytiga®(abiterone acetate) 500mg tablets
Restriction: In line with NICE Guidance only
|
04.10.01 |
Acamprosate |
Restriction: Initiation by substance abuse unit, no prescribing by General Practice
Patients with alcohol dependence should be referred using the GP surgeries clinical systems online referral form.
- Staffordshire CCG’s – Humankind - Staffordshire treatment and recovery service (STARS) – Link to website
- Stoke-on-Trent CCG – North Staffordshire Combined Healthcare – Community drug and alcohol service (CDAS) - Link to website
|
06.01.02.03 |
Acarbose Glucobay® |
Acarbose Tablets 50mg Acarbose Tablets 100mg |
09.06.04 |
Accrete D3® Colecalciferol and calcium carbonate |
Maintenance dose (with calcium)
Colecalciferol 10microgram (equivalent to 400unit of vitamin D3) plus Calcium carbonate 1500mg (equivalent to 600mg of elemental calcium) tablets
Reserve for patients that cannot tolerate chewable tablets |
11.06 |
Acetazolamide |
Acetazolamide 250mg tablets Acetazolamide SR 250mg capsules
|
11.03.03 |
Aciclovir Zovirax® |
Aciclovir 3% opthalmic ointment
DISCONTINUED: GSK, the sole supplier of aciclovir eye ointment, plans to discontinue it from the worldwide market in 2018. Stock is anticipated to continue to be available in the UK until the end of June 2019, subject to demand.
An alternative agent is Ganciclovir 0.15% w/w eye gel (licensed for acute herpetic keratitis). |
13.10.03 |
Aciclovir |
Aciclovir 5% cream 2g,10g
Cold sores resolve after 7–10days without treatment.
Self Care Medicine. Available OTC for self care. (Please note exceptions may apply)
|
02.12 |
Acipimox Olbetam® |
Acipimox 250mg capsules |
13.05.02 |
Acitretin |
Acitretin 10mg capsules Acitretin 25mg capsules
Restriction: Initiation on specialist dermatological advice
|
03.01.04 |
Aclidinium & formoterol Duaklir®Genuair |
Aclidinium Bromide 396mcg/dose/Formoterol 11.8mcg/dose DPI Duaklir 340mcg/dose/ 12mcg/dose Genuair
Long-Acting Antimuscarinic + Long-Acting Beta2 Adrenorecepter Agonist combination.
For use in COPD with end of day deterioration.
The combination product offers cost & compliance advantages compared to prescribing LAMA and LABA drugs as separate devices. |
03.01.02 |
Aclidinium Bromide Eklira Genuair® |
Aclidinium Bromide 375mcg/dose Dry Powder Inhaler Eklira 322mcg/dose Genuair Inhalation Powder
Long Acting Antimuscarinic For use in COPD with end of day deterioration
NOTE: This is a twice daily preparation therefore not suitable for all patients. |
13.08.01 |
Actikerall® Fluorouracil 0.5% and salicylic acid 10% cutaneous solution |
Actikerall 5mg/g / 100mg/g cutaneous solution
For low or moderately thick hyperkeratotic actinic keratoses |
01.05.03 |
Adalimumab Hyrimoz®, Amgevita®, Imraldi®, Hulio®, Humira® |
Restriction: In line with NICE Guidance only
Clinicians must ensure the biosimilar brand for their region is prescribed first-line. (Hyrimoz is the first line biosimilar in West Midlands region; Amgevita is used in patients intolerant to citrate content i.e injection site reactions) |
10.01.03 |
Adalimumab Hyrimoz®, Amgevita®, Imraldi®, Hulio®, Humira®
| Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
Clinicians must ensure the biosimilar brand for their region is prescribed first-line. (Hyrimoz is the first line biosimilar in West Midlands region; Amgevita is used in patients intolerant to citrate content i.e injection site reactions) |
11.04.01 |
Adalimumab Hyrimoz®, Amgevita®, Imraldi®, Hulio®, Humira® |
Restriction: In line with NICE Guidance only
Clinicians must ensure the biosimilar brand for their region is prescribed first-line. (Hyrimoz is the first line biosimilar in West Midlands region; Amgevita is used in patients intolerant to citrate content i.e injection site reactions) |
13.05.03 |
Adalimumab Hyrimoz®, Amgevita®, Imraldi®, Hulio®, Humira® |
Restriction: In line with NICE Guidance only
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people is commissioned by NHS England for patients treated in specialised dermatology centres and CCGs for treatments in non-specialist centres where commissioned.
Clinicians must ensure the biosimilar brand for their region is prescribed first-line. (Hyrimoz is the first line biosimilar in West Midlands region; Amgevita is used in patients intolerant to citrate content i.e injection site reactions)
|
13.06 |
Adalimumab Hyrimoz®, Amgevita®, Imraldi®, Hulio®, Humira® |
For Acne inversa
Restriction: In line with NICE Guidance
Clinicians must ensure the biosimilar brand for their region is prescribed first-line. (Hyrimoz is the first line biosimilar in West Midlands region; Amgevita is used in patients intolerant to citrate content i.e injection site reactions)
|
13.06.01 |
Adapalene Differin® |
Differin®Adapalene 0.1% cream 45g Differin®Adapalene 0.1% gel 45g |
13.06.01 |
Adapalene with benzoyl peroxide Epiduo® |
Topical retinoids and related preparations with benzoyl peroxide
Epiduo®- Adapalene 0.1% and benzoyl peroxide 2.5% gel 45g |
09.06.04 |
Adcal-D3® Colecalciferol and calcium carbonate |
Maintenance dose (with calcium)
Colecalciferol 10microgram (equivalent to 400unit of vitamin D3) plus Calcium carbonate 1500mg (equivalent to 600mg of elemental calcium) chewable tablets |
09.06.04 |
Adcal-D3® Colecalciferol and calcium carbonate |
Maintenance dose (with calcium)
Colecalciferol 5microgram (equivalent to 200unit of vitamin D3) plus Calcium carbonate 750mg (equivalent to 300mg of elemental calcium) caplets |
05.03.03.01 |
Adefovir Dipivoxil Hepsera® |
Adefovir Dipivoxil Tablets 10mg
Restriction: In line with NICE Guidance
This is a Specialised Drug which would not be routinely commissioned by CCGs for Hepatitis B. This would go through the CCGs Individual Funding Request (IFR). |
02.03.02 |
Adenosine |
Restriction: Anaesthetics and cardiology only |
03.04.03 |
Adrenaline / epinephrine |
Solution for injection auto-injectors Solution for injection pre-filled syringes
17th October 2018 - Please prescribe generically - There are variable stock shortages of each of the three brands Jext, Emerade and Epipen therefore it is best to prescribe generically |
08.01.05 |
Afatinib dimaleate Giotrif® |
Restriction: In line with NICE Guidance only |
11.08.02 |
Aflibercept Eylea® |
Eylea 2mg/50microlitres solution for injection vials
Restriction: In line with NICE Guidance only |
13.08.01 |
Aldara® Imiquimod 5% cream |
Aldara®- Imiquimod 5% cream 250mg sachets (12 sachets)
For Bowen’s Disease [unlicensed indication]
Restriction: To be initiated by a dermatology consultant
|
13.08.01 |
Aldara® Imiquimod 5% cream |
Aldara®- Imiquimod 5% cream 250mg sachets (12 sachets)
2nd line for superficial basal cell carcinoma
Restriction: Initiation by a consultant dermatologist or GP with a special interest
|
08.01.05 |
Alectinib hydrochloride Alecensa® |
Restriction: In line with NICE Guidance only |
08.02.03 |
Alemtuzumab Lemtrada® |
Restriction: In line with NICE Guidance only
MHRA advice (May 2019): Lemtrada (alemtuzumab) and serious cardiovascular and immune-mediated adverse reactions: new restrictions to use and strengthened monitoring requirements |
06.06.02 |
Alendronic acid |
Alendronic acid Tablets 10mg Alendronic acid Tablets 70mg Alendronic acid Oral Solution 70mg/100ml SF Alendronic acid Effervescent Tablets 70mg
1st line for Osteoporosis
If a liquid formulation is required, the effervescent tablets are preferred over the oral solution. (Applicable in Primary care)
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
09.06.04 |
Alfacalcidol |
One-Alpha® - Alfacalcidol 2mcg/1ml solution for injection ampoules (0.5ml and 1ml) One-Alpha® - Alfacalcidol 2mcg/1ml oral drops Alfacalcidol 250nanogram capsules Alfacalcidol 500nanogram capsules Alfacalcidol 1microgram capsules
One drop of alfacalcidol 2 microgram/mL oral drops contains approximately 100 nanograms alfacalcidol.
|
07.04.01 |
Alfuzosin hydrochloride |
Alfuzosin MR 10mg tablets
Modified release preparations only |
02.12 |
Alirocumab Praluent® |
Restriction: In line with NICE Guidance only |
02.05.05.03 |
Aliskiren |
Not approved for inclusion in the North Staffordshire Joint Formulary |
NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)
NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs
|
13.05.01 |
Alitretinoin Toctino® |
Restriction: In line with NICE Guidance
Alitretinoin is teratogenic and must not be given to women of child-bearing potential unless they practise effective contraception and then only after detailed assessment and explanation by the physician. |
10.01.04 |
Allopurinol |
Allopurinol 100mg tablets Allopurinol 300mg tablets |
04.07.04.01 |
Almotriptan Almogran® |
Almotriptan (as Almotriptan hydrogen malate) Tablets 12.5mg
3rd line triptan (As per Anti-Migraine Prescribing Guide) |
06.01.02.03 |
Alogliptin Vipidia® |
Alogliptin Tablets 6.25mg Alogliptin Tablets 12.5mg Alogliptin Tablets 25mg
Preferred DPP-4 inhibitor
Reduce dose to 12.5 mg once daily if eGFR 30–50 mL/minute/1.73 m2. Reduce dose to 6.25 mg once daily if eGFR less than 30 mL/minute/1.73 m2. |
09.06.05 |
Alpha tocopheryl acetate Vitamin E |
Alpha tocopheryl acetate 75unit capsules Alpha tocopheryl acetate 100unit capsules Alpha tocopheryl acetate 200unit capsules Alpha tocopheryl acetate 250unit capsules Alpha tocopheryl acetate 400unit capsules Alpha tocopheryl acetate 600unit capsules Alpha tocopheryl acetate 1000unit capsules Alpha tocopheryl acetate 500mg per 5ml oral suspension
( - Oral suspension reserved for patients with swallowing difficulties as expensive) (Applicable in Primary care only)
|
13.09 |
Alphosyl 2 in 1® Coal Tar Extract 5% alcoholic |
Alphosyl 2 in 1®- Coal Tar Extract 5% alcoholic shampoo 250ml
Self Care Medicine. Available OTC for self care
|
07.04.05 |
Alprostadil Caverject® |
There are differences in the delivery devices so prescribe by brand
Caverject®- Alprostadil 10microgram powder and solvent for solution for injection vials Caverject®- Alprostadil 20microgram powder and solvent for solution for injection vials Caverject®- Alprostadil 40microgram powder and solvent for solution for injection vials
Caverject®Dual Chamber - Alprostadil 10microgram powder and solvent for solution pre-filled disposable injection Caverject®Dual Chamber - Alprostadil 20microgram powder and solvent for solution pre-filled disposable injection Caverject®Dual Chamber - Alprostadil 40microgram powder and solvent for solution pre-filled disposable injection
The prescription must be endorsed 'SLS'. |
07.04.05 |
Alprostadil MUSE® |
There are differences in the delivery devices so prescribe by brand
Muse®- Alprostadil 250microgram urethral sticks Muse®- Alprostadil 500microgram urethral sticks Muse®- Alprostadil 1000microgram urethral sticks
The prescription must be endorsed 'SLS'. |
02.10.02 |
Alteplase Actilyse® |
Injection
Restriction: In line with NICE Guidance only |
09.04 |
Altraplen Compact |
|
09.04 |
Altrashot |
Initiation by specialist dietician services prior to continuation within primary care. |
12.01.01 |
Aluminium acetate |
Available as 8% and 13% ear drops for treatment of inflammation in otitis externa.
For the 8% preparation, dilute 8 parts aluminium acetate ear drops (13%) with 5 parts purified water. Must be freshly prepared.
An alternative astringent is EarCalm® spray (Acetic acid 2%),
|
13.12 |
Aluminium chloride hexahydrate antiperspirant |
Anhydrol Forte® 20% solution, 60ml Driclor® 20% solution 20ml,75ml
Self Care Medicine. Available to purchase over the counter for hyperhidrosis
|
09.05.02.02 |
Aluminium hydroxide Alu-Cap® |
Alu-Cap®Aluminium hydroxide 475mg capsules
DISCONTINUED (May 2004) |
04.09.01 |
Amantadine |
Amantadine Capsules 100mg
Restriction: Initiation by specialist |
02.05.01 |
Ambrisentan Volibris® |
Ambrisentan 5mg Tablet Ambrisentan 10mg Tablet
Restriction: In accordance with NHS England prescribing policy. To be initiated by Specialist Only (for pulmonary arterial hypertension). |
10.02.01 |
Amifampridine Firdapse® |
Amifampridine phosphate 10mg tablets
Restriction: In accordance with NHS England prescribing policy
Not routinely commissioned by NHS England for Lambert-Eaton myasthenic syndrome (LEMS) except by prior IFR approval. |
02.02.03 |
Amiloride Hydrochloride |
Amiloride 5mg Tablet |
03.01.03 |
Aminophylline |
Brand must be stated
Aminophylline has a narrow therapeutic index and bioavailability differs between brands. Patients should be maintained on the same brand. |
02.03.02 |
Amiodarone Hydrochloride |
Amiodarone Hydrochloride 100mg Tablet Amiodarone Hydrochloride 200mg Tablet
Restriction: Initiation under direction of cardiologist
Beware of potential problems and recognise who is responsible for spotting them e.g. Micro-corneal deposits, Photosensitivity, Thyroid, Liver and Lung Disorders (check every 6 months).
MHRA/CHM advice: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir (May 2015); simeprevir with sofosbuvir (August 2015): risk of severe bradycardia and heart block when taken with amiodarone
NICE CG180 (Atrial fibrillation): Do not offer amiodarone for long-term rate control.
NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)
NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs |
04.02.01 |
Amisulpride |
Amisulpride Tablet 50mg Amisulpride Tablet 100mg Amisulpride Tablet 200mg Amisulpride Tablet 400mg Amisulpride Oral Solution 100mg/ml SF |
04.03.01 |
Amitriptyline Hydrochloride |
Amitriptyline Hydrochloride Tablet 10mg Amitriptyline Hydrochloride Tablet 25mg Amitriptyline Hydrochloride Tablet 50mg Amitriptyline Hydrochloride Oral Solution 25mg/5ml S/F Amitriptyline Hydrochloride Oral Solution 50mg/5ml S/F
Standard release preparations only |
04.07.03 |
Amitriptyline Hydrochloride |
Amitriptyline Hydrochloride Tablets 10mg Amitriptyline Hydrochloride Tablets 25mg Amitriptyline Hydrochloride Tablets 50mg Amitriptyline Hydrochloride Oral Solution 25mg/5ml S/F Amitriptyline Hydrochloride Oral Solution 50mg/5ml S/F
Restriction: 1st line therapy in line with the Non-Malignant Chronic Pain Guide |
04.07.04.02 |
Amitriptyline Hydrochloride |
Amitriptyline Hydrochloride Tablet 10mg Amitriptyline Hydrochloride Tablet 25mg Amitriptyline Hydrochloride Tablet 50mg Amitriptyline Hydrochloride Oral Solution 25mg/5ml S/F Amitriptyline Hydrochloride Oral Solution 50mg/5ml S/F
For patients already established (As per Anti-Migraine Prescribing Guide) |
02.06.02 |
Amlodipine |
Amlodipine 5mg Tablet Amlodipine 10mg Tablet |
12.03.02 |
Amphotericin Lozenges Fungilin® |
DISCONTINUED
Consider alternatives within the drug class i.e. Nystatin or Miconazole oral gel. |
09.01.04 |
Anagrelide |
Anagrelide hydrochloride 500microgram capsules
Link to ESCA |
10.01.03 |
Anakinra Kineret® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
Not routinely commissioned by NHS England for adult and paediatric indications except by prior IFR approval. Commissioned by NHS England for cryopyrin associated periodic syndrome -highly specialised criteria only. |
08.03.04.01 |
Anastrozole |
Anastrozole 1mg tablets |
01.07.02 |
Anusol |
Anusol Cream
Anusol Ointment
Anusol Suppository
Self Care Medicine-Available OTC for self care
|
01.07.02 |
Anusol-HC |
Anusol HC Ointment Anusol HC Suppository
Self Care Medicine-Available OTC for self care |
02.08.02 |
Apixaban Eliquis® |
Apixaban Tablet 2.5mg
Restriction: In line with NICE Guidance only. Orthopaedic consultant use only.
Complete course to be supplied by the hospital |
02.08.02 |
Apixaban Eliquis® |
Apixaban Tablet 2.5mg Apixaban Tablet 5mg
- Prevention of stroke and systemic embolism in people with non-valvular AF
- Treatment and secondary prevention of DVT and/or PE
Restriction: In line with NICE guidance and locally agreed guidelines
MHRA/CHM advice: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (June 2019) |
04.09.01 |
Apomorphine |
APO-go PEN 30mg/3ml Solution for Injection APO-go 50mg/5ml Solution for Injection Amps APO-go PFS 50mg/10ml Solution for Infusion pre-filled syringes
Link to ESCA |
11.08.02 |
Apraclonidine Iopidine® |
Apraclonidine 5mg/ml eye drops Apraclonidine 1% eye drops (0.25ml unit dose)
Used to control or prevent post surgical elevations in intraocular pressure that occur in patients after anterior segment laser surgery. |
10.01.03 |
Apremilast Otezla® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies |
13.05.03 |
Apremilast Otezla® |
Restriction: In line with NICE Guidance only |
02.11 |
Aprotinin Trasylol® |
Injection
Restriction: Cardiology and Anaesthetics only |
13.02.01 |
Aquadrate®cream Urea 10% |
Creamy with Urea Content
Pack size 100g
Self Care Medicine-Available OTC for self care.
|
13.02.01.01 |
Aqueous cream |
1st Line
Use only as a soap substitute
Pack size 100g, 500g
Self Care Medicine-Available OTC for self care.
|
02.08.01 |
Argatroban Exembol® |
50mg/50mL solution for infusion vials 250mg/2.5mL concentrate for solution for infusion vials
Restriction: For use when danaparoid is not available.
Anticoagulation in patients with heparin induced thrombocytopenia 1st line for Renal & Critical Care patients |
04.02.01 |
Aripiprazole |
FIRST CHOICE Aripiprazole Tablet 5mg Aripiprazole Tablet 10mg Aripiprazole Tablet 15mg Aripiprazole Tablet 30mg
SECOND CHOICE Aripiprazole Orodispersible Tablet 10mg S/F Aripiprazole Orodispersible Tablet 15mg S/F
THIRD CHOICE Aripiprazole Oral Solution 5mg/5ml- Use liquid only in patients with swallowing difficulties due to higher costs (Applicable in Primary care only)
Prescribe generically. |
04.02.02 |
Aripiprazole Abilify Maintena® |
Aripiprazole 400mg powder and solvent for sust-release susp for inj in vial or pre-filled syringe |
08.01.05 |
Arsenic trioxide Trisenox® |
Restriction: In line with NICE Guidance only |
09.06.03 |
Ascorbic acid Vitamin C |
Ascorbic acid 50mg tablets Ascorbic acid 100mg tablets Ascorbic acid 200mg tablets Ascorbic acid 500mg tablets
|
04.07.04.01 |
Aspirin |
Aspirin Dispersible Tablets 300mg
900mg dose effective in the treatment of acute migraine as per Anti-Migraine Prescribing Guide.
|
02.09 |
Aspirin (AcetylsalicylicAcid) |
Aspirin Dispersible Tablet 75mg
Use of low dose aspirin for the primary prevention of heart attacks and strokes in people without cardiovascular disease including diabetic patients is no longer recommended as the increased risk of bleeding outweighs any vascular benefits.
Prescribing of antiplatelets for secondary prevention should be in line with NICE Guidelines.
Patients with mild to moderate dyspeptic symptoms taking aspirin should be prescribed a PPI or H2 antagonist before switching to clopidogrel (which may also cause gastro-intestinal adverse effects). |
02.04 |
Atenolol |
Atenolol 25mg Tablet Atenolol 50mg Tablet Atenolol 100mg Tablet Atenolol 25mg/5ml SF Oral Solution
1st line beta-blocker |
08.01.05 |
Atezolizumab Tecentriq® |
Restriction: In line with NICE Guidance only |
04.04 |
Atomoxetine Strattera® |
Atomoxetine (as Atomoxetine hydrochloride) Capsule 10mg Atomoxetine (as Atomoxetine hydrochloride) Capsule 18mg Atomoxetine (as Atomoxetine hydrochloride) Capsule 25mg Atomoxetine (as Atomoxetine hydrochloride) Capsule 40mg Atomoxetine (as Atomoxetine hydrochloride) Capsule 60mg Atomoxetine (as Atomoxetine hydrochloride) Capsule 80mg Atomoxetine (as Atomoxetine hydrochloride) Capsule 100mg
Restriction: Initiation and stabilisation by specialist
Medicines for Children Leaflet: Atomoxetine for ADHD
Link to ESCA |
02.12 |
Atorvastatin |
Atorvastatin 10mg Tablet Atorvastatin 20mg Tablet Atorvastatin 40mg Tablet Atorvastatin 80mg Tablet
1st line agent. Use in accordance with locally agreed hyperlipidaemia guidelines |
11.05 |
Atropine sulfate |
Atropine sulfate 1% eye drops 10ml (£131.92) Minims Atropine sulfate 1% eye drops 0.5ml unit dose x 20 (£15.10)
Atropine Minims are more cost-effective ( Applicable in Primary care only) |
07.04.05 |
Avanafil Spedra® |
Spedra®- Avanafil 50mg tablet Spedra®- Avanafil 100mg tablet Spedra®- Avanafil 200mg tablet
2nd line for patients not responding to Sildenafil
The prescription must be endorsed 'SLS'. |
09.01.04 |
Avatrombopag Doptelet® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Avelumab Bavencio® |
Restriction: In line with NICE Guidance only |
08.02.04 |
Axicabtagene ciloleucel Yescarta® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Axitinib Inlyta® |
Restriction: In line with NICE Guidance only |
09.04 |
Aymes® Savoury |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Aymes®Complete Milkshake Style |
|
09.04 |
Aymes®Shake |
|
08.01.03 |
Azacitidine Vidaza® |
Restriction: In line with NICE Guidance only |
11.06 |
Azarga® Brinzolamide 1% & timolol 0.5% |
Azarga®- Brinzolamide 1% & timolol 0.5% eye drops
Restriction: Initiation by Consultant Ophthalmologist only
|
01.05.03 |
Azathioprine |
Azathioprine 25mg Tablet
Azathioprine 50mg Tablet
For the treatment of Inflammatory Bowel Disease [unlicensed indication]
Link to ESCA |
08.02.01 |
Azathioprine |
Azathioprine 25mg tablets Azathioprine 50mg tablets
Link to ESCA |
08.02.01 |
Azathioprine |
All post-transplant immunosuppressants are RED for patients newly prescribed these medicines from April 2013
Azathioprine 25mg tablets Azathioprine 50mg tablets |
10.01.03 |
Azathioprine |
Azathioprine 25mg tablets Azathioprine 50mg tablets
Link to ESCA |
13.05.03 |
Azathioprine |
For the treatment of Inflammatory Skin Disease [unlicensed indication]
Azathioprine 25mg tablets Azathioprine 50mg tablets
Link to ESCA |
13.06.01 |
Azelaic acid Skinoren® |
Skinoren®- Azelaic acid 20% cream 30g
Do not confuse with Azelaic Acid 15% (Finacea) which is licensed for rosacea |
12.02.01 |
Azelastine hydrochloride Rhinolast® |
Rhinolast®- Azelastine hydrochloride 140microgram/dose nasal spray. |
05.01.02.03 |
Aztreonam lysine powder nebuliser solution Cayston® |
75 mg powder and solvent for nebuliser solution (with Altera Nebuliser Handset)
Restriction: In accordance with NHS England prescribing policy.
This is an NHS England Specialised Commissioning Drug for Cystic Fibrosis |
10.02.02 |
Baclofen |
Baclofen 10mg tablets Baclofen 5mg/5ml oral solution SF
Intrathecal Injection (Hospital only): Baclofen 50mcg/ml solution for injection ampoules Baclofen 10mg/5ml solution for infusion ampoules Baclofen 10mg/20ml solution for infusion ampoules
|
12.02.03 |
Bactroban®nasal Mupirocin calcium |
Bactroban®- Mupirocin calcium 2% nasal ointment
Restriction: For the eradication (in both patients and staff) of nasal carriage of MRSA, in accordance with hospital or local guidelines.
Restriction: For the suppression of S. aureus prior to elective high risk surgery, on request of the consultant surgeon
|
13.02.01 |
Balneum®cream Urea 5% |
Creamy with Urea Content
Pack size 50g, 500g |
13.02.01 |
Balneum®Plus cream Urea 5% + lauromacrogol 3% |
Creamy with Urea Content
Restricted for pruritus
Pack size 100g, 500g |
01.05.01 |
Balsalazide Colazide® |
Balsalazide 750mg Capsule
Restriction: For acute relapses of ulcerative colitis |
10.01.03 |
Baricitinib Olumiant® |
Restriction: In line with NICE Guidance |
08.02.02 |
Basiliximab Simulect® |
Restriction: In line with NICE Guidance only |
08.02.04 |
BCG bladder instillation |
Powder for instillation fluid for intravesical use containing 2-8 x 108 CFU Tice BCG. |
03.02 |
Beclometasone Clenil® |
Clenil Modulite Inhalation 100mcg (200D) Clenil Modulite Inhalation 200mcg (200D) Clenil Modulite Inhalation 250mcg (200D) Clenil Modulite Inhalation 50mcg (200D)
For use in Asthma only. Restriction: See APC Advice
APC advice - CFC-free beclomethasone inhalers should be prescribed by brand, not generically. Clenil modulite requires no dose adjustment from CFC-BDP inhalers. Prescribing of this brand will minimise potential errors associated with changing doses and will reduce patient confusion. |
03.02 |
Beclometasone Qvar® |
Qvar 50 Easi-Breathe Inhalation 50mcg (200 D) Qvar 50 Inhalation 50mcg (200 D) Qvar 100 Easi-Breathe Inhalation 100mcg (200 D) Qvar 100 Inhalation 100mcg (200 D)
Qvar does not have a paediatric license. Qvar has microfine particles and is used at half the dose of Clenil.
For use in Asthma only.
Restriction: See APC Advice
APC advice - CFC-free beclomethasone inhalers should be prescribed by brand, not generically. Clenil modulite requires no dose adjustment from CFC-BDP inhalers. Prescribing of this brand will minimise potential errors associated with changing doses and will reduce patient confusion. |
03.02 |
Beclometasone & formoterol Fostair® |
Fostair Inhalation 100mcg/6mcg (120D) Fostair Inhalation 200mcg/6mcg (120D) (ASTHMA ONLY)
For use in both Asthma and COPD - high strength is for Asthma only |
12.02.01 |
Beclometasone dipropionate nasal spray |
Beclometasone dipropionate 50microgram/dose nasal spray
1st line for the treatment and prophylaxis of allergic perennial rhinitis
Self Care Medicine- Available OTC for self-care for adults over 18s
|
03.02 |
Beclometasone dipropionate, formoterol fumarate, & glycopyrronium bromide Trimbow® |
Trimbow 87mcg/dose / 5mcg/dose /9mcg/dose Contains three components Beclometasone/fomoterol/glycopyronnium
For use in COPD only
See APC Advice The NMC acknowledged that locally approved guidelines reflect the GOLD guidelines for management of COPD whereas the licensed indication for Trimbow® and Trelegy® places its use after ICS and LABA. The APC considered this and supported the use of Trimbow® and Trelegy® in line with GOLD and local guidelines; prescribers need to be aware of this. |
10.01.03 |
Belimumab Benlysta® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
MHRA advice (May 2019):Belimumab (Benlysta▼)- increased risk of serious psychiatric events seen in clinical trials |
08.01.01 |
Bendamustine hydrochloride |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Bendamustine (Levact®): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation (July 2017) |
02.02.01 |
Bendroflumethiazide |
Bendroflumethiazide 2.5mg Tablet
Not to be prescribed for patients newly diagnosed with hypertension (doses higher than 2.5mg are not indicated in hypertension) |
03.04.02 |
Benralizumab Fasenra® |
30 mg solution for injection in pre-filled syringe
Restriction: In line with NICE Guidance only
This is an NHS England specialised commissioning drug for the treatment of severe eosinophilic asthma in adults. |
04.09.02 |
Benzatropine |
Benzatropine Injection 1mg/ml Amp
Discontinued |
13.06.01 |
Benzoyl peroxide |
Acnecide® - Benzoyl peroxide 5% gel 30g,60g Acnecide®Wash - Benzoyl peroxide 5% gel wash 50g
Panoxyl Aquagel® - Benzoyl peroxide 2.5%, 5% or 10% gel, 40g
|
13.06.01 |
Benzoyl peroxide with clindamycin Duac® Once Daily |
Benzoyl peroxide with Antibacterial
Duac®Once Daily gel (3% and 1%) 30g,60g Duac®Once Daily gel (5% and 1%) 30g,60g
For mild papular/pustular acne where an antimicrobial is indicated. |
12.03.01 |
Benzydamine hydrochloride |
Benzydamine hydrochloride 0.15% oromucosal spray sugar free Benzydamine hydrochloride 0.15% mouthwash sugar free
Self Care Medicine-Available OTC for self-care for oral ulceration and inflammation.
|
03.05.02 |
Beractant Survanta® |
Restriction: Neonatal use only
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised commissioning drug for RESPIRATORY DISTRESS SYNDROME. |
04.06 |
Betahistine Dihydrochloride |
Betahistine Dihydrochloride Tablet 8mg Betahistine Dihydrochloride Tablet 16mg |
11.04.01 |
Betamethasone |
Betamethasone sodium phosphate 0.1% eye/ear/nose drops Betamethasone (Betnesol) 0.1% eye ointment |
13.04 |
Betamethasone (as dipropionate) 0.05% with salicylic acid 2% scalp application Diprosalic® |
Scalp applications
Potent
Diprosalic®scalp application 100ml |
13.04 |
Betamethasone (as dipropionate) 0.05% with salicylic acid 3% Diprosalic® |
Topical corticosteroids with salicylic acid
Potent
Diprosalic®ointment 30g, 100g |
13.04 |
Betamethasone (as valerate) 0.025% Betnovate-RD® |
Moderate potency
Betnovate-RD®cream 100g Betnovate-RD®ointment 100g |
13.04 |
Betamethasone (as valerate) 0.1% |
Potent
Betamethasone valerate 0.1% cream 30g, 100g Betamethasone valerate 0.1% ointment 30g, 100g |
13.04 |
Betamethasone (as valerate) 0.1% with clioquinol 3% |
Topical corticosteroids with antimicrobials
Potent
Betamethasone valerate 0.1% & clioquinol 3% cream 30g Betamethasone valerate 0.1% & clioquinol 3% ointment 30g
Limit duration of treatment with steroid/antimicrobial combinations; usually twice daily for 1 week.
|
13.04 |
Betamethasone (as Valerate) 0.1% with fucidic acid 2% Fucibet® |
Topical corticosteroids with antimicrobials
Potent
Fucibet®cream 30g
Limit duration of treatment with steroid/antimicrobial combinations; usually twice daily for 1 week. |
12.01.01 |
Betamethasone sodium phosphate |
Betamethasone sodium phosphate 0.1% eye/ear/nose drops |
12.01.01 |
Betamethasone sodium phosphate with neomycin sulfate Betnesol N® |
Betnesol N® - Betamethasone 0.1% with Neomycin 0.5% ear/eye/nose drops |
13.04 |
Betamethasone valerate 0.1% scalp application Betacap® |
Scalp applications
Potent
Betacap®scalp application 100ml |
11.06 |
Betaxolol hydrochloride Betoptic® |
Betoptic®- Betaxolol hydrochloride 0.25% eye drops Betoptic®- Betaxolol hydrochloride 0.25 % eye drops (0.25ml Unit Doses) - P/free Betoptic®- Betaxolol hydrochloride 0.5% eye drops |
02.12 |
Bezafibrate |
Bezafibrate 200mg Tablet Bezafibrate 400mg MR Tablet
Fibrates should not be offered routinely for the primary or secondary prevention of cardiovascular disease alone or in combination with a statin, including for those with chronic kidney disease or Type 1 or 2 Diabetes Mellitus. This does not apply to those diagnosed with familial hypercholesterolaemia (NICE CG181).
|
08.03.04.02 |
Bicalutamide |
Bicalutamide 50mg tablets Bicalutamide 150mg tablets |
11.06 |
Bimatoprost |
Lumigan®- Bimatoprost 100microgam/ml eye drops Bimatoprost 300microgam/ml eye drops Bimatoprost 300 micrograms/ml eye drops (0.4ml unit dose) - P/free
2nd line prostaglandin analogue after Latanoprost
|
11.06 |
Bimatoprost with timolol Ganfort® |
2nd line after latanoprost & timolol eye drops
Ganfort®- Bimatoprost 300microgram/ml & Timolol 5mg/ml eye drops |
11.06 |
Bimatoprost with timolol Ganfort® |
Ganfort®- Bimatoprost 300microgram/ml & Timolol 5mg/ml eye drops (0.4ml unit dose) - P/free |
06.01.01.02 |
Biphasic Insulin Aspart NovoMix® 30 |
100 units/ml solution for injection cartridges (Penfill) 100 units/ml solution for injection prefilled pen (FlexPen) |
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix25 |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (KwikPen) |
06.01.01.02 |
Biphasic Insulin Lispro Humalog® Mix50 |
100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (KwikPen) |
06.01.01.02 |
Biphasic Isophane Insulin Humulin® M3 |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (KwikPen) |
06.01.01.02 |
Biphasic Isophane Insulin Hypurin® Porcine 30/70 Mix |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges
|
06.01.01.02 |
Biphasic Isophane Insulin Insuman® Comb |
Insuman Comb 15 100 units/ml solution for injection cartridges
Insuman Comb 25 100 units/ml solution for injection vials Insuman Comb 25 100 units/ml solution for injection cartridges Insuman Comb 25 100 units/ml solution for injection prefilled pen (SoloStar Pen)
Insuman Comb 50 100 units/ml solution for injection cartridges
DISCONTINUATION (from June 2020)
Insuman Comb 15 100IU/mL suspension for injection in a cartridge (expected end of supply June 2020). Alternative is Humulim M3 cartridge.
Insuman Comb 25 100IU/mL suspension for injection in a vial (expected end of supply June 2020). Alternative is Humumlin M3 vial, Insuman Comb 25 cartridge/solostar. |
01.06.02 |
Bisacodyl |
Bisacodyl 5mg EC Tablet
Bisacodyl 10mg Suppository
Self Care Medicine-Available OTC for self care.
|
02.04 |
Bisoprolol Fumarate |
Bisoprolol Fumarate 1.25mg Tablet Bisoprolol Fumarate 2.5mg Tablet Bisoprolol Fumarate 3.75mg Tablet Bisoprolol Fumarate 5mg Tablet Bisoprolol Fumarate 7.5mg Tablet Bisoprolol Fumarate 10mg Tablet |
02.08.01 |
Bivalirudin Angiox® |
250mg powder for concentrate for solution for infusion vials
Restriction: Initiation by Cardiology consultants only and should only be used during percutaneous coronary intervention (PCI) procedure |
08.02.03 |
Blinatumomab Blincyto® |
Restriction: In line with NICE Guidance only |
05.03.03.02 |
Boceprevir Victrelis® |
Boceprevir Capsules 200mg
Restriction: In line with NICE Guidance This is an NHS England Specialised Commissioning Drug for Hepatitis C
Boceprevir is no longer available in the UK |
08.01.05 |
Bortezomib Velcade® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Bosutinib Bosulif® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice (May 2016): Risk of hepatitis B virus reactivation with BCR-ABL tyrosine kinase inhibitors |
04.12 |
Botulinum neurotoxin Type A Xeomin® |
Restriction: In line with NICE Guidance only
An option for treating chronic sialorrhoea caused by neurological conditions in adults. Specialist use only. |
04.07.04.02 |
Botulinum Toxin Type A Botox® |
Restriction: In line with NICE Guidance only
Commissioned by the CCG for chronic migraine and other agreed indications. |
04.09.03 |
Botulinum Toxin Type A |
Restriction: Initiation by specialist only where alternative funding is secured |
08.01.05 |
Brentuximab vedotin Adcetris® |
Restriction: In line with NICE Guidance only |
07.03.01 |
Brevinor® |
Monophasic
|
08.01.05 |
Brigatinib Alunbrig® |
Restriction: In line with NICE guidance only |
11.06 |
Brimonidine tartrate |
Brimonidine tartrate 0.2% eye drops |
11.06 |
Brinzolamide |
Brinzolamide 10mg/ml eye drops |
04.08.01 |
Brivaracetam Briviact® |
Brivaracetam Tablets 10mg Brivaracetam Tablets 25mg Brivaracetam Tablets 50mg Brivaracetam Tablets 75mg Brivaracetam Tablets 100mg Brivaracetam Oral Solution 10mg/ml Brivaracetam Solution for Injection 50mg/5ml vials
3rd line agent.
For adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adult, adolescent and paediatric patients from 4 years of age with severe refractory epilepsy warranting epilepsy specialist input who have
- Tried 3 or more antiepileptic medications, and
- Have used levetiracetam and has documented intolerance, and would not be suitable for other third line agents; and
- Is currently on a 3rd line agent which would be replaced by Brivaracetam; or
- Has tried 3 or more antiepileptic medications and has insufficient symptom control and requires rapid attainment of therapeutic levels.
Restriction: For initiation and stabilisation by a specialist Unnecessary to maintain patient on specific manufacturer's products.
After stabilisation, primary care may continue its prescribing on receipt of Specialist Clinic patient-specific letter which must include:
- The previous antiepileptic medications tried
- Intolerance to Levetiracetam
- An improvement in side effects after switching from Levetiracetam to Brivaracetam
|
13.05.03 |
Brodalumab Kyntheum® |
Restriction: In line with NICE Guidance only |
06.07.01 |
Bromocriptine |
Bromocriptine Tablets 1mg Bromocriptine Tablets 2.5mg Bromocriptine Capsules 5mg (Parlodel) Bromocriptine Capsules 10mg (Parlodel)
MHRA advice: Ergot-derived dopamine agonists: risk of fibrotic reactions (Oct 2008).
Not recommended in post partum lactation suppression. Caution with antihypertensive therapy and avoid other ergot alkaloids. Discontinue immediately if hypertension, unremitting headache, or signs of CNS toxicity develop.
|
01.05.02 |
Budesonide Budenofalk® |
Budenofalk 3mg gastro-resistant Capsule
MHRA/CHM advice: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration (August 2017)
|
01.05.02 |
Budesonide Budenofalk® |
Budesonide 2mg/dose foam enema
Steroid foam enemas are interchangable. Due to current stock issues with hydrocortisone (Colifoam), budesonide enema is the current preferred choice. |
03.02 |
Budesonide |
Budesonide 500mcg/2ml nebuliser liquid Udv Budesonide 1mg/2ml nebuliser liquid Udv
Restriction: Nebuliser use only |
12.02.01 |
Budesonide Rhinocort Aqua® |
Budesonide 64microgram/dose nasal spray
Recommendation: Licensed for the treatment of nasal polyps
Rhinocort Aqua® is not licensed for use in children (but generic products are). |
03.02 |
Budesonide & formoterol Symbicort® |
Symbicort Turbohaler 100mcg/6mcg (120 D) Symbicort Turbohaler 200mcg/6mcg (120 D) Symbicort Turbohaler 400mcg/12mcg (60 D)
For paediatric use only
Restriction: For use in Asthma only |
03.02 |
Budesonide & formoterol DuoResp®Spiromax |
DuoResp Spiromax 160mcg/dose / 4.5mcg/dose DPI
In asthma, the 160/4.5 inhaler may be used both as regular maintenance treatment and as needed in response to symptoms
DuoResp Spiromax 320mcg/dose / 9mcg/dose DPI
The 320/9 inhaler must be used with a separate reliever.
For use in both Asthma and COPD
NOT to be used for anyone under the age of 18.
|
02.02.02 |
Bumetanide |
Bumetanide 1mg Tablet Bumetanide 5mg Tablet Bumetanide 1mg/5ml S/F Oral Solution Expensive Item
Monitor Potassium Levels - Risk of Hypokalaemia
2nd line if furosemide ineffective |
04.07.02 |
Buprenorphine Temgesic® |
Buprenorphine sublingual Tablets 200mcg Buprenorphine sublingual Tablets 400mcg
Tablets only. Prescribe by brand |
04.07.02 |
Buprenorphine |
For the 5, 10, 20 microgram/hour transdermal patch [7 day patch], Butec® (equivalent to Butrans®) is more cost effective (Applicable in Primary care only)
For the 35 and 70 microgram/hour transdermal patch [72 hourly patch], Hapoctasin® is more cost effective (Applicable in Primary care only)
Note: Low dose may be useful for frail elderly patients or similar patients sensitive to side-effects of morphine sulphate or fentanyl
Restriction: Only to be used in line with the Non-Malignant Chronic Pain Guide.
Buprenorphine patches are available as 72-hourly, 96-hourly (non-formulary) and 7-day formulations |
04.07.02 |
Buprenorphine Transtec® |
Not approved for inclusion in the North Staffordshire Joint Formulary
This includes the 35, 52.5 and 70 microgram/hour transdermal patch [96 hourly patch]. Brands include Transtec®, Relevtec®, Buplast® and Bupeaze®
|
|
04.10.03 |
Buprenorphine Subutex® |
Buprenorphine Tab Subling 400mcg S/F Buprenorphine Tab Subling 2mg S/F Buprenorphine Tab Subling 8mg S/F Subutex Tab Subling 2mg Subutex Tab Subling 400mcg Subutex Tab Subling 8mg
Restriction: Initiation by substance abuse specialist only |
04.10.02 |
Bupropion hydrochloride Zyban® |
Bupropion HCl Tablet 150mg M/R
2nd line for smoking cessation.
Restriction: As part of a smoking cessation programme only.
APC Advice: Varenicline (Champix®), revised May 2008.
- Nicotine Replacement Therapy remains the pharmacological agent of choice for smoking cessation.
- Consider varenicline or bupropion if NRT ineffective, not tolerated or inappropriate.
- Only use as a component of a smoking cessation programme.
- Current evidence is insufficient to recommend an additional treatment course in those who have stopped smoking after the initial 12 weeks of therapy
|
03.04.03 |
C1 esterase inhibitor |
500unit powder and solvent for solution for injection vials 1500unit powder and solvent for solution for injection vials (Berinert only)
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for HEREDITARY ANGIOEDEMA - ACUTE TREATMENT, PROPHYLACTIC TREATMENT and for PROPHYLACTIC TREATMENT IN CHILDREN (CINRYZE ONLY)
Brands include BERINERT and CINRYZE. |
08.01.05 |
Cabazitaxel Jevtana® |
Restriction: In line with NICE Guidance only |
06.07.01 |
Cabergoline Dostinex® |
Cabergoline Tablets 500mcg
Restriction: Initiation under direction of a specialist
BNF 62 - Suppression of lactation. Although bromocriptine and cabergoline are licensed to suppress lactation, they are not recommended for routine suppression (or for the relief of symptoms of postpartum pain and engorgement) that can be adequately treated with simple analgesics and breast support. If a dopamine-receptor agonist is required, cabergoline is preferred.
MHRA advice: Ergot-derived dopamine agonists: risk of fibrotic reactions (Oct 2008). |
08.01.05 |
Cabozantinib Cabometyx® |
Restriction: In line with NICE Guidance only |
09.06.04 |
Calceos® Colecalciferol and calcium carbonate |
Maintenance dose (with calcium)
Colecalciferol 10microgram (equivalent to 400unit of vitamin D3) plus Calcium carbonate 1250mg (equivalent to 500mg of elemental calcium) chewable tablets |
09.05.01.01 |
Calcichew ® |
Calcichew ®Calcium carbonate 1.25g (500mg) tablets (12.6mmol Ca2+) |
13.05.02 |
Calcipotriol |
Calcipotriol 50microgram/g ointment 30g, 60g, 120g |
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Dovobet® |
Restriction: See APC/NMC Advice
Dovobet®ointment 30g,60g,120g Dovobet®gel 60g,120g
Dovobet gel: Usual duration of therapy for scalp psoriasis is 4 weeks and for mild to moderate plaque psoriasis for 8 weeks; may be continued or repeated on the advice of a specialist
Dovobet ointment: Indicated for once daily treatment of stable plaque psoriasis for 4 weeks; if necessary treatment may be continued beyond 4 weeks or repeated on the advice of a specialist.
APC/NMC Advice: Betamethasone 0.05% / calcipotriol 50micrograms per gram (May 2017). Dovobet® & Enstilar® are included in the NSJF as a second line agent for the treatment of psoriasis when patients are unable to comply with the individual preparations i.e. betamethasone applied mane and calcipotriol applied nocte. (Green status on the NSJF) |
13.05.02 |
Calcipotriol 50micrograms/g with Betamethasone 0.05% Enstilar® |
Restriction: See APC/NMC Advice
Enstilar®cutaneous foam 60g, 120g
The foam presentation may be preferred to the gel or ointment presentations, depending on the site of the psoriasis and patient preference. The recommended duration of therapy is 4 weeks.
APC/NMC Advice: Betamethasone 0.05% / calcipotriol 50micrograms per gram (May 2017). Dovobet® & Enstilar® are included in the NSJF as a second line agent for the treatment of psoriasis when patients are unable to comply with the individual preparations i.e. betamethasone applied mane and calcipotriol applied nocte. (Green status on the NSJF) |
06.06.01 |
Calcitonin (salmon) / Salcatonin |
50units/ml Solution for Injection Amps 100units/ml Solution for Injection Amps 400units/2ml Solution for Injection Vials |
09.06.04 |
Calcitriol |
Calcitriol 250nanogram capsules Calcitriol 500nanogram capsules
|
09.05.01.01 |
Calcium gluconate |
Calcium gluconate 100mg/1ml (10%) solution for injection ampoules (1 g contains calcium 89 mg or Ca2+ 2.23 mmol.)
The MHRA has advised that repeated or prolonged administration of calcium gluconate injection packaged in 10 mL glass containers is contra-indicated in children under 18 years and in patients with renal impairment owing to the risk of aluminium accumulation; in these patients the use of calcium gluconate injection packaged in plastic containers is recommended. |
09.05.02.02 |
Calcium Salts |
Calcichew ®Calcium carbonate 1.25g (500mg) tablets (12.6mmol Ca2+) Phosphex®Calcium acetate 1gram tablets (equivalent to 250mg calcium; 6.2 mmol Ca2+) |
09.04 |
Calogen® |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Calogen® Extra |
Initiation by specialist dietician services prior to continuation within primary care. |
06.01.02.03 |
Canagliflozin Invokana® |
Canagliflozin Tablets 100mg Canagliflozin Tablets 300mg
Restriction: In line with NICE Guidance only
For mono, dual & triple therapy - should not be initiated in patients with an eGFR < 60 mL/min/1.73 m2 or CrCl < 60 mL/min. In patients tolerating canagliflozin whose eGFR falls persistently below 60 mL/min/1.73 m2 or CrCl 60 mL/min, the dose of canagliflozin should be adjusted to or maintained at 100 mg once daily. Canagliflozin should be discontinued when eGFR is persistently below 45 mL/min/1.73 m2 or CrCl persistently below 45 mL/min
MHRA/CHM advice (updated April 2016): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin or empagliflozin)
MHRA/CHM advice (updated March 2017): Increased risk of lower-limb amputation (mainly toes)
MHRA advice- SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) |
02.05.05.02 |
Candesartan Cilexetil |
Candesartan Cilexetil 2mg Tablet Candesartan Cilexetil 4mg Tablet Candesartan Cilexetil 8mg Tablet Candesartan Cilexetil 16mg Tablet Candesartan Cilexetil 32mg Tablet
1st line angiotensin II antagonist |
04.08.01 |
Cannabidiol Epidyolex® |
Restriction: In line with NICE Guidance only
- For treating seizures associated with Lennox-Gastaut syndrome [adjunctive treatment with clobazam] specialist use only
- For treating seizures associated with Dravet syndrome [adjunctive treatment with clobazam] specialist use only
|
08.01.03 |
Capecitabine Xeloda® |
Restriction: In line with NICE Guidance only |
02.05.05.01 |
Captopril |
Captopril 12.5mg Tablet Captopril 25mg Tablet Captopril 50mg Tablet
Restriction: Initiation by a Paediatrician |
04.02.03 |
Carbamazepine |
Carbamazepine Tablets 100mg Carbamazepine Tablets 200mg Carbamazepine Tablets 400mg Carbamazepine MR Tablets 200mg Carbamazepine MR Tablets 400mg Carbamazepine Suppositories 125mg Carbamazepine Suppositories 250mg Carbamazepine Oral Solution 100mg/5ml
Restriction: Initiation by psychiatrist
Suppositories of 125 mg may be considered to be approximately equivalent in therapeutic effect to tablets of 100 mg but final adjustment should always depend on clinical response (plasma concentration monitoring recommended). |
04.07.03 |
Carbamazepine |
Carbamazepine Tablets 100mg Carbamazepine Tablets 200mg Carbamazepine Tablets 400mg |
04.08.01 |
Carbamazepine MR |
Carbagen SR Tablets 200mg - Discontinued Carbagen SR Tablets 400mg - Discontinued Tegretol MR Tablets 200mg Tegretol MR Tablets 400mg
Restriction: Initiation and stabilisation by specialist Maintain patient on specific manufacturer's products
Additional Information July 2006:
- Carbamazepine suppositories are licensed for short-term treatment (maximum 7 days) only when oral therapy is temporarily not possible.
- Carbamazepine 125mg suppositories should be considered equivalent to 100mg tablets but plasma monitoring is recommended.
|
06.02.02 |
Carbimazole Neo-Mercazole® |
Carbimazole Tablets 5mg and 20mg
Carbimazole and Propylthiouracil are associated with rare cases of neutropenia and agranulocytosis due to bone marrow suppression. • Patients should be advised to report symptoms suggestive of infection, especially sore throat. • Blood Count should be performed if there is clinical evidence of infection. • Carbimazole/Propylthiouracil should be stopped if there is clinical or lab evidence of neutropenia.
Feb 2018: Women of childbearing potential should use effective contraception during treatment with carbimazole. If carbimazole is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended.
MHRA advice: Carbimazole- increased risk of congenital malformations; strengthened advice on contraception (Feb 2019)
MHRA advice: Carbimazole- risk of acute pancreatitis (Feb 2019) |
03.07 |
Carbocisteine |
2nd line
Prescribe generically.
Restriction within secondary care: Paediatrics & Respiratory initiation only |
07.01.01 |
Carboprost Hemabate® |
Carboprost trometamol 250microgram/1ml solution for injection ampoules |
08.01.05 |
Carfilzomib Kyprolis® |
Restriction: In line with NICE Guidance only
MHRA advice (Aug 2019): Carfilzomib (Kyprolis▼)- reminder of risk of potentially fatal cardiac events |
12.03.01 |
Carmellose Sodium Gelatin mouth Preps |
Protective paste 30g.
Orabase is formulated to adhere to mucous membranes and raw weeping areas. It can be used in the mouth , around wounds or ostomies that need protection.
Self Care Medicine - Available OTC for self-care this product can be purchased online.
|
08.01.01 |
Carmustine Gliadel® |
Restriction: In line with NICE Guidance only
|
11.06 |
Carteolol Teoptic® |
Carteolol 1% eye drops Carteolol 2% eye drops
DISCONTINUED 2017 |
10.01.01 |
Celecoxib |
Celecoxib 100mg capsules Celecoxib 200mg capsules
If an NSAID is needed, use ibuprofen (1200mg a day or less) or naproxen (1000mg a day or less)
MHRA Advice: COX-2 NSAIDs have a higher cardiovascular risk profile |
08.01.05 |
Cemiplimab Libtayo® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Ceritinib Zykadia® |
Restriction: In line with NICE Guidance only |
10.01.03 |
Certolizumab Pegol Cimzia® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies |
03.04.01 |
Cetirizine Hydrochloride |
Cetirizine Hydrochloride Oral Solution 1mg/1ml S/F Cetirizine Hydrochloride Tablet 10mg
Self Care Medicine - Available OTC for self-care
|
13.02.01 |
Cetraben®cream |
Creamy (equivalent to Epaderm® Cream)
2nd Line
Pack size 150g, 500g
Self Care Medicine-Avilable OTC self care.
|
13.02.01 |
Cetraben®ointment |
Greasy (equivalent to Epaderm® Ointment)
2nd Line
Pack size 125g, 450g
Self Care Medicine-Available OTC for self care.
|
08.01.05 |
Cetuximab Erbitux® |
Restriction: In line with NICE Guidance only |
11.03.01 |
Chloramphenicol |
Chloramphenicol 0.5% eye drops Chloramphenicol 1% eye ointment
1st line
Self Care Medicine-Available OTC for self care and patients should be advised to purchase a suitable product over the counter. First line for bacterial conjunctivitis.(Please note exceptions may apply)
|
04.01.02 |
Chlordiazepoxide Hydrochloride |
Chlordiazepoxide Hydrochloride Capsule 5mg Chlordiazepoxide Hydrochloride Capsule 10mg
Restriction: To be used only in community detoxification clinics or GPs with special interest
CSM Advice: Hypnotics and Anxiolytics are indicated for the short-term relief of sleep disturbance and/or anxiety. (For continuous use up to a maximum of 14 days) |
12.03.04 |
Chlorhexidine gluconate |
Chlorhexidine gluconate 0.2% mouthwash Chlorhexidine gluconate 0.2% oral spray Chlorhexidine gluconate 1% dental gel
Self Care Medicine-Available OTC for self-care for the prevention of dental caries.
|
13.11.02 |
Chlorhexidine gluconate preparations |
Chlorhexidine gluconate 0.05% Sachets 25mL Chlorhexidine gluconate 0.05% Sachets 100mL (Brands include Unisept®)
Chlorhexidine 0.015% with Cetrimide 0.15% (Tisept®)
Chlorhexidine 4% solution (Brands include Hydrex® surgical scrub and Hibiscrub® cleansing solution). Can be purchased over the counter. |
10.01.03 |
Chloroquine Avloclor® |
Avloclor® - Chloroquine phosphate 250mg tablets
|
03.04.01 |
Chlorphenamine Maleate |
Chlorphenamine Maleate Oral Solution 2mg/5ml Chlorphenamine Maleate Tablet 4mg
Self Care Medicine-Available OTC for self care.
|
03.04.03 |
Chlorphenamine maleate |
Chlorphenamine Maleate Oral Solution 2mg/5ml Chlorphenamine Maleate Tablet 4mg
|
04.02.01 |
Chlorpromazine Hydrochloride |
Chlorpromazine Hydrochloride Oral Solution 100mg/5ml Chlorpromazine Hydrochloride Oral Solution 25mg/5ml Chlorpromazine Hydrochloride Tablet 25mg Chlorpromazine Hydrochloride Tablet 50mg Chlorpromazine Hydrochloride Tablet 100mg |
11.03.01 |
Chlortetracycline |
Eye ointment
Discontinued in the UK 2004, but may be available as an import.
|
12.03.01 |
Choline salicylate Bonjela® |
Bonjela® Original gel
Self Care Medicine. Available to purchase over the counter for oral ulceration and inflammation.
Not to be used in children and adolescents under the age of 16. Bonjela Junior® gel could be used instead for children from 5 months and above. |
06.05.01 |
Chorionic Gonadotrophin Pregnyl® |
1500 unit powder and solvent for solution for injection ampoules 5000 unit powder and solvent for solution for injection ampoules
Restriction: Specialist use only
Fertility drugs should not be prescribed in Primary care. They are funded as part of the fertility treatment and will be provided from the fertility clinic. |
03.02 |
Ciclesonide Alvesco® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
08.02.02 |
Ciclosporin |
Brand must be stated
MHRA/CHM advice: ciclosporin must be prescribed and dispensed by brand name (December 2009)
Link to ESCA |
08.02.02 |
Ciclosporin Cyclosporin |
All post-transplant immunosuppressants are RED for patients newly prescribed these medicines from April 2013
Brand must be stated
MHRA/CHM advice: ciclosporin must be prescribed and dispensed by brand name (December 2009) |
10.01.03 |
Ciclosporin Prescribe by brand |
Ciclosporin 10mg capsules (only available as Neoral®) Ciclosporin 25mg capsules Ciclosporin 50mg capsules Ciclosporin 100mg capsules
MHRA/CHM advice: ciclosporin must be prescribed and dispensed by brand name (December 2009)
Link to ESCA |
11.08.01 |
Ciclosporin Ikervis® |
Ikervis®- Ciclosporin 0.1% eye drops (0.3ml unit dose) - P/free
Restriction: In line with NICE Guidance only
|
13.05.03 |
Ciclosporin |
Restriction: Initiation on specialist dermatological advice
Brand must be stated
MHRA/CHM advice: ciclosporin must be prescribed and dispensed by brand name (December 2009) |
01.05.03 |
Ciclosprin |
For use in severe acute ulcerative colitis refractory to corticosteroid treatment [unlicensed indication] |
07.03.01 |
Cilest® |
Monophasic
DISCONTINUED (July 2019)
Two alternative products are currently available in the UK with the same active ingredients - Cilique® and Lizinna® |
09.05.01.02 |
Cinacalcet hydrochloride Mimpara® |
Cinacalcet 30mg Tablet Cinacalcet 60mg Tablet Cinacalcet 90mg Tablet
Restriction: In line with NICE Guidance |
04.06 |
Cinnarizine |
Cinnarizine Tablet 15mg |
04.03.03 |
Citalopram |
Citalopram Hydrobromide Tablet 10mg Citalopram Hydrobromide Tablet 20mg Citalopram Hydrobromide Tablet 40mg Citalopram (as Citalopram Hydrochloride) Oral Drops 40mg/ml S/F
Cost effective choice in patients where QT interval prolongation is not an issue (see MHRA advice below for detail) Maximum daily dose 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment. |
08.01.03 |
Cladribine Mavenclad ® |
Restriction: In line with NICE Guidance only
|
13.06.02 |
Clarithromycin |
Clarithromycin 250mg tablets Clarithromycin 500mg tablets |
07.02.02 |
Clindamycin Dalacin® |
Clindamycin cream 2% |
04.08.01 |
Clobazam |
Clobazam Oral Suspension 5mg/5ml - For patients with swallowing difficulty Clobazam Oral Suspension 10mg/5ml - For patients with swallowing difficulty Clobazam Tablets 10mg
Not NHS except on specialist recommendation for epilepsy and endorsed 'SLS'.
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's product.
- Liquid Suspension
|
13.04 |
Clobetasol propionate 0.05% Dermovate® |
Very potent
Dermovate®cream 30g, 100g Dermovate®ointment 30g, 100g |
13.04 |
Clobetasol propionate 0.05% scalp application Dermovate® |
Scalp applications
Very potent
Dermovate®scalp application 30ml, 100ml |
13.04 |
Clobetasol propionate 500microgram/neomycin sulfate 5mg/ and nystatin 100,000unit/g |
Topical corticosteroids with antimicrobials
Very potent
Clobetasol propionate 500microgram/neomycin sulfate 5mg/ and nystatin 100,000unit/g cream 30g Clobetasol propionate 500microgram/neomycin sulfate 5mg/ and nystatin 100,000unit/g ointment 30g
Generic expensive. Dermovate NN is no longer available as the brand
|
13.04 |
Clobetasone butyrate 0.05% Eumovate® |
Moderate potency
Eumovate®cream 30g, 100g Eumovate®ointment 30g, 100g
|
13.04 |
Clobetasone butyrate 0.05% with oxytetracycline 3% and nystatin 100,000 units/g Trimovate® |
Topical corticosteroids with antimicrobials
Moderate potency
Trimovate®cream 25g, 30g
Limit duration of treatment with steroid/antimicrobial combinations; usually twice daily for 1 week. |
04.01.01 |
Clomethiazole Heminevrin® |
Clomethiazole 192mg capsules |
06.05.01 |
Clomifene citrate |
Clomifene citrate Tablets 50mg
Fertility drugs should not be prescribed in Primary care. They are funded as part of the fertility treatment and will be provided from the fertility clinic.
The CSM has recommended that clomifene should not normally be used for longer than 6 cycles (possibly increased risk of ovarian cancer). |
04.03.01 |
Clomipramine Hydrochloride |
Clomipramine Hydrochloride Capsule 10mg Clomipramine Hydrochloride Capsule 25mg Clomipramine Hydrochloride Capsule 50mg
Standard release preparations only |
04.08.01 |
Clonazepam |
Clonazepam Tablets 500mcg Clonazepam Tablets 2mg Clonazepam Oral solution 500mcg/5ml Clonazepam Oral Solution 2mg/5ml
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
04.08.02 |
Clonazepam |
Clonazepam Tablets 500mcg Clonazepam Tablets 2mg Clonazepam Oral solution 500mcg/5ml Clonazepam Oral Solution 2mg/5ml |
02.05.02 |
Clonidine Hydrochloride Catapres® |
Clonidine Hydrochloride 100microgram Tablet
Restriction: Anaesthetics and Cardiology only
|
02.09 |
Clopidogrel |
Clopidogrel Tablet 75mg
Restriction: For patients post cardiac stent and for NICE approved indications* only
NICE approved indications:
- Acute Coronary Syndrome without ST-segment elevation
- Patients intolerant of low-dose aspirin who have experienced a recent MI or Ischemic stroke or who have symptomatic peripheral arterial disease.
|
07.02.02 |
Clotrimazole |
Clotrimazole Combi/Pack (500mg pessary/2% cream) Clotrimazole cream 1% Clotrimazole cream 2% Clotrimazole cream 10% (intravaginal stat treatment) Clotrimazole pessary 100mg, 200mg and 500mg
|
13.10.02 |
Clotrimazole Canesten® |
Clotrimazole 1% (cream, powder, solution)
Self Care Medicine. Available OTC for self care
|
12.01.01 |
Clotrimazole 1% ear solution Canesten® |
Note this is called '1% solution' rather than 'ear drops'. Prescribe as Canestan solution 1% otherwise pharmacies can not find it on their computers. |
04.02.01 |
Clozapine Clozaril® |
Clozapine Tablet 25mg Clozapine Tablet 50mg Clozapine Tablet 100mg Clozapine Tablet 200mg
Restriction: Initiation by psychiatrist registered with Clozapine monitoring service
Patient, prescriber and supplying pharmacist must be registered with the Patient Monitoring Service. Treatment is only continued if there are acceptable leucocyte and neutrophil counts.
Brands include Clozaril, Denzapine or Zaponex.
|
13.05.02 |
Coal Tar |
As per skin department formulary
Coal tar bath emulsion (Psoriderm 40% bath additive) 200ml Coal tar cream (Psoriderm cream) 225ml Coal tar emollient (Polytar 2.5% solution) 500ml Coal tar lotion (Exorex 5%) 100ml, 250ml Coal tar scalp ointment (Sebco 12%, Cocois) 40g, 100g
Most of these preparations are available for purchase over the counter in pharmacies.
MHRA/CHM advice (updated December 2018): Emollients: new information about risk of severe and fatal burns with paraffin-containing and paraffin-free emollients
|
02.02.04 |
Co-amilofruse |
Co-Amilofruse 2.5mg/20mg Tablet Co-Amilofruse 5mg/40mg Tablet
For patients on multiple tablets only.
Careful monitoring of U&Es is required. |
04.09.01 |
Co-Beneldopa Madopar® |
Co-Beneldopa Capsule 12.5mg/50mg Co-Beneldopa Capsule 25mg/100mg Co-Beneldopa Capsule 25mg/100mg M/R Co-Beneldopa Capsule 50mg/200mg Co-Beneldopa Tablet Dispersible 12.5mg/50mg S/F Co-Beneldopa Tablet Dispersible 25mg/100mg S/F
Restriction: Initiation by specialist |
04.09.01 |
Co-Careldopa Sinemet® |
Co-careldopa Tablets 12.5/50mg (Sinemet 62.5) Co-careldopa Tablets 10/100mg (Sinemet-110) Co-careldopa Tablets 25/100mg (Sinemet Plus) Co-careldopa Tablets 25/100mg MR (Half-Sinemet CR) Co-careldopa Tablets 25/250mg (Sinemet-275) Co-careldopa Tablets 50/200mg (Sinemet CR)
Restriction: Initiation by specialist |
13.09 |
Cocois® |
Cocois®ointment 40g, 100g
Self Care Medicine. Available OTC for self care
|
13.06.02 |
Co-Cyprindiol (cyproterone acetate 2mg with ethinylestradiol 35micrograms) Dianette® |
2nd line
Prescribe generically.
CSM Advice: Co-cyprindiol is licensed for use in women with severe acne which has not responded to oral antibacterials and for moderately severe hirsutism; it should not be used solely for contraception. It is contra-indicated in those with a personal or close family history of venous thromboembolism. Women with severe acne or hirsutism may have an inherently increased risk of cardiovascular disease. |
01.06.02 |
Co-danthramer |
Co-Danthramer 25mg/200mg Capsule (Withdrawn from UK market-August 2016) Co-Danthramer 37.5mg/500mg Capsule Strong (Withdrawn from UK market) Co-Danthramer 25mg/200mg/5ml S/F Oral Suspension
Suspension for Swallowing difficulties.
Restriction: Terminally ill patients only |
01.06.02 |
Co-danthrusate |
Co-danthrusate 50mg/60mg/5ml S/F Oral Suspension
Restriction: Terminally ill patients only |
01.04.02 |
Codeine phosphate |
Codeine phosphate 15mg Tablet Codeine phosphate 30mg Tablet Codeine phosphate 25mg/5ml Syrup
Any patient with altered bowel habit of either constipation or diarrhoea for more than 2-3 weeks with no known cause, should be investigated further. |
04.07.02 |
Codeine phosphate |
Codeine Phosphate Tablet 15mg Codeine Phosphate Tablet 30mg Codeine Phosphate Tablet 60mg Codeine Phosphate Linctus 15mg/5ml S/F |
10.01.04 |
Colchicine |
Colchicine 500microgram tablets |
01.09.02 |
Colestyramine |
Colestyramine 4g oral powder sachets sugar free |
02.12 |
Colestyramine |
Colestyramine 4gram oral powder sachets |
05.01.07 |
Colistimethate Promixin® |
Promixin 1,000,000u powder for nebuliser solution UDV Promixin 1,000,000u powder for solution for injection vials
Restriction: Non-CF Bronchiectasis. 2nd Line only at the recommendation of respiratory consultant |
05.01.07 |
Colistimethate Inhaler Colobreathe® |
Colobreathe 1,662,500u inhalation powder capsules, to be used with only the Turbospin powder inhaler.
Restriction:
- CF - In line with NICE Guidance & in accordance with NHS England prescribing policy. This is an NHS England Specialised Commissioning Drug for Cystic Fibrosis.
- Non-CF Bronchiectasis. 3rd line only. Prior approval is required from CCG. Respiratory consultant prescription only.
|
05.01.07 |
Colistimethate sodium Colomycin® |
Colistimethate Sodium Injection 1,000,000u Vl (Dry) Colistimethate Sodium Injection 2,000,000u Vl (Dry)
Restriction: Non-CF Bronchiectasis. 1st line
Treatment by Inhalation not IV. Note Colomycin® Injection may be used for nebulisation; administer required dose in 2-4 mL of sodium chloride 0.9%, (or water for injections) or a 1:1 mixture of sodium chloride 0.9% and water for injection. |
10.03.01 |
Collagenase Xiapex® |
Collagenase 0.9mg powder and solvent for solution for injection ampoules
Restriction: In line with NICE Guidance
10/2/2020 - NICE have withdrawn the TA459 guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK. |
01.01.01 |
Co-magaldrox |
Mucogel Suspension Maalox Suspension
Magnesium hydroxide, dried aluminium hydroxide (low Na+)
Combination of aluminium and magnesium may reduce GI side effects.
Self Care Medicine-Available OTC for self-care.
|
13.06.02 |
Combined Oral Contraceptive |
1st line |
03.04.03 |
Conestat Alfa Ruconest® |
2100unit powder for solution for injection vials
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY |
13.02.02 |
Conotrane®cream |
Pack size 100g, 500g |
08.01.05 |
Crizotinib Xalkori® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice (November 2015): Risk of cardiac failure |
04.06 |
Cyclizine |
Cyclizine Hydrochloride Tablet 50mg |
11.05 |
Cyclopentolate hydrochloride |
Mydrilate®- Cyclopentolate hydrochloride 0.5% solution eye drops Mydrilate®- Cyclopentolate hydrochloride 1% solution eye drops Minims Cyclopentolate hydrochloride 0.5% eye drops 0.5ml unit dose Minims Cyclopentolate hydrochloride 1% eye drops 0.5ml unit dose |
06.04.02 |
Cyproterone acetate |
Cyproterone Acetate Tablets 50mg Cyproterone Acetate Tablets 100mg
Restriction: Initiation under direction of a specialist |
08.03.04.02 |
Cyproterone acetate |
Cyproterone acetate 50mg tablets Cyproterone acetate 100mg tablets |
13.06.02 |
Cyproterone acetate |
Cyproterone acetate 50mg tablets Cyproterone acetate 100mg tablets
Restriction: Initiation on specialist dermatological advice
|
08.01.03 |
Cytarabine–daunorubicin liposomal Vyxeos® |
Restriction: In line with NICE Guidance only |
02.08.02 |
Dabigatran Pradaxa® |
Dabigatran Etexilate Capsule 75mg Dabigatran Etexilate Capsule 110mg Dabigatran Etexilate Capsule 150mg
- Prevention of stroke and systemic embolism in AF
- Treatment and secondary prevention of DVT and/or PE
If used for DVT or PE it needs to have an initial 5 days of parenteral anticoagulation prescribed.
Restriction: In line with NICE Guidance and locally agreed guidelines
MHRA/CHM advice: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (June 2019) |
02.08.02 |
Dabigatran Pradaxa® |
Dabigatran Etexilate Capsule 75mg Dabigatran Etexilate Capsule 110mg Dabigatran Etexilate Capsule 150mg
Restriction: In line with NICE Guidance only. Orthopaedic consultant use only.
Complete course to be supplied by the hospital |
08.01.05 |
Dabrafenib mesilate Tafinlar® |
Restriction: In line with NICE Guidance only |
05.03.03.02 |
Daclatasvir Daklinza® |
Daclatasvir Tablets 30mg Daclatasvir Tablets 60mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy This is an NHS England Specialised Commissioning Drug for Hepatitis C
MHRA/CHM advice: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR (January 2017)
MHRA/CHM advice: Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation (January 2017)
MHRA/CHM advice: Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes (December 2018)
Bristol-Myers Squibb has discontinued daclatasvir (Daklinza) |
08.02.04 |
Daclizumab Zinbryta® |
Restriction: In line with NICE Guidance only
WITHDRAWN FROM MARKET
MHRA advice: Daclizumab (Zinbryta▼): suspension and recall for safety reasons; review patients as soon as possible and start alternative therapy (March 2018). |
08.01.05 |
Dacomitinib Vizimpro® |
Restriction: In line with NICE Guidance only |
09.06.07 |
Dalivit®drops |
Dalivit® oral drops
Not licensed for use in children under 6 weeks.
Contains Vitamins A, B's, C, D. See SPC for full details. (0.6ml= 14 drops = 5000 units vitamin A) |
02.08.01 |
Dalteparin Sodium |
Solution for injection ampoules/ pre-filled syringes
In Obstetrics
Link to ESCA |
02.08.01 |
Dalteparin Sodium |
Solution for injection ampoules/ pre-filled syringes
Treatment of DVT and PE in adult cancer patients
Link to ESCA |
02.08.01 |
Dalteparin Sodium |
Solution for injection ampoules/ pre-filled syringes
Treatment of DVT and PE in medical patients
|
02.08.01 |
Danaparoid |
750units/ 0.6mL solution for injection ampoules
Restriction: For heparin induced thrombocytopenia only |
06.07.02 |
Danazol |
Danazol Capsules 100mg Danazol Capsules 200mg
DRUG DISCONTINUATION (MAY 2020) Danazol 100mg and 200mg capsules have been discontinued in the UK, and remaining supplies are now exhausted. Clinicians are advised to no longer initiate new patients on this drug. (See DHSC alert SDA/2020/009)
|
10.02.02 |
Dantrolene sodium Dantrium® |
Dantrium®- Dantrolene sodium 25mg capsules Dantrium®- Dantrolene sodium 100mg capsules |
06.01.02.03 |
Dapagliflozin Forxiga® |
Dapagliflozin Tablets 5mg
Restriction: as per NICE Guidance - Dapagliflozin with insulin for treating type 1 diabetes
Initiation and stabilisation by diabetic specialist and 6 month review to take place by the specialist
For mono, dual & triple therapy - should not be initiated in patients with a glomerular filtration rate [GFR] < 60 mL/min and should be discontinued at GFR persistently below 45 mL/min
MHRA/CHM advice (updated April 2016): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin or empagliflozin)
MHRA advice- SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
|
06.01.02.03 |
Dapagliflozin Forxiga® |
Dapagliflozin Tablets 5mg Dapagliflozin Tablets 10mg
Restriction: In line with NICE Guidance only
For mono, dual & triple therapy - should not be initiated in patients with a glomerular filtration rate [GFR] < 60 mL/min and should be discontinued at GFR persistently below 45 mL/min
MHRA/CHM advice (updated April 2016): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin or empagliflozin)
MHRA advice- SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) |
08.01.05 |
Daratumumab Darzalex® |
Restriction: In line with NICE Guidance only
MHRA advice (Aug 2019): Daratumumab (Darzalex▼)- risk of reactivation of hepatitis B virus |
09.01.03 |
Darbepoetin Alfa Aranesp® |
Restriction: In line with NICE Guidance only
Restriction: In accordance with NHS England prescribing policy
MHRA/CHM advice: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (updated January 2018)
MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin concentration
MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour progression and survival in patients with cancer |
05.03.03.02 |
Dasabuvir Sodium Monohydrate Exviera® |
Dasabuvir Tablets 250mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy This is an NHS England Specialised Commissioning Drug for Hepatitis C
MHRA/CHM advice: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR (January 2017)
MHRA/CHM advice: Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation (January 2017)
MHRA/CHM advice: Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes (December 2018) |
08.01.05 |
Dasatinib Sprycel® |
Restriction: In line with NICE Guidance only |
08.03.04.02 |
Degarelix acetate Firmagon® |
Firmagon (degarelix axetate) 80mg powder and solvent for solution for injection vials Firmagon (degarelix axetate) 120mg powder and solvent for solution for injection vials
Restriction: In line with NICE Guidance only
|
06.05.02 |
Demeclocycline hydrochloride Ledermycin® |
Demeclocycline hydrochloride 150mg Capsules
Link to ESCA |
06.06.02 |
Denosumab |
Xgeva, 70mg/ml 1.7ml Vial Prolia, 60mg/ml Prefilled Syringe
Restriction: In line with NICE Guidance only
- Prolia: Use in accordance with NICE TA204 [Oct 2010] when oral bisphosphonates cannot be used.
- Xgeva: This presentation is indicated for reduction of bone damage in patients with bone metastases from breast and solid tumours (other than prostate cancer) in line with NICE TA265 [Oct 2012].
Supplementation of at least calcium 500 mg and Vitamin D 400 units daily should also be taken unless hypercalcaemia is present.
MHRA/CHM advice: Denosumab: atypical femoral fractures (February 2013)
MHRA/CHM advice: Denosumab: minimising the risk of osteonecrosis of the jaw; monitoring for hypocalcaemia—updated recommendations (September 2014) and Denosumab: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Denosumab: reports of osteonecrosis of the external auditory canal (June 2017)
MHRA/CHM advice: Denosumab (Xgeva®) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation (June 2018)
MHRA/CHM advice: Denosumab (Xgeva®) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronic acid (zoledronate) (June 2018) |
13.02.01.01 |
Dermalo®bath emollient |
2nd Line
Pack size 500ml
NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)
NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs
|
13.02.01 |
Dermol®500 lotion |
Light with Antimicrobial Effect
Pack size 500ml
Self Care Medicine-Available OTC self care.
|
13.02.01.01 |
Dermol®600 bath emollient |
Emollient bath and shower preparations with antimicrobial effect
4th Line
Pack size 600ml
NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)
NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs
|
13.02.01 |
Dermol®cream |
Creamy with Antimicrobial Effect
Pack size 100g, 500g
Self Care Medicine-Available OTC for self care.
|
09.01.03 |
Desferrioxamine mesilate |
500mg powder for solution for injection vials |
06.05.02 |
Desmopressin |
Tablets 100mcg Tablets 200mcg DDAVP 4mcg/ml Solution for Injection Nasal Spray 10mcg/dose Desmomelt Oral Lyophilisates 120mcg Desmomelt Oral Lyophilisates 240mcg DDAVP Intranasal Solution 100mcg/ml drops
For Licensed Indications, please refer to individual formulations as per BNF
Generic tablets now cover all indications. Children requiring an intranasal dose of less than 10 micrograms should be given DDAVP® intranasal solution. |
07.04.02 |
Desmopressin acetate |
Desmopressin acetate 100mcg tablets Desmopressin acetate 200mcg tablets
Noqdirna - Desmopressin acetate 25mcg oral lyophilisate tablets Noqdirna - Desmopressin acetate 50mcg oral lyophilisate tablets
DDAVP Melt - Desmopressin acetate 60mcg oral lyophilisate tablets DDAVP Melt - Desmopressin acetate 120mcg oral lyophilisate tablets DDAVP Melt - Desmopressin acetate 240mcg oral lyophilisate tablets
DesmoMelt - Desmopressin acetate 120mcg oral lyophilisate tablets DesmoMelt - Desmopressin acetate 240mcg oral lyophilisate tablets
DDAVP® and Desmotabs ® tablets may be crushed. |
07.03.02 |
Desogestrel |
Desogestrel 75mcg tablets
Administration can be delayed for 12 hours without loss of contraceptive effect. |
09.06.04 |
Desunin® Colecalciferol |
Maintenance dose (without calcium)
Desunin®Colecalciferol 400unit tablets |
06.03.02 |
Dexamethasone |
Dexamethasone Tablets 500mcg Dexamethasone Tablets 2mg
Dexamethasone Soluble tablets 2mg, 4mg and 8mg
Oral Solution 400mcg/1ml, 2mg/1ml and 4mg/1ml - Very expensive(Applicable in Primary care only)
If a liquid preparation is needed, please precribe the soluble tablets as it is much more cost effective. Tablets must be dispersed in at least 50ml of water prior to swallowing. |
11.04.01 |
Dexamethasone Maxidex® |
Dexamethasone 0.1% eye drops Minims Dexamethasone sodium phosphate 0.1% eye drops (0.5ml unit dose) |
11.04.01 |
Dexamethasone Ozurdex® |
Ozurdex® 700micrograms intravitreal implant
Restriction: In line with NICE Guidance only

|
12.01.01 |
Dexamethasone with framycetin & gramicidin Sofradex® |
Sofradex®- Dexamethasone 0.05%, Framycetin Sulphate 0.5%, Gramicidin 0.005% ear/eye drops |
12.01.01 |
Dexamethasone with neomycin and glacial acetic acid Otomize® |
Otomize®spray - Dexamethasone 0.1%, Neomycin Sulphate (3250 units per mL) and Glacial Acetic Acid 2% ear spray |
04.04 |
Dexamfetamine Sulfate |
Dexamfetamine Sulfate Tablet 5mg
Restriction: Initiation and stabilisation by specialist
Link to ESCA |
04.07.02 |
Diamorphine Hydrochloride |
Diamorphine Hydrochloride 10mg Tablets
Diamorphine Hydrochloride 5mg Powder for Soln for Injection Ampoules Diamorphine Hydrochloride 10mg Powder for Soln for Injection Ampoules Diamorphine Hydrochloride 30mg Powder for Soln for Injection Ampoules Diamorphine Hydrochloride 100mg Powder for Soln for Injection Ampoules
Diamorphine Hydrochloride 500mg Powder for Soln for Injection Ampoules |
04.01.02 |
Diazepam |
Diazepam Tablet 2mg Diazepam Tablet 5mg Diazepam Tablet 10mg Diazepam 2mg/5ml Oral Solution SF
CSM Advice: Hypnotics and Anxiolytics are indicated for the short-term relief of sleep disturbance and/or anxiety. (For continuous use up to a maximum of 14 days). |
04.08.02 |
Diazepam |
Diazepam Solution 5mg/2.5ml Rectal Tube Diazepam Solution 10mg/2.5ml Rectal Tube Diazepam Injection 10mg/2ml Amps
Use IV and Rectal solution for Status Epilepticus |
10.02.02 |
Diazepam |
Diazepam 2mg tablets Diazepam 5mg tablets Diazepam 10mg tablets Diazepam 2mg/5ml oral suspension Diazepam 2mg/5ml oral solution SF
|
10.01.01 |
Diclofenac |
Diclofenac 25mg E/C tablet Diclofenac 50mg E/C tablet Diclofenac 50mg tablet Diclofenac 75mg MR tablet and capsule Diclofenac 100mg MR tablet and capsule Diclofenac 12.5mg suppositories Diclofenac 25mg suppositories Diclofenac 50mg suppositories Diclofenac 100mg suppositories Diclofenac 75mg/3ml solution for injection ampoules
Paediatrics only |
10.01.01 |
Diclofenac |
Diclofenac 25mg E/C tablet Diclofenac 50mg E/C tablet Diclofenac 50mg tablet Diclofenac 75mg MR tablet and capsule Diclofenac 100mg MR tablet and capsule Diclofenac 12.5mg suppositories Diclofenac 25mg suppositories Diclofenac 50mg suppositories Diclofenac 100mg suppositories Diclofenac 75mg/3ml solution for injection ampoules
Diclofenac is now contraindicated in those with: ischaemic heart disease; peripheral arterial disease; cerebrovascular disease; or established congestive heart failure (New York Heart Association [NYHA] classification II-IV). Naproxen and ibuprofen are preferred when NSAIDs are indicated. |
01.02 |
Dicycloverine |
Dicycloverine Hydrochloride 10mg/5ml Oral Solution Dicycloverine Hydrochloride 10mg Tablet Dicycloverine Hydrochloride 20mg Tablet
Please note very expensive. ONLY to be used for patients with swallowing difficulties. (Applicable in Primary care only) |
08.03.01 |
Diethylstilbestrol |
Diethylstilbestrol 1mg tablets Diethylstilbestrol 5mg tablets
|
13.04 |
Diflucortolone valerate 0.3% Nerisone®Forte |
Very potent
Nerisone®Forte ointment 15g Nerisone®Forte oily cream 15g |
02.01.01 |
Digibind® |
Restriction: Consultant use only |
02.01.01 |
Digifab® |
Restriction: Consultant use only |
02.01.01 |
Digoxin |
Digoxin 62.5microgram Tablet Digoxin 125microgram Tablet Digoxin 250microgram Tablet Digoxin 50microgram/mL Elixir
For plasma-digoxin concentration assay, blood should be taken at least 6 hours after a dose. Toxicity increased by electrolyte disturbances. |
02.03.02 |
Digoxin also 02.01.01 |
Digoxin 62.5microgram Tablet Digoxin 125microgram Tablet Digoxin 250microgram Tablet Digoxin 50microgram/mL Elixir
For plasma-digoxin concentration assay, blood should be taken at least 6 hours after a dose. Toxicity increased by electrolyte disturbances. |
04.07.02 |
Dihydrocodeine Tartrate |
Dihydrocodeine Tartrate Tablet 30mg
Standard release preparations only |
02.06.02 |
Diltiazem Hydrochloride |
Diltiazem Hydrochloride 60mg Tablet - FIRST LINE. For administration three times a day. No requirement for brand name prescribing.
Modified- release formulations should be prescribed by brand name.
Drug discontinuations Slozem® 120mg, 180mg, 240mg and 300mg capsules* –discontinued from December 2019 (stock should run out by end of Feb 2020). |
08.02.04 |
Dimethyl fumarate Tecfidera® |
Restriction: In line with NICE Guidance only |
13.05.03 |
Dimethyl Fumarate Skilarence® |
Skilarence® 30mg G/R tablets Skilarence® 120mg G/R tablets
Restriction: In line with NICE Guidance only |
07.04.04 |
Dimethyl sulphoxide bladder instillation 50% |
Restriction: Named patient supply; requires consultant letter.
Unlicensed medicine
|
07.01.01 |
Dinoprostone |
Prostin E2 - Dinoprostone 3mg vaginal tablet Prostin E2 - 1mg Dinoprostone 400microgram/1ml vaginal gel Prostin E2 - 2mg Dinoprostone 800microgram/1ml vaginal gel Propess - Dinoprostone 10mg vaginal delivery system
Note: Prostin E2 Vaginal tablets and Vaginal Gel are not bioequivalent. |
08.01.05 |
Dinutuximab beta Qarziba® |
Restriction: In line with NICE Guidance only |
13.02.01 |
Diprobase ®cream |
Creamy (equivalent to Epaderm® Cream)
3rd Line
Pack size 50g, 500g
Self Care Medicine-Available OTC for self care.
|
02.09 |
Dipyridamole |
Dipyridamole M/R Capsule 200mg Dipyridamole Oral Suspension 50mg/5ml SF
There is a difference in indication between the modified-release preparation of dipyridamole and the standard-release tablets and liquid.
National recommendations for secondary prevention of occlusive vascular events recommend the use of modified-release dipyridamole, according to the licensed indications. |
06.06.02 |
Disodium pamidronate |
15mg/1ml Solution for Infusion Amps 30mg/2ml Solution for Infusion Amps 60mg/4ml Solution for Infusion Amps 90mg/6ml Solution for Infusion Amps
For Osteolytic lesions and bone pain in bone metastases associated with breast cancer or multiple myeloma, and hypercalcemia of malignancy.
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
02.03.02 |
Disopyramide |
Disopyramide 100mg Capsule Disopyramide 150mg Capsule
Restriction: Initiation by cardiologist only |
04.10.01 |
Disulfiram |
Restriction: Initiation by substance abuse unit, no prescribing by General Practice
Patients with alcohol dependence should be referred using the GP surgeries clinical systems online referral form.
- Staffordshire CCG’s – Humankind - Staffordshire treatment and recovery service (STARS) – Link to website
- Stoke-on-Trent CCG – North Staffordshire Combined Healthcare – Community drug and alcohol service (CDAS) - Link to website
|
13.05.02 |
Dithranol Dithrocream® |
Dithrocream®0.1% cream 50g Dithrocream®0.25% cream 50g Dithrocream®0.5% cream 50g Dithrocream®1% cream 50g Dithrocream®2% cream 50g
Dithranol should not be used in people with acute or pustular psoriasis or inflamed psoriasis. Avoid using dithranol on the face.
Prescription only medicine if dithranol content more than 1%, otherwise may be sold to the public.
|
02.07.01 |
Dobutamine |
5mg/mL solution for infusion vials 12.5mg/mL concentrate for solution for infusion ampoules |
08.01.05 |
Docetaxel |
Restriction: In line with NICE Guidance only |
01.06.02 |
Docusate sodium |
Docusate sodium 100mg Capsule Docusate sodium 50mg/5ml SF Oral Solution Docusate sodium Paediatric 12.5mg/5ml SF Oral Solution Docusate sodium Micro-Enema 120mg in 10g unit
- Time to effect is approximately 24 to 48 hours |
01.02 |
Domperidone |
Domperidone 10mg Tablet Domperidone 5mg/5ml SF Oral Suspension
MHRA/CHM advice—Domperidone: risk of cardiac side-effects—restricted indication, new contra-indications, reduced dose and duration of use (May 2014)
MHRA (Dec 2019): Domperidone is no longer licensed for use in children younger than 12 or those weighing less than 35 kg. |
04.06 |
Domperidone |
Domperidone Oral Suspension SF 1mg/ml Domperidone (as Domperidone maleate) Tablet 10mg
Babies and children up to 18 years
MHRA (Dec 2019): Domperidone is no longer licensed for use in children younger than 12 or those weighing less than 35 kg. |
04.06 |
Domperidone |
Domperidone (as Domperidone maleate) Tablet 10mg
The MHRA has advised that there is a small risk of serious ventricular arrhythmia and sudden cardiac death with domperidone.
MHRA advice: Domperidone- risk of cardiac side-effects (Dec 2014)
MHRA (Dec 2019): Domperidone is no longer licensed for use in children younger than 12 or those weighing less than 35 kg. |
04.11 |
Donepezil |
Donepezil HCl Tablet 5mg Donepezil HCl Tablet 10mg Donepezil HCl Orodispersible Tablet 5mg Donepezil HCl Orodispersible Tablet 10mg
|
02.07.01 |
Dopamine |
40mg/mL solution for infusion ampoules 160mg/mL solution for infusion ampoules |
02.07.01 |
Dopexamine Dopacard® |
50mg/5mL concentrate for solution for infusion |
03.07 |
Dornase Alfa Pulmozyme® |
Dornase alfa 2.5mg/2.5mL nebuliser liquid
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for Cystic Fibrosis ONLY
FORMULARY CLASSIFICATION:
- Red - for patients commencing treatment after April 2013
- Amber - for patients commencing treatment before April 2013
|
11.06 |
Dorzolomide hydrochloride |
Dorzolomide hydrochloride 20mg/ml eye drops Trusopt®- Dorzolomide hydrochloride 20mg/ml eye drops (0.2ml unit dose) P/free |
03.05.01 |
Doxapram Dopram® |
IV infusion or injection |
02.05.04 |
Doxazosin |
Doxazosin Mesilate 1mg Tablet Doxazosin Mesilate 2mg Tablet Doxazosin Mesilate 4mg Tablet
**Not MR Preparation**. NHS England have advised there should be no prescribing of MR preparation. Patients can be converted to the normal release tablets.
ONLY use when other classes of antihypertensives have been tried, or are contraindicated. |
08.01.05 |
Doxorubicin hydrochloride Caelyx® |
Restriction: In line with NICE Guidance only |
13.06.02 |
Doxycycline |
Doxycycline 50mg capsules Doxycycline 100mg capsules Doxycycline 100mg dispersible tablets Efracea® - Doxycycline 40mg MR capsules (for papulopustular facial rosacea, without ocular involvement)
1st line choice. Counsel on need to minimise sun exposure due to photosensitivity |
02.03.02 |
Dronedarone Multaq® |
Dronedarone 400mg Tablet
Restriction: Initiation by cardiologist only
Link to ESCA
NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)
NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs |
04.06 |
Droperidol |
Restriction: For initiation by specialists in anaesthetics only
Rescue therapy (3rd line antiemetic) for post-operative nausea and vomiting (PONV) in children and adolescents aged 2 – 18 years old who do not respond adequately to dexamethasone or ondansetron (as monotherapy or in combination) |
04.03.04 |
Duloxetine Cymbalta® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
04.07.03 |
Duloxetine Cymbalta® |
Duloxetine (as Duloxetine hydrochloride) Capsule G/R 30mg Duloxetine (as Duloxetine hydrochloride) Capsule G/R 60mg
Restriction: 3rd line for diabetic neuropathy in line with the Non-Malignant Chronic Pain Guide |
13.05.03 |
Dupilumab Dupixent® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Durvalumab Imfinzi® |
Restriction: In line with NICE Guidance only |
06.04.01.02 |
Dydrogesterone Duphaston |
Dydrogesterone Tablets 10mg |
13.02.01 |
E45®cream Hospital only |
Light (low paraffin)
Pack size 50g, 125g, 500g |
09.01.03 |
Eculizumab Soliris® |
Restriction: In line with NICE Guidance only
Restriction: In accordance with NHS England prescribing policy |
02.08.02 |
Edoxaban Lixiana® |
Edoxaban 15mg tablets Edoxaban 30mg tablets Edoxaban 60mg tablets
- Treatment and prevention of DVT and/or PE
- Prevention of stroke and systemic embolism in people with non-valvular AF
If used for DVT or PE it needs to have an initial 5 days of parenteral anticoagulation prescribed.
Restriction: In line with NICE Guidance and locally agreed guidelines
MHRA/CHM advice: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (June 2019) |
13.08.01 |
Efudix® Fluorouracil 5% cream |
Efudix®- Fluorouracil 5% cream 40g
For the treatment of actinic keratosis
1st line for superficial basal cell carcinoma
Restriction: Initiation by a consultant dermatologist or GP with a special interest
|
05.03.03.02 |
Elbasvir & Grazoprevir Zepatier® |
Elbasvir & Grazoprevir Tablets 50/100mg
Restriction: In line with NICE Guidance This is an NHS England Specialised Commissioning Drug for Hepatitis C
|
09.08.01 |
Elosulfase alfa Vimizim® |
Elosulfase alfa 5mg/5ml concentrate for solution for infusion vials
Restriction: In line with NICE Guidance only
Restriction: In accordance with NHS England prescribing policy |
09.01.04 |
Eltrombopag Revolade® |
Restriction: In line with NICE Guidance
MHRA/CHM advice: Eltrombopag (Revolade®): reports of interference with bilirubin and creatinine test results (July 2018) |
01.04.02 |
Eluxadoline Truberzi® |
Restriction: In line with NICE Guidance only
Initiation and stabilisation in secondary care with referral to primary care after the 1 month follow up in secondary care has taken place.
MHRA/CHM advice: Eluxadoline (Truberzi®): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders (December 2017) |
13.02.01 |
Emollin®spray |
Very Greasy
Restriction: Under specialist advice only
Pack size 150ml, 240ml |
06.01.02.03 |
Empagliflozin Jardiance▼® |
Empagliflozin Tablets 10mg Empagliflozin Tablets 25mg
Restriction: In line with NICE Guidance only
For mono, dual & triple therapy - should not be initiated in patients with an eGFR 2 or CrCl 2 or CrCl below 60 ml/min, the dose of empagliflozin should be adjusted to or maintained at 10 mg once daily. Empagliflozin should be discontinued when eGFR is persistently below 45 ml/min/1.73 m2 or CrCl persistently below 45 ml/min
MHRA/CHM advice (updated April 2016): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 (SGLT2) inhibitors (canagliflozin, dapagliflozin or empagliflozin)
MHRA advice- SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019) |
08.01.05 |
Encorafenib Braftovi® |
Restriction: In line with NICE guidance only |
02.01.02 |
Enoximone |
Restriction: Anaesthetics and CICU only |
09.04 |
Ensure®Compact |
|
09.04 |
Ensure®Plus Milkshake style |
|
09.04 |
Ensure®Plus Juce |
|
09.04 |
Ensure®Shake |
|
09.04 |
Ensure® Plus Advance |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Ensure® Plus Fibre |
Initiation by specialist dietician services prior to continuation within primary care.
|
09.04 |
Ensure® TwoCal |
Initiation by specialist dietician services prior to continuation within primary care. |
04.09.01 |
Entacapone |
Entacapone Tablet 200mg
Restriction: Initiation by specialist |
05.03.03.01 |
Entecavir Monohydrate Baraclude® |
Entecavir Monohydrate Tablets 500mcg Entecavir Monohydrate Tablets 1mg
Restriction: In line with NICE Guidance
This is an NHS England Specialised Commissioning Drug for Hepatitis B |
08.01.05 |
Entrectinib Rozlytrek® |
Restriction: In line with NICE Guidance only |
02.05.05 |
Entresto® Sacubitril with valsartan |
Entresto® 24/26mg Tablet Entresto® 49/51mg Tablet Entresto® 97/103mg Tablet
The proportions are expressed in the form x/y where x and y are the strength in milligrams of sacubitril and valsartan respectively. Valsartan, in this formulation, is more bioavailable than other tablet formulations—26 mg, 51 mg, and 103 mg valsartan is equivalent to 40 mg, 80 mg and 160 mg, respectively.
Restriction: In line with NICE Guidance
To be initiated, titrated and dose stabilised by heart failure specialists ONLY (APC decision Nov 2019)
|
08.03.04.02 |
Enzalutamide Xtandi® |
Restriction: In line with NICE Guidance only
|
02.07.02 |
Ephedrine |
30mg/10mL solution for injection (ampoules or pre-filled syringes) |
12.02.02 |
Ephedrine hydrochloride |
Ephedrine hydrochloride 0.5% nasal drops Ephedrine hydrochloride 1% nasal drops
CHM/MHRA advice: With intranasal use in children
The CHM/MHRA has stated that non-prescription cough and cold medicines containing ephedrine can be considered for up to 5 days’ treatment in children aged 6–12 years after basic principles of best care have been tried; these medicines should not be used in children under 6 years of age.
Maximum duration of 7 days to avoid rebound congestion.
|
13.02.01 |
Epimax ®Original Cream |
Creamy (equivalent to Epaderm® Cream)
1st line
Pack size 100g, 500g
Self Care Medicine-Available OTC for self care.
|
13.02.01 |
Epimax®Isomol Gel |
Rich Cream (equivalent to Doublebase®)
1st line
Pack size 100g, 500g |
02.02.03 |
Eplerenone |
Eplerenone 25mg Tablet Eplerenone 50mg Tablet
Restriction: Initiation by Consultant Cardiologists only for patients who have had an acute myocardial infarction (MI) and who have symptoms and/or signs of heart failure and left ventricular systolic dysfunction |
09.01.03 |
Epoetin Alfa Eprex® |
Restriction: In line with NICE Guidance only
Restriction: In accordance with NHS England prescribing policy
MHRA/CHM advice: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (updated January 2018)
MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin concentration
MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour progression and survival in patients with cancer
|
09.01.03 |
Epoetin Beta NeoRecormon® |
Restriction: In line with NICE Guidance only
Restriction: In accordance with NHS England prescribing policy
MHRA/CHM advice: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (updated January 2018)
MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin concentration
MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour progression and survival in patients with cancer
|
09.01.03 |
Epoetin Zeta Retacrit® |
Restriction: In line with NICE Guidance only
Restriction: In accordance with NHS England prescribing policy
MHRA/CHM advice: Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (updated January 2018)
MHRA/CHM advice (December 2007) Erythropoietins—haemoglobin concentration
MHRA/CHM advice (December 2007 and July 2008) Erythropoietins—tumour progression and survival in patients with cancer
|
02.08.01 |
Epoprostenol Flolan® |
500mcg powder for solution for infusion vials 1.5mg powder for solution for infusion vials
Restriction: Consultant use only
Restriction: In accordance with NHS England prescribing policy
MHRA advice: Veletri (epoprostenol) powder for solution for infusion: incompatibilities with some models of administration devices (December 2014) |
03.07 |
Erdosteine Erdotin® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
07.01.01 |
Ergometrine maleate Syntometrine® |
Syntometrine® contains Oxytocin 5units/ml and Ergometrine maleate 500mcg/ml solution for injection ampoules
|
08.01.05 |
Eribulin Halaven® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Erlotinib hydrochloride Tarceva® |
Restriction: In line with NICE Guidance only
Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012) |
06.01.02.03 |
Ertugliflozin Steglatro® |
Ertugliflozin Tablets 5mg Ertugliflozin Tablets 15mg
Restriction: In line with NICE Guidance only
For mono, dual & triple therapy - should not be initiated in patients with a glomerular filtration rate [GFR] < 60 mL/min and should be discontinued at GFR persistently below 45 mL/min
MHRA/CHM advice (updated April 2016): Risk of diabetic ketoacidosis with sodium-glucose co-transporter 2 (SGLT2) inhibitors
MHRA/CHM advice: SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (February 2019) |
13.06.02 |
Erythromycin |
Erythromycin GR 250mg tablets Erythromycin stearate 500mg tablets Erythormycin ethyl succinate 125mg/5ml oral suspension Erythormycin ethyl succinate 250mg/5ml oral suspension Erythormycin ethyl succinate 500mg/5ml oral suspension
For use in pregnancy, under 12’s and patients with contraindications/intolerance to tetracyclines. |
04.01.02 |
Escitalopram |
Escitalopram 5mg tablets Escitalopram 10mg tablets Escitalopram 20mg tablets Escitalopram 20mg/ml Oral drops
Restriction: For the treatment of Generalised Anxiety Disorder (GAD) only |
04.03.03 |
Escitalopram |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
04.08.01 |
Eslicarbazepine Zebinix® |
Eslicarbazepine Tablets 200mg Eslicarbazepine Tablets 800mg
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
01.03.05 |
Esomeprazole granules |
Restriction: For use in paediatric patients for gastro-oesophageal reflux disease only
Third choice (for those unable to use Omeprazole dispersible and Lansoprazole orodispersible preparations; Expensive) |
02.11 |
Etamsylate Dicynene® |
Etamsylate 500mg tablets
Unlicensed preparation. Available from special-order manufacturers. |
10.01.03 |
Etanercept Enbrel®, Benepali®, Erelzi® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
|
13.05.03 |
Etanercept Enbrel®, Benepali®, Erelzi® |
Restriction: In line with NICE Guidance only
|
09.05.01.02 |
Etelcalcetide hydrochloride Parsabiv® |
2.5mg/0.5ml solution for injection vials 5mg/1ml solution for injection vials 10mg/2ml solution for injection vials
Restriction: In line with NICE Guidance |
04.08.01 |
Ethosuximide |
Ethosuximide Capsules 250mg Ethosuximide Oral Solution 250mg/5ml
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
07.03.02.02 |
Etonorgestrel Nexplanon® |
Nexplanon Implant 68mg
It is strongly recommended that Nexplanon be inserted and removed only by healthcare professionals (HCPs) who have completed training for the use of the Nexplanon applicator and techniques for insertion and removal of the Nexplanon implant, and, where appropriate, that supervision be requested prior to inserting or removing the implant.
FSRH: CEU statement on Nexplanon insertion site (Jan 2020) |
13.03 |
Eurax®cream Crotamiton 10% |
Pack size 30g, 100g
Self Care Medicine-Available OTC for self care.
|
08.01.05 |
Everolimus |
Restriction: In line with NICE Guidance only |
02.12 |
Evolocumab Repatha® |
Restriction: In line with NICE Guidance only |
08.03.04.01 |
Exemestane |
Exemestane 25mg tablets
|
06.01.02.03 |
Exenatide Bydureon® |
Bydureon 2 mg powder and solvent for prolonged-release suspension for injection pre-filled pen
PRODUCT DISCONTINUATION
Bydureon 2 mg powder and solvent for prolonged-release suspension for injection in pre-filled pen (exenatide once-weekly) will be discontinued from 31/12/2020. Clinicians should note that the old device is being replaced by the Bydureon BCise pen (exenatide 2mg prolonged-release injectable suspension); a once weekly, single use, fixed dose pen with a hidden needle that automatically injects the required dose, allowing for simpler administration compared to the old Bydureon device. Prior to prescribing and administration of this new device, patient and caregivers training must be undertaken by a healthcare professional.
Restriction: Only for patients who cannot tolerate twice daily exenatide (Byetta® )
Restriction: Treatment should be initiated by a diabetes specialist clinician and transferred to primary care after six months as long as the patient has had a beneficial metabolic process, i.e. at least a 1% HbA1c reduction AND at least a 3% reduction in weight.
For modified-release injection, avoid if eGFR less than 50 mL/minute/1.73 m2.
|
06.01.02.03 |
Exenatide Byetta® |
Byetta 5micrograms/0.02mL solution for injection 1.2mL pre-filled pen Byetta 10micrograms/0.04mL solution for injection 2.4mL pre-filled pen
Restriction: Treatment should be initiated by a diabetes specialist clinician and transferred to primary care after six months as long as the patient has had a beneficial metabolic process, i.e. at least a 1% HbA1c reduction AND at least a 3% reduction in weight.
For standard-release injection, avoid if eGFR less than 30 mL/minute/1.73 m2. |
13.02.01 |
Exocream® |
Light (low paraffin)
Pack size 50g, 500g |
02.12 |
Ezetimibe Ezetrol® |
Ezetimibe Tablet 10mg
Combined preparation with simvastatin (Inegy®) non-formulary
Use in accordance with locally agreed hyperlipidaemia guidelines
In line with NICE Guidance |
10.02.01 |
Fampridine Fampyra® |
Fampridine 10mg MR tablets
Restriction: In accordance with NHS England prescribing policy
Not routinely commissioned by NHS England for multiple sclerosis except by prior IFR approval |
10.01.04 |
Febuxostat Adenuric® |
Febuxostat 80mg tablets Febuxostat 120mg tablets
Restriction: In line with NICE Guidance
MHRA/CHM advice: Serious hypersensitivity reactions (June 2012) |
02.06.02 |
Felodipine |
Felodipine 2.5mg M/R Tablet Felodipine 5mg M/R Tablet Felodipine 10mg M/R Tablet |
07.03.01 |
Femodene ED® |
Monophasic
Recommendation: - Second Line due to increased risk of thromboembolism |
07.03.01 |
Femodene® |
Monophasic
Recommendation: - Second Line due to increased risk of thromboembolism |
07.03.01 |
Femodette® |
Monophasic
Low strength ethinylestradiol pill
Recommendation: - Second Line due to increased risk of thromboembolism |
07.03.02 |
Femulen® Etynodiol diacetate |
DISCONTINUED
Administration can be delayed for 3 hours without loss of contraceptive effect. |
04.07.02 |
Fentanyl |
Fentanyl Transdermal Patch 12mcg/hr Fentanyl Transdermal Patch 25mcg/hr Fentanyl Transdermal Patch 50mcg/hr Fentanyl Transdermal Patch 75mcg/hr Fentanyl Transdermal Patch 100mcg/hr
Restriction: Patches only.
Prescribe by brand. Cost effective brands include Fencino®, Matrifen® and Mezolar® (Applicable in Primary care only).
NMC/APC Advice (Feb 2006)
Fentanyl patches are an established alternative to oral opioid analgesics & may be useful in:
- Patients with stable/controlled pain unable to swallow medicines, where the subcutaneous route via a syringe driver is not appropriate, and
- Patients with stable/controlled pain unable to remember to take medicines regularly.
Fentanyl patches should only be initiated on the advice of the palliative care team, the UHNM chronic pain team, or via the UHNM pain clinic. |
04.07.02 |
Fentanyl citrate nasal spray PecFent® |
PecFent 100 micrograms/spray nasal spray, solution PecFent 400 micrograms/spray nasal spray, solution
Restriction: For breakthrough pain in head and neck cancer patients during/post radiotherapy
NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). |
04.07.02 |
Fentanyl lozenges Actiq® |
Not approved for inclusion in the North Staffordshire Joint Formulary |
NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017).
|
04.07.02 |
Fentanyl sublingual tablets Abstral® |
Abstral 100 microgram sublingual tablets Abstral 200 microgram sublingual tablets Abstral 300 microgram sublingual tablets Abstral 400 microgram sublingual tablets Abstral 600 microgram sublingual tablets Abstral 800 microgram sublingual tablets
Restriction: Consultant recommendation in palliative, haematology and oncology patients only.
NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). |
09.01.01.02 |
Ferric carboxymaltose Ferinject® |
100mg/2ml solution for injection vials
Restriction: For use in renal patients.
Also for use in haematology, gastroenterology & surgery outpatients and day case patients
MHRA advice: Intravenous iron and serious hypersensitivity reactions- strengthened recommendations (Dec 2014) |
09.01.01.01 |
Ferrous fumarate Galfer® |
Galfer®(ferrous fumarate) 140mg per 5ml syrup (5ml ≡ 45mg of elemental iron) |
09.01.01.01 |
Ferrous gluconate |
Ferrous gluconate 300mg tablets (300 mg contains 35 mg iron) |
09.01.01.01 |
Ferrous sulfate |
Ferrous sulfate 200mg tablets (200 mg is equivalent to 65 mg iron)
Standard release preparations only. Modified-release preparations of iron are licensed for once-daily dosage, but have no therapeutic advantage and should not be used. |
03.04.01 |
Fexofenadine Hydrochloride |
Fexofenadine Hydrochloride 120mg tablets Fexofenadine Hydrochloride 180mg tablets |
06.04.02 |
Finasteride |
Finasteride Tablets 5mg
MHRA/CHM advice: rare reports of depression and suicidal thoughts (May 2017)
Not NHS: Finasteride is not prescribable in NHS primary care for the treatment of androgenetic alopecia in men i.e. using 1mg tablets
|
08.02.04 |
Fingolimod Gilenya® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Multiple sclerosis therapies: signal of rebound effect after stopping or switching therapy (April 2017)
MHRA/CHM advice: Fingolimod—not recommended for patients at known risk of cardiovascular events. Advice for extended monitoring for those with significant bradycardia or heart block after the first dose and following treatment interruption (January 2013)
MHRA/CHM advice: Fingolimod: new contra-indications in relation to cardiac risk (December 2017)
MHRA/CHM advice: Fingolimod: updated advice about risk of cancers and serious infections (December 2017)
MHRA advice (Sep 2019): Fingolimod (Gilenya▼): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception |
02.03.02 |
Flecainide Acetate |
Flecainide Acetate 50mg Tablet Flecainide Acetate 100mg Tablet
Restriction: Initiation under direction of cardiologist |
13.02.01 |
Flexitol ®heel balm Urea 25% |
Creamy with Urea Content
For severe hyperkeratosis
Pack size 40g, 75g |
08.01.03 |
Fludarabine phosphate |
Restriction: In line with NICE Guidance only |
06.03.01 |
Fludrocortisone acetate |
Fludrocortisone acetate Tablets 100mcg |
13.04 |
Fludroxycortide 4micrograms/square cm tape 7.5cm Haelan®tape |
Moderate potency
Pack size 20cm
For chronic localised recalcitrant dermatoses (but not acute or weeping) |
12.01.01 |
Flumetasone pivalate with Clioquinol |
Flumetasone pivalate 0.02%/clioquinol 1% ear drops
Locorten-vioform discontinued, thus generic prescribing please |
11.04.01 |
Fluocinolone acetonide Iluvien® |
Iluvien® 190micrograms intravitreal implant
Restriction: In line with NICE Guidance only
|
13.04 |
Fluocinolone acetonide 0.0025% Synalar®1 in 10 Dilution cream |
Mild potency
Pack size 30g, 100g |
13.04 |
Fluocinolone acetonide 0.00625% Synalar®1 in 4 Dilution |
Moderate potency
Synalar®1 in 4 Dilution cream 50g Synalar®1 in 4 Dilution ointment 50g |
13.04 |
Fluocinolone acetonide 0.025% Synalar® |
Potent
Synalar®cream 50g Synalar®ointment 50g |
13.04 |
Fluocinolone acetonide 0.025% gel Synalar® |
Scalp applications
Potent
Synalar®gel 30g |
13.04 |
Fluocinolone acetonide 0.025% with clioquinol 3% Synalar®C |
Topical corticosteroids with antimicrobials
Potent
Synalar®C cream 15g Synalar®C ointment 15g |
13.04 |
Fluocinolone acetonide 0.025% with neomycin sulfate 0.5% Synalar®N |
Topical corticosteroids with antimicrobials
Potent
Synalar®N cream 30g Synalar®N ointment 30g |
11.08.02 |
Fluorescein sodium Minims® |
Minims Fluorescein sodium 1% eye drops (0.5ml unit dose) Minims Fluorescein sodium 2% eye drops (0.5ml unit dose) |
11.04.01 |
Fluorometholone FML® |
Fluorometholone 0.1% opthalmic suspension |
04.03.03 |
Fluoxetine |
Fluoxetine (as Fluoxetine Hydrochloride) Capsule 20mg Fluoxetine (as Fluoxetine Hydrochloride) Liquid 20mg/5ml (Prescribe Liquid for doses less than 20mg)
1st line SSRI for depression |
04.02.01 |
Flupentixol |
Flupentixol Tablets 500mcg Flupentixol Tablets 1mg Flupentixol Tablets 3mg |
04.02.02 |
Flupentixol decanoate Depixol® |
Flupentixol Decanoate Injection 20mg/ml 1ml Amp Flupentixol Decanoate Injection 20mg/ml 2ml Amp Flupentixol Decanoate Injection 100mg/ml 0.5ml Amp Flupentixol Decanoate Injection 100mg/ml 1ml Amp Flupentixol Decanoate Injection 200mg/ml 1ml Amp
Restriction: Initiation under direction of a psychiatrist |
04.02.02 |
Fluphenazine decanoate Modecate® |
Fluphenazine Decanoate Injection 20mg/ml 5ml Amp Fluphenazine Decanoate Injection 25mg/ml 0.5ml Amp Fluphenazine Decanoate Injection 25mg/ml 1ml Amp Fluphenazine Decanoate Injection 25mg/ml 2ml Amp Fluphenazine Decanoate Injection 100mg/ml 0.5ml Amp Fluphenazine Decanoate Injection 100mg/ml 1ml Amp
Restriction: Initiation under direction of a psychiatrist
(Discontinued by manufacturer by the end of 2018) |
08.03.04.02 |
Flutamide |
Flutamide 250mg tablets |
12.02.01 |
Fluticasone furoate Avamys® |
Avamys®- Fluticasone furoate 27.5microgram/dose nasal spray
2nd line for the treatment and prophylaxis of allergic perennial rhinitis
|
03.02 |
Fluticasone furoate & vilanterol Relvar®Ellipta |
Relvar Ellipta 184mcg/dose / 22mcg/dose DPI (ASTHMA only) Relvar Ellipta 92mcg/dose / 22mcg/dose DPI (ASTHMA and COPD)
For use in both Asthma and COPD |
03.02 |
Fluticasone furoate, vilanterol & umeclidinium Trelegy®Ellipta |
Trelegy Ellipta 92micrograms/dose / 55micrograms/dose / 22micrograms/dose dry powder inhaler Contains three components Fluticasone/Vilanterol/Umeclidinium
For use in COPD only
See APC Advice: The New Medicines Committee acknowledged that locally approved guidelines reflect the GOLD guidelines for management of COPD whereas the licensed indication for Trimbow® and Trelegy® places its use after ICS and LABA. The APC considered this and supported the use of Trimbow® and Trelegy® in line with GOLD and local guidelines; prescribers need to be aware of this. |
03.02 |
Fluticasone propionate & formoterol Flutiform® |
Fluticasone/Formoterol Inhalation 125/5mcg 120D Fluticasone/Formoterol Inhalation 250/10mcg 120D Fluticasone/Formoterol Inhalation 50/5mcg 120 D
For use in Asthma only |
03.02 |
Fluticasone propionate & salmeterol Seretide® |
Fluticasone/Salmeterol Inhalation 50/25mcg 120D Fluticasone/Salmeterol Inhalation 125/25mcg 120D Fluticasone/Salmeterol Inhalation 250/25mcg 120 D
For paediatric use only
Restriction: For use in Asthma only |
12.02.01 |
Fluticasone with azelastine Dymista® |
Dymista®- Fluticasone propionate 50microgram/dose & azelastine hydrochloride 137microgram/dose nasal spray.
2nd line for moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or intranasal glucocorticoid is insufficient.
|
09.01.02 |
Folic acid |
Folic acid 400microgram tablets Folic acid 5mg tablets Folic acid 2.5mg/5ml oral solution SF |
06.05.01 |
Follitropin alfa Gonal-F® |
75 units (powdered vial) 300 units (in 0.5ml pre-filled pen) 450 units (in 0.75ml pre-filled pen)
Restriction: Specialist use only
Fertility drugs should not be prescribed in Primary care. They are funded as part of the fertility treatment and will be provided from the fertility clinic.
Bemfola is an approved biosimilar to the reference product Gonal-F® |
02.08.01 |
Fondaparinux Arixtra® |
Solution for injection pre-filled syringes
Restriction: For patients with unstable angina and non-ST elevation myocardial infarction |
02.08.01 |
Fondaparinux |
Not approved for inclusion in the North Staffordshire Joint Formulary for the prevention and treatment of venous thromboembolic events
|
|
09.04 |
Foodlink Complete® |
|
09.04 |
Foodlink Complete® with Fibre |
Initiation by specialist dietician services prior to continuation within primary care. |
09.06.07 |
Forceval® |
Forceval®capsules
Restriction: Only for use in patients who have undergone bariatric surgery
|
13.07 |
Formaldehyde Veracur® |
Formaldehyde (as formaldehyde solution BP) 0.75% w/w gel, 15g
Self Care Medicine. Available OTC for self care
|
03.01.01.01 |
Formoterol Fumarate |
Formoterol Dry Powder Inhaler 12mcg/actuation (120 dose) Formoterol Easyhaler 12mcg/dose dry powder inhaler (120 dose)
Long Acting Beta2 Adrenoreceptor Agonist Indicated for COPD ONLY.
MHRA/CHM advice: Pressurised metered dose inhalers (pMDI): risk of airway obstruction from aspiration of loose objects (July 2018) |
09.04 |
Fortisip® 2kcal |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fortisip® Compact Fibre |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fortisip® Compact Protein |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fortisip® Extra |
Initiation by specialist dietician services prior to continuation within primary care. |
05.01.13 |
Fosfomycin Monuril® |
Fosfomycin 3g granules sachets.
Restriction: At the recommendation of microbiologist in line with proforma
|
04.07.04.02 |
Fremanezumab |
Restriction: In line with NICE Guidance only |
09.04 |
Fresubin® 2kcal Creme |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fresubin® 3.2kcal Drink |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fresubin® Thickened Level 2 |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fresubin® Thickened Level 3 |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Fresubin® 5kcal Shot |
Initiation by specialist dietician services prior to continuation within primary care. |
04.07.04.01 |
Frovatriptan |
Frovatriptan (as Frovatriptan succinate monohydrate) Tablets 2.5mg
Restriction: For menstrual-related migraine not responding to standard treatment. (As per Anti-Migraine Prescribing Guide)
NICE (CG150) Recommend this for Menstrual-related Migraine. If this is not tolerated then consider Zolmitriptan 2.5mg tablets instead (Unlicensed indication). |
09.06.04 |
Fultium D3® Colecalciferol |
Maintenance dose (without calcium)
Fultium D3®Colecalciferol 800unit capsules |
09.06.04 |
Fultium D3® Colecalciferol |
HIGH DOSE BOOST
Fultium D3®Colecalciferol 20,000unit capsules |
08.03.04.01 |
Fulvestrant Faslodex® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
02.02.02 |
Furosemide |
Furosemide 20mg/5ml S/F Oral Solution Furosemide 40mg/5ml S/F Oral Solution Furosemide 20mg Tablet Furosemide 40mg Tablet
1st line loop diuretic
Monitor Potassium Levels - Risk of Hypokalaemia |
11.03.01 |
Fusidic acid |
Fusidic acid 1% modified-release eye drops
Restriction: 2nd line to chloramphenicol Only covers staphylococcal infections |
13.10.01.02 |
Fusidic acid (sodium fusidate) Fucidin® |
Fusidic acid cream 15g Fusidic acid ointment 15g
Restriction: For acute impetigo, minor infections only
|
04.07.03 |
Gabapentin |
Gabapentin Capsules 100mg Gabapentin Capsules 300mg Gabapentin Capsules 400mg Gabapentin Tablets 600mg Gabapentin Oral Solution 50mg/ml
As of the 1st April 2019 Gabapentin is re-classified as a Schedule 3 Controlled Drug
Restriction: 2nd line in line with the Non-Malignant Chronic Pain Guide
Reserve liquid preparation for patients with swallowing difficulties as expensive. For cost effective prescribing choose generic in non-epileptic indications.(Applicable in Primary care only)
MHRA/CHM advice: Gabapentin (Neurontin®): risk of severe respiratory depression (October 2017)
|
04.07.04.02 |
Gabapentin |
Gabapentin Capsules 100mg Gabapentin Capsules 300mg Gabapentin Capsules 400mg Gabapentin Tablets 600mg Gabapentin Oral Solution 50mg/ml
As of the 1st April 2019 Gabapentin is re-classified as a Schedule 3 Controlled Drug
2nd line (As per Anti-Migraine Prescribing Guide)
MHRA/CHM advice: Gabapentin (Neurontin®): risk of severe respiratory depression (October 2017) |
04.08.01 |
Gabapentin |
Gabapentin Capsules 100mg Gabapentin Capsules 300mg Gabapentin Capsules 400mg Gabapentin Tablets 600mg Gabapentin Oral Solution 50mg/ml
As of the 1st April 2019 Gabapentin is re-classified as a Schedule 3 Controlled Drug
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
04.11 |
Galantamine |
Galantamine Tablet 8mg Galantamine Tablet 12mg Galantamine Tablet 8mg MR Galantamine Tablet 16mg MR Galantamine Tablet 24mg MR
Gatalin XL®, Gazylan XL are preferred cost-effective MR Brands (Applicable in primary care only). |
01.01.02 |
Gaviscon®Advance Liquid |
Self Care Medicine-Available OTC for self-care.
|
01.01.02 |
Gaviscon®Infant Oral Powder Sachets |
Each half of the dual-sachet is identified as ‘one dose’.
To avoid errors prescribe with directions in terms of ‘dose’. |
08.01.05 |
Gefitinib Iressa® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012) |
08.01.03 |
Gemcitabine |
Restriction: In line with NICE Guidance only
|
07.01.01 |
Gemeprost |
Gemeprost 1mg pessaries |
08.01.05 |
Gemtuzumab ozogamicin Mylotarg® |
Restriction: In line with NICE Guidance only |
05.01.04 |
Gentamicin (nebulised) |
80mg/2ml Solution for Injection Amps
Restriction: Non-CF Bronchiectasis. 3rd line only in patients who do not tolerate colistimethate and tobramycin nebules due to bronchospasm and side effect. |
11.03.01 |
Gentamicin 0.3% |
Gentamicin 0.3% ear/eye drops |
12.01.01 |
Gentamicin sulfate Genticin® |
Gentamicin sulfate 0.3% ear/eye drops |
08.01.05 |
Gilteritinib Xospata® |
Restriction: In line with NICE Guidance only |
12.03.05 |
Glandosane®spray |
Glandosane®synthetic saliva spray (natural, peppermint or lemon)
May be prescribed under ACBS for patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.
Spray onto oral and pharyngeal mucosa as required. |
08.02.04 |
Glatiramer acetate Copaxone® |
Restriction: In line with DH drug treatments for multiple sclerosis: risk-sharing scheme (HSC 2002/004) briefing note November 2006
Restriction: In line with NICE Guidance only |
05.03.03.02 |
Glecaprevir & Pibrentasvir Maviret® |
Glecaprevir & Pibrentasvir Tablets 100/40mg
Restriction: In line with NICE Guidance NHS England Commissioned |
06.01.02.01 |
Gliclazide |
Gliclazide Tablets 40mg Gliclazide Tablets 80mg
1st line sulphonylurea
Standard release preparations only |
06.01.04 |
Glucagon GlucaGen® HypoKit |
GlucaGen®HypoKit 1mg powder and solvent for solution for injection |
10.01.05 |
Glucosamine |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). |
06.01.04 |
Glucose |
40% gel (25g triple pack) |
A2.07 |
Glucose |
|
01.06.02 |
Glycerol Glycerin |
Glycerol Suppositories 4g Adult Glycerol Suppositories 2g Children Glycerol Suppositories 1g Infant
Self Care Medicine-Available OTC for self care.
|
01.07.04 |
Glyceryl Trinitrate 0.4% Rectogesic® |
Rectogesic 0.4% Ointment |
02.06.01 |
Glyceryl Trinitrate buccal |
Restriction: Only for regular use in place of IV |
02.06.01 |
Glyceryl Trinitrate patches |
Glyceryl Trinitrate 5mg/24hours patch Glyceryl Trinitrate 10mg/24hours patch
More expensive than Isosorbide mononitrate tablets. |
02.06.01 |
Glyceryl Trinitrate spray |
Glyceryl Trinitrate 400 mcg/spray (180 dose) Glyceryl Trinitrate 400 mcg/spray (200 dose)
For the infrequent user it is more cost effective to have the spray. |
02.06.01 |
Glyceryl Trinitrate sublingual tablets |
Glyceryl Trinitrate 300microgram S/L Tablet Glyceryl Trinitrate 500microgram S/L Tablet Glyceryl Trinitrate 600microgram S/L Tablet
AVOID Suscard Buccal tablets as very expensive. |
01.02 |
Glycopyrronium bromide Sialanar®oral solution |
Sialanar® 320mcg/ml glycopyrronium (equivalent to 400mcg/ml glycopyrronium bromide) - 60mL oral solution, 250mL oral solution.
Restriction: For Initiation and stabilisation by a specialist prior to transferring into primary care |
03.01.02 |
Glycopyrronium Bromide Seebri®Breezhaler |
Glycopyrronium Bromide Inhalation Capsule 55mcg + Device Seebri Breezhaler 44mcg Inhalation Powder Capsules + Device
Long-Acting Antimuscarinic For use in COPD ONLY. |
03.01.04 |
Glycopyrronium bromide & Indacaterol Ultibro®Breezhaler |
Ultibro Breezhaler 85microgram/43microgram inhalation powder capsules with device
Long-Acting Antimuscarinic + Long-Acting Beta2 Adrenorecepter Agonist combination.
For use in COPD only
The combination product offers cost & compliance advantages compared to prescribing LAMA and LABA drugs as separate devices. |
01.05.03 |
Golimumab Simponi® |
Restriction: In line with NICE Guidance only |
10.01.03 |
Golimumab Simponi® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies |
06.05.01 |
Gonadorelin HRF® |
100mcg powder for solution for injection
Restriction: Specialist use only
(Assessment of pituitary function) |
06.07.02 |
Goserelin Zoladex® |
Goserelin 3.8mg Implant SafeSystem pre-filled syringes Goserelin LA 10.8mg Implant SafeSystem pre-filled syringes
Restriction: Initiation under direction of a specialist |
08.03.04.02 |
Goserelin acetate Zoladex® |
Zoladex (goserelin acetate) 3.6mg implant SafeSystem pre-filled syringes - monthly Zoladex LA (goserelin acetate) 10.8mg implant SafeSystem pre-filled syringes -three monthly |
04.06 |
Granisetron |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
03.04.02 |
Grass pollen extract Grazax® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
13.05.03 |
Guselkumab Tremfya® |
Restriction: In line with NICE Guidance only |
04.02.01 |
Haloperidol |
Haloperidol Capsule 500mcg Haloperidol Tablet 1.5mg Haloperidol Tablet 5mg Haloperidol Tablet 10mg Haloperidol Tablet 20mg Haloperidol Oral Solution 5mg/5ml SF Haloperidol Oral Solution 10mg/5ml SF |
04.09.03 |
Haloperidol |
Haloperidol Tablets 0.5mg Haloperidol Tablets 1.5mg Haloperidol Tablets 5mg Haloperidol Tablets 10mg Haloperidol Tablets 20mg Haloperidol Oral Solution 5mg/5ml SF Haloperidol Oral Solution 10mg/5ml SF
Restriction: Initiation by specialist |
04.02.02 |
Haloperidol decanoate Haldol® |
Haloperidol Decanoate Injection 50mg/ml 1ml Amp Haloperidol Decanoate Injection 100mg/ml 1ml Amp
Restriction: Initiation under direction of a psychiatrist |
02.08.01 |
Heparin |
Solution for injection ampoules/ vials All Heparin Infusion bags
These are all hospital only prescribing only. The heparin flushes listed below may be prescribed in primary care. |
02.08.01 |
Heparin unfractionated flushes |
Heparin sodium 50 units/5ml patency solution ampoules Heparin sodium 50 units/5ml i.v flush solution ampoules
Heparin sodium 200 units/2ml patency solution ampoules Heparin sodium 200 units/2ml i.v flush solution ampoules
These are flushes for maintaining patency of peripheral venous catheters- note there are two strengths, so confirm with original specialist which is needed. |
13.13 |
Heparinoid Hirudoid® |
Hirudoid® 0.3% cream 50g Hirudoid® 0.3% gel, 50g |
11.08.02 |
Holoclar® |
Restriction: In line with NICE Guidance only
Not approved for inclusion in the North Staffordshire Joint Formulary:
UHNM is not commissioned to provide this treatment. All appropriate patients should be referred to a tertiary specialist commissioned centre.
|
|
10.03.01 |
Hyaluronidase |
Hyaluronidase 1,500unit powder for solution for injection ampoules |
02.05.01 |
Hydralazine Hydrochloride |
Hydralazine Hydrochloride 25mg Tablet Hydralazine Hydrochloride 50mg Tablet
Can be used for hypertensive emergencies (including in pregnancy) |
01.05.02 |
Hydrocortisone |
Standard release
Hydrocortisone 10mg Tablet
Hydrocortisone 20mg Tablet |
03.04.03 |
Hydrocortisone |
Solution for injection |
06.03.02 |
Hydrocortisone |
Hydrocortisone Standard release 10mg and 20mg tablets Hydrocortisone Sodium Succinate Injection 100mg vial (Solu-Cortef) Hydrocortisone Sodium Phosphate Injection 100mg/ml Amps Hydrocortisone Acetate Suspension for Injection 25mg/ml Amps (Hydrocortistab)
MHRA/CHM advice: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration (August 2017) |
13.04 |
Hydrocortisone 0.5% & 1% |
Mild potency
Hydrocortisone 0.5% cream 15g, 30g Hydrocortisone 0.5% ointment 15g, 30g Hydrocortisone 1% cream 15g, 30g Hydrocortisone 1% ointment 15g, 30g
Hydrocortisone 1% cream Self Care Medicine-Available OTC for self care (Please note exceptions may apply) |
13.04 |
Hydrocortisone 1% with clotrimazole 1% Canesten®HC |
Topical corticosteroids with antimicrobials
Mild potency
Canesten HC®cream 30g
Limit duration of treatment with steroid/antimicrobial combinations; usually twice daily for 1 week. |
13.04 |
Hydrocortisone 1% with miconazole nitrate 2% Daktacort® |
Topical corticosteroids with antimicrobials
Mild potency
Daktacort®cream 30g Daktacort®ointment 30g
Limit duration of treatment with steroid/antimicrobial combinations; usually twice daily for 1 week. |
10.01.02.02 |
Hydrocortisone acetate Hydrocortistab® |
Hydrocortistab® - Hydrocortisone acetate 25mg/1ml suspension for injection ampoules
MHRA/CHM advice: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration (August 2017) |
13.04 |
Hydrocortisone acetate 1% with fusidic acid 2% Fucidin®H |
Topical corticosteroids with antimicrobials
Mild potency
Fucidin®H cream 30g Fucidin®H ointment 30g
Limit duration of treatment with steroid/antimicrobial combinations; usually twice daily for 1 week. |
12.01.01 |
Hydrocortisone acetate with gentamicin sulfate Gentisone HC® |
Hydrocortisone acetate 1% & Gentamicin sulfate 0.3% ear drops |
13.04 |
Hydrocortisone butyrate 0.1% Locoid® |
Potent
Locoid®cream 30g, 100g Locoid®ointment 30g, 100g
|
01.05.02 |
Hydrocortisone foam enema Colifoam® |
Hydrocortisone foam 10% aerosol
1st line rectal preparation |
12.03.01 |
Hydrocortisone sodium succinate Corlan® |
Hydrocortisone sodium succinate 2.5mg muco-adhesive buccal tablets sugar free |
12.03.04 |
Hydrogen peroxide Peroxyl® |
Hydrogen peroxide 1.5% mouthwash (in primary care as Peroxyl®) Hydrogen peroxide 6% solution (in secondary care)
|
13.11.06 |
Hydrogen peroxide |
Hydrogen peroxide 3% solution (10vols) 200ml Hydrogen peroxide 6% solution (20vols) 200ml
Restriction: On specialist advice only
|
13.02.01.01 |
Hydromol ® bath and shower |
3rd Line
Pack size 350ml, 500ml
NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)
NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs
Self Care Medicine-Available OTC for self care.
|
13.02.01 |
Hydromol ®ointment |
Greasy (equivalent to Epaderm® Ointment)
1st line
Pack size 125g, 500g |
09.01.02 |
Hydroxocobalamin |
Hydroxocobalamin 1mg/1ml solution for injection ampoules
|
08.01.05 |
Hydroxycarbamide |
|
10.01.03 |
Hydroxychloroquine sulfate |
Hydroxychloroquine sulfate 200mg tablets
(Rheumatology)
Link to ESCA |
03.04.01 |
Hydroxyzine Hydrochloride |
Hydroxyzine Hydrochloride Tablet 10mg Hydroxyzine Hydrochloride Tablet 25mg Hydroxyzine Hydrochloride Oral Solution 10mg/5ml
MHRA advice: Risk of QT-interval prolongation and torsade de pointes (April 2015) |
01.02 |
Hyoscine Butylbromide |
Hyoscine Butylbromide 10mg Tablet Hyoscine Butylbromide 20mg/1ml Amps for palliative care
MHRA/CHM advice: Hyoscine butylbromide (Buscopan®) injection: risk of serious adverse effects in patients with underlying cardiac disease (February 2017).
Hyoscine butylbromide injection is contra-indicated in patients with tachycardia and should be used with caution in patients with cardiac disease. |
04.06 |
Hyoscine hydrobromide Scopolamine hydrobromide |
Hyoscine hydrobromide Patch 1mg/72 hour Hyoscine hydrobromide Tablets 150mcg Hyoscine hydrobromide Tablets 300mcg
Hyoscine hydrobromide injection is not formulary |
06.06.02 |
Ibandronic acid |
Ibandronic acid Tablets 150mg
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015)
|
06.06.02 |
Ibandronic acid |
Ibandronic acid Tablets 50mg
Restriction: For the prevention of skeletal events in breast cancer and metastatic bone disease only
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
06.06.02 |
Ibandronic acid Bondronat® |
3mg/3ml Solution for Injection Pre-filled Syringes 2mg/2ml Concentrate for Solution for Infusion Vials 6mg/6ml Concentrate for Solution for Infusion Vials
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
08.01.05 |
Ibrutinib Imbruvica® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Ibrutinib (Imbruvica®): reports of ventricular tachyarrhythmia; risk of hepatitis B reactivation and of opportunistic infections (August 2017) |
10.01.01 |
Ibuprofen |
1st line NSAID
Ibuprofen 200mg tablets Ibuprofen 400mg tablets Ibuprofen 100mg/5ml oral suspension Ibuprofen 100mg/5ml oral suspension SF |
10.03.02 |
Ibuprofen gel |
Ibuprofen 5% gel |
03.04.03 |
Icatibant Firazyr® |
30mg/3ml solution for injection pre-filled syringes
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY |
08.01.05 |
Idelalisib Zydelig® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Idelalisib (Zydelig®): Updated indications and advice on minimising the risk of infection (September 2016) |
08.01.05 |
Imatinib mesilate |
Restriction: In line with NICE Guidance only
|
13.07 |
Imiquimod |
Aldara® 5% cream 250mg sachets (12 sachets) Bascellex® 50mg/g cream 250mg sachets (12 sachets)
Restriction: Initiation by specialist for anogenital warts
Should be rubbed in and allowed to stay on the treated area for 6–10 hours for warts, then washed off with mild soap and water (uncircumcised males treating warts under foreskin should wash the area daily). The cream should be washed off before sexual contact. Maximum 16 weeks course length.
|
03.01.01.01 |
Indacaterol Onbrez®Breezhaler |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
02.02.01 |
Indapamide |
Indapamide 2.5mg Tablet
1st line thiazide-like diuretic for hypertension
Indapamide MR is non-formulary |
07.01.01.01 |
Indometacin Indocid PDA® |
Indomethacin 1mg vial
Discontinued - Replaced by Ibuprofen Pedea® 10mg/2ml Injection (Unlicensed use for treatment of PDAs in neonates only) |
10.01.01 |
Indometacin |
Indometacin 25mg capsules Indometacin 50mg capsules
If an NSAID is needed, use ibuprofen (1200mg a day or less) or naproxen (1000mg a day or less)
|
01.05.03 |
Infliximab Flixabi®, Inflectra®, Remicade®, Remsima® |
Restriction: In line with NICE Guidance only |
10.01.03 |
Infliximab Flixabi®, Inflectra®, Remicade®, Remsima® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
Not routinely commissioned by NHS England for Connective tissue disease, interstital lung disease, renal or sarcoidosis except by prior IFR approval. |
13.05.03 |
Infliximab Flixabi®, Inflectra®, Remicade®, Remsima® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Inotuzumab ozogamicin Besponsa® |
Restriction: In line with NICE Guidance only |
06.01.01.01 |
Insulin Humulin®S |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges |
06.01.01.01 |
Insulin Actrapid® |
100 units/ml solution for injection vials |
06.01.01.01 |
Insulin Aspart NovoRapid® |
100 units/ml solution for injection vials 100 units/ml solution for injection pre-filled pen (Flexpen) 100 units/ml solution for injection pre-filled pen (FlexTouch) 100 units/ml solution for injection cartridges (Penfill) 100 units/ml solution for injection cartridges (PumpCart)
Restriction: For use only by practitioners experienced in the use of insulins |
06.01.01.01 |
Insulin Aspart Fiasp® |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges (Fiasp Penfill) 100 units/ml solution for pre-filled pen (Fiasp Flextouch)
Restriction: For use only by practitioners experienced in the use of insulins |
06.01.01.02 |
Insulin degludec Tresiba® |
HIGH STRENGTH
Tresiba Flextouch 200units/ml 3ml pre-filled pen
(Long-acting insulin) |
06.01.01.02 |
Insulin degludec Tresiba® |
Tresiba Penfill 100units/ml 3ml cartridges Tresiba Flextouch 100units/ml 3ml pre-filled pen
(Long-acting insulin) |
06.01.01.02 |
Insulin Detemir Levemir® |
100 units/ml solution for injection prefilled pen (FlexPen) 100 units/ml solution for injection prefilled pen (InnoLet) 100 units/ml solution for injection cartridges (Penfill)
(Long-acting Insulin) |
06.01.01.02 |
Insulin Glargine Toujeo® |
HIGH STRENGTH
Toujeo 300 units/ml solution for injection 1.5ml pre-filled pen (SoloStar)
(Long-acting insulin) |
06.01.01.02 |
Insulin Glargine |
100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (KwikPen)
This is a bio-similar product to insulin glargine. Prescribe by brand name.
Restriction: For use only by practitioners experienced in the use of insulins
(Long-acting insulin) |
06.01.01.02 |
Insulin Glargine Lantus® |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (SoloStar Pen)
Restriction: For use only by practitioners experienced in the use of insulins
(Long-acting insulin) |
06.01.01.01 |
Insulin Glulisine Apidra® |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled Solostar pen
Restriction: For use only by practitioners experiencxed in the use of insulins |
06.01.01.01 |
Insulin Lispro Humalog® |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (Junior KwikPen/ KwikPen)
Restriction: For use only by practitioners experienced in the use of insulins |
06.01.01.01 |
Insulin Lispro Humalog®kwikpen |
HIGH STRENGTH
200 units/ml solution for injection prefilled pen (KwikPen)
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
06.01.01.02 |
Insulin Zinc suspension Hypurin®Bovine Lente |
100 units/ml solution for injection vials
(Long-acting insulin)
DISCONTINUED (July 2017) |
08.02.04 |
Interferon Alfa |
|
08.02.04 |
Interferon Beta |
Restriction: In line with DH drug treatments for multiple sclerosis: risk-sharing scheme (HSC 2002/004) briefing note November 2006
Restriction: In line with NICE Guidance only |
09.06.04 |
Invita D3® Colecalciferol |
HIGH DOSE BOOST
Invita D3®Colecalciferol 25,000unit per 1ml oral solution Invita D3®Colecalciferol 50,000unit per 1ml oral solution |
06.02.02 |
Iodine |
Aqueous iodine oral (Lugol's) solution BP |
13.11.04 |
Iodine |
Weak iodine solution and povidone-iodine
Povidone-Iodine 10% antiseptic solution, 500ml Povidone-Iodine 2.5% dry powder spray, 100ml
Alternative for patients with chlorhexidine intolerance/allergy |
08.01.05 |
Ipilimumab Yervoy® |
Restriction: In line with NICE Guidance only
|
03.01.02 |
Ipratropium Bromide |
Ipratropium Bromide Inhalation Solution 500mcg/2ml Unit Dose Vials Ipratropium Bromide Inhalation 20mcg/dose (200 D) CFC Free Ipratropium Bromide 500mcg/2ml nebs Unit Dose Vials
|
12.02.02 |
Ipratropium bromide Rinatec® |
Rinatec®- Ipratropium bromide 21microgram/dose nasal spray |
02.05.05.02 |
Irbesartan |
Irbesartan 75mg Tablet Irbesartan 150mg Tablet Irbesartan 300mg Tablet
Restriction: For use by renal physicians or as a second-line angiotensin II antagonist |
09.01.01.02 |
Iron dextran CosmoFer® |
100mg/2ml solution for injection Amps
MHRA advice: Intravenous iron and serious hypersensitivity reactions- strengthened recommendations (Dec 2014) |
09.01.01.02 |
Iron Isomaltoside Monofer® |
100mg/mL solution for injection vials
MHRA advice: Intravenous iron and serious hypersensitivity reactions- strengthened recommendations (Dec 2014) |
09.01.01.02 |
Iron sucrose Venofer® |
100mg/5ml solution for injection vials
MHRA advice: Intravenous iron and serious hypersensitivity reactions- strengthened recommendations (Dec 2014)
|
06.01.01.02 |
Isophane Insulin Hypurin® Bovine Isophane |
DISCONTINUED |
06.01.01.02 |
Isophane Insulin Hypurin® Porcine Isophane |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges
(Intermediate-acting insulin) |
06.01.01.02 |
Isophane Insulin Insulatard® |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges (Penfill) 100 units/ml solution for injection prefilled pen (InnoLet)
(Intermediate-acting insulin) |
06.01.01.02 |
Isophane Insulin Humulin® I |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (KwikPen)
(Intermediate-acting insulin) |
06.01.01.02 |
Isophane Insulin Insuman® Basal |
100 units/ml solution for injection vials 100 units/ml solution for injection cartridges 100 units/ml solution for injection prefilled pen (SoloStar Pen)
(Intermediate-acting insulin)
DISCONTINUATION (from May 2020)
Insuman Basal 100IU/mL suspension for injection in a vial (expected end of supply May 2020). Alternative is Humulin I vial, Insuman Basal cartridge/Solostar.
|
02.07.01 |
Isoprenaline |
0.2mg/mL solution for injection ampoule |
02.06.01 |
Isosorbide Mononitrate |
Isosorbide Mononitrate 10mg Tablet Isosorbide Mononitrate 20mg Tablet |
13.06.01 |
Isotretinoin Isotrex® |
Isotrex®- Isotretinoin 0.05% gel
Discontinued
Prescribers to consider alternative topical preparations within the drug class. |
13.06.02 |
Isotretinoin Roaccutane® |
Restriction: Initiation on specialist dermatological advice
Contraindicated in pregnancy.
Each prescription for isotretinoin should be limited to a supply of up to 30 days’ treatment and dispensed within 7 days of the date stated on the prescription; repeat prescriptions or faxed prescriptions are not acceptable.
MHRA/CHM advice: Isotretinoin (Roaccutane®): rare reports of erectile dysfunction and decreased libido (October 2017) |
13.06.01 |
Isotretinoin with erythromycin Isotrexin® |
Topical retinoids and related preparations with antibacterial
Isotrexin®- Isotretinoin 0.05% and erythromycin 2.0% gel 30g |
01.06.01 |
Ispaghula Husk Fybogel®or Ispagel® |
Ispaghula Husk 3.5g Effervescent Granules Sachets GF/SF
- Adequate fluid intake is important to prevent obstruction (6 – 8 cups per day) and should not to be taken immediately before bed - Time to effect is approximately 48 – 72 hours
Self Care Medicine-Available OTC for self care.
|
02.06.03 |
Ivabradine Procoralan® |
Ivabradine 5mg Tablet Ivabradine 7.5mg Tablet
Restriction: In line with NICE Guidance only
MHRA advice on Ivabradine: risk of cardiac side-effects (December 2014) |
03.07 |
Ivacaftor Kalydeco® |
Ivacaftor 150mg tablets
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for Cystic Fibrosis ONLY
  
|
13.06 |
Ivermectin Soolantra® |
Soolantra®10mg/g cream
Restriction: 2nd line treatment for papulopustular rosacea if treatment with topical metronidazole has failed
Provide a 4 month course initially and review after 3 months. The course may be repeated if required. |
08.01.05 |
Ixazomib Ninlaro® |
Restriction: In line with NICE Guidance only |
10.01.03 |
Ixekizumab Taltz® |
Restriction: In line with NICE Guidance |
13.05.03 |
Ixekizumab Taltz® |
Restriction: In line with NICE Guidance only |
07.03.01 |
Katya 30/75® |
Monophasic
Recommendation: - Second Line due to increased risk of thromboembolism |
13.09 |
Ketoconazole |
Ketoconazole 2% shampoo 120ml
Self Care Medicine. Available OTC for self care
|
13.10.02 |
Ketoconazole Nizoral® |
Nizoral® - Ketoconazole 2% cream 30g
Restriction: For treatment of seborrhoeic dermatitis and pityriasis versicolor only (primary care prescriptions should be endorsed ‘SLS’ i.e Nizoral® cream)
|
11.08.02 |
Ketorolac trometamol Acular® |
Ketorolac trometamol 0.5% eye drops |
02.04 |
Labetalol Hydrochloride |
Labetalol Hydrochloride 50mg Tablet Labetalol Hydrochloride 100mg Tablet Labetalol Hydrochloride 200mg Tablet Labetalol Hydrochloride 400mg Tablet
Also licensed for Hypertension in Pregnancy |
04.08.01 |
Lacosamide Vimpat ® |
Vimpat 50 mg film-coated tablets Vimpat 100 mg film-coated tablets Vimpat 150 mg film-coated tablets Vimpat 200 mg film-coated tablets Vimpat Syrup 10mg/ml
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
01.06.04 |
Lactulose |
Lactulose 3.1g-3.7g/5ml Solution
- Tolerence may develop with continued use - Better than stimulant laxative in diverticular disease - Time to effect is approximately 24 to 48 hours.
Self Care Medicine-Available OTC for self care.
|
04.08.01 |
Lamotrigine |
Lamotrigine Tablet 25mg Lamotrigine Tablet 50mg Lamotrigine Tablet 100mg Lamotrigine Tablet 200mg Lamotrigine Tablet Dispersible 5mg S/F Lamotrigine Tablet Dispersible 25mg S/F Lamotrigine Tablet Dispersible 100mg S/F
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
03.04.03 |
Lanadelumab Takhzyro® |
300mg/2mL solution for injection vial
Restriction: In line with NICE guidance only
This is an NHS England Specialised Commissioning Drug for preventing attacks of hereditary angioedema
|
08.03.04.03 |
Lanreotide acetate |
Restriction: In accordance with NHS England prescribing policy
- Acromegaly
- Cancer indication
- Congenital hyperinsulism
Somatuline® LA (lanreotide acetate) 30mg powder and solvent for suspension for injection vials
Somatuline® Autogel (lanreotide acetate) 120mg per 1ml solution for injection pre-filled syringes with safety system
Somatuline® Autogel (lanreotide acetate) 180mg per 1ml solution for injection pre-filled syringes with safety system
Somatuline® Autogel (lanreotide acetate) 240mg per 1ml solution for injection pre-filled syringes with safety system
|
08.03.04.03 |
Lanreotide acetate |
- Non NHS England indications i.e. palliative care
Somatuline® LA (lanreotide acetate) 30mg powder and solvent for suspension for injection vials
Somatuline® Autogel (lanreotide acetate) 120mg per 1ml solution for injection pre-filled syringes with safety system
Somatuline® Autogel (lanreotide acetate) 180mg per 1ml solution for injection pre-filled syringes with safety system
Somatuline® Autogel (lanreotide acetate) 240mg per 1ml solution for injection pre-filled syringes with safety system
|
01.03.05 |
Lansoprazole |
Lansoprazole 15mg (G/R Granules) Capsule Lansoprazole 30mg (G/R Granules) Capsule Lansoprazole Orodispersible 15mg Tablet Lansoprazole Orodispersible 30mg Tablet
2nd line PPI
(Orodispersible 1st line in patients with enteral feeding tubes or swallowing difficulties) |
09.05.02.02 |
Lanthanum carbonate Fosrenol® |
For the treatment of Hyperphosphataemia
Fosrenol®Lanthanum carbonate 500mg chewable tablets Fosrenol®Lanthanum carbonate 750mg chewable tablets Fosrenol®Lanthanum carbonate 1gram chewable tablets Fosrenol®Lanthanum carbonate 750mg oral powder sachets Fosrenol®Lanthanum carbonate 1gram oral powder sachets
Commissioned by NHS England when used for adult renal dialysis
Link to ESCA |
08.01.05 |
Larotrectinib |
Restriction: In line with NICE Guidance only
|
11.06 |
Latanoprost |
Latanoprost 50microgram/ml eye drops
1st line Prostaglandin analogue
|
11.06 |
Latanoprost with timolol |
Latanoprost 50microgram/ml & Timolol 5mg/ml eye drops |
05.03.03.02 |
Ledipasvir & Sofosbuvir Harvoni® |
Ledipasvir & Sofosbuvir Tablets 90/400mg
Restriction: In line with NICE Guidance This is an NHS England Specialised Commissioning Drug for Hepatitis C
|
10.01.03 |
Leflunomide |
Leflunomide 10mg tablets Leflunomide 20mg tablets
Link to ESCA
|
08.02.04 |
Lenalidomide Revlimid® |
Restriction: In line with NICE Guidance only
Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form. |
09.01.06 |
Lenograstim Granocyte® |
13.4 mega unit vial and pre-filled syringe 33.6 mega unit vial and pre-filled syringe.
Restriction: Specialist use only
Granocyte® solution for injection contains 105 micrograms of lenograstim per 13.4 mega unit vial and 263 micrograms lenograstim per 33.6 mega unit vial. |
08.01.05 |
Lenvatinib |
Restriction: In line with NICE Guidance only |
05.03.02.02 |
Letermovir Prevymis® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy |
08.03.04.01 |
Letrozole |
Letrozole 2.5mg tablets |
08.03.04.02 |
Leuprorelin acetate |
Prostap SR DCS (leuprorelin acetate) 3.75mg powder and solvent for suspension for injection pre-filled syringes - monthly
Prostap 3 DCS (leuprorelin acetate) 11.25mg powder and solvent for suspension for injection pre-filled syringes - three monthly
|
04.08.01 |
Levetiracetam |
Levetiracetam Tablet 250mg Levetiracetam Tablet 500mg Levetiracetam Tablet 750mg Levetiracetam Tablet 1gram Levetiracetam Oral Solution 500mg/5ml S/F
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
04.09.01 |
Levodopa and carbidopa with entacapone |
Stanek 50 mg/12.5 mg/200 mg Stanek 75 mg/18.75 mg/200 Stanek 100 mg/25 mg/200 mg Stanek 125 mg/31.25 mg/200 mg Stanek 150 mg/37.5 mg/200 mg Stanek 175 mg/43.75 mg/200 mg Stanek 200 mg/50 mg/200 mg
Stanek® (equivalent to Stalevo®) is the preferred cost-effective brand (Applicable in primary care). |
11.03.01 |
Levofloxacin Oftaquix® |
Levofloxacin 5mg/ml eye drops
Restriction: Initiation by Consultant Ophthalmologist only |
05.01.12 |
Levofloxacin nebuliser solution Quinsair® |
240mg Nebuliser Solution Amps
Restriction: CF - In line with NHSE Commissioning Policy
This is a Specialised Drug which would not be routinely commissioned by CCGs for Cystic Fibrosis. This would go through the CCGs Individual Funding Request (IFR).
MHRA advice- Fluoroquinolones (March 2019):
- systemic (by mouth, injection, or inhalation) fluoroquinolones can very rarely cause long-lasting (up to months or years), disabling, and potentially irreversible side effects, sometimes affecting multiple systems, organ classes, and senses
- advise patients to stop treatment at the first signs of a serious adverse reaction, such as tendinitis or tendon rupture, muscle pain, muscle weakness, joint pain, joint swelling, peripheral neuropathy, and central nervous system effects, and to contact their doctor immediately for further advice.
|
04.02.01 |
Levomepromazine Methotrimipramine |
Levomepromazine Tablets 25mg Levomepromazine solution for injection ampoules 25mg/ml
Restriction: For use in Palliative Care
|
07.03.05 |
Levonogrestrel |
Levonelle 1500microgram tablets
Do not prescribe Levonelle One Step as more expensive and it is an OTC preparation. Prescribe as Levonorgestrel 1.5mg tablets.
See APC/NMC recommendation |
07.03.02.03 |
Levonorgestrel Levosert® |
Levosert® 20 mcg/24 hours intrauterine delivery system
1st line for Heavy Menstrual Bleeding (HMB) in women requiring reversible contraception. Not to be used for Contraception.
The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.
MHRA/CHM advice (June 2015) Intra-uterine contraception: uterine perforation—updated information on risk factors |
07.03.02.03 |
Levonorgestrel Mirena® |
Mirena® 20 mcg/24 hours intrauterine delivery system
The doctor or nurse administering (or removing) the system should be fully trained in the technique and should provide full counselling reinforced by the patient information leaflet.
MHRA/CHM advice (June 2015) Intra-uterine contraception: uterine perforation—updated information on risk factors |
06.02.01 |
Levothyroxine sodium |
Levothyroxine sodium 25microgram Tablets Levothyroxine sodium 50microgram Tablets Levothyroxine sodium 100microgram Tablets
Levothyroxine sodium Oral Solution 5mcg/1ml, 10mcg/1ml and 20mcg/1ml - Very expensive (Applicable in primary care only). |
04.07.03 |
Lidocaine 5% plasters Versatis® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). |
02.03.02 |
Lidocaine Hydrochloride |
Restriction: Initiation under direction of cardiologist |
01.06.07 |
Linaclotide |
Restriction: To be initiated by Gastroenterologist when conventional treatments are not effective and transferred to Primary Care following review after initial 4 weeks |
06.01.02.03 |
Linagliptin Trajenta® |
Linagliptin Tablets 5mg |
06.02.01 |
Liothyronine |
Liothyronine Tablets 20microgram
Liothyronine Tablets 5microgram (Unlicensed)
Only to be presribed for clinically appropriate patients after specialist initiation when Levothyroxine not clinically tolerated.
20–25 micrograms of liothyronine sodium is equivalent to approximately 100 micrograms of levothyroxine sodium.
NHS England has identified this product as an item that should not be routinely prescribed in primary care (July 2017). Although this drug is clinically effective, there are more cost-effective products are available. |
13.02.01 |
Liquid and White Soft Paraffin Ointment (50:50) |
Very Greasy
Pack size 250g, 500g
Self Care Medicine-Available OTC self care.
|
06.01.02.03 |
Liraglutide Victoza® |
Liraglutide 6 mg/ml 3ml prefilled pen
Restriction: Liraglutide should be used second line to exenatide in patients where exenatide is not tolerated or not effective (i.e. exenatide twice daily (Byetta® ) was not effective OR exenatide twice daily (Byetta® ) was not tolerated and exenatide once weekly (Bydureon® ) was not effective).
Patients should receive at least 3 months of exenatide before liraglutide is prescribed. Treatment should be initiated by a diabetes specialist clinician and transferred to primary care after 6 months treatment with liraglutide as long as the patient has had a beneficial metabolic process, i.e. at least a 1% HbA1c reduction AND at least a 3% reduction in weight |
04.02.03 |
Lithium Carbonate Prescribe by brand |
Prescribe by Brand and maintain patient on the same Brand
Current Brands Available: Camcolit, Lithonate, Liskonum and Priadel Tablets
Restriction: Initiation by psychiatrist
Note change in bioavailability when changing from Tablets to Liquid. Note Lithium citrate tetrahydrate 520 mg (liquid) is equivalent to lithium carbonate 204 mg (tablet).
Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment (Lithium Carbonate)
Link to ESCA |
04.02.03 |
Lithium Citrate |
Prescribe by Brand and maintain patient on the same Brand
Current Brands Available: Priadel Liquid and Li-liquid
Restriction: Initiation by psychiatrist
Note change in bioavailability when changing from Tablets to Liquid. Note Lithium citrate tetrahydrate 520 mg (liquid) is equivalent to lithium carbonate 204 mg (tablet).
Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment (Lithium Carbonate).
Link to ESCA |
07.03.01 |
Loestrin 20® |
Monophasic
Low Strength ethinylestradiol pill
DISCONTINUED |
07.03.01 |
Loestrin 30® |
Monophasic
DISCONTINUED |
04.03.01 |
Lofepramine |
Lofepramine Hydrochloride Tablet 70mg
1st line TCA for depression |
04.10.03 |
Lofexidine BritLofex® |
Lofexidine Tablets 200mcg
Restriction: Initiation by substance abuse specialist only |
07.03.01 |
Logynon ED® |
Triphasic |
07.03.01 |
Logynon® |
Triphasic |
01.04.02 |
Loperamide Hydrochloride |
Loperamide Hydrochloride 2mg Capsule Loperamide Hydrochloride 1mg/5ml Oral Solution
MHRA/CHM advice: reports of serious cardiac adverse reactions with high doses of loperamide associated with abuse or misuse (September 2017) |
03.04.01 |
Loratadine |
Loratadine Oral Solution 5mg/5ml Loratadine Tablet 10mg
Self Care Medicine- Available OTC for self-care
|
04.01.02 |
Lorazepam |
Lorazepam Tablet 1mg Lorazepam Tablet 2.5mg Lorazepam Tablet 500mcg
CSM Advice: Hypnotics and Anxiolytics are indicated for the short-term relief of sleep disturbance and/or anxiety. (For continuous use up to a maximum of 14 days). |
04.08.02 |
Lorazepam |
Lorazepam Injection 4mg/ml Amp Lorazepam Oral Solution 1mg/ml SF Lorazepam Tablets 1mg Lorazepam Tablets 2.5mg
|
08.01.05 |
Lorlatinib |
Restriction: In line with NICE Guidance only
|
02.05.05.02 |
Losartan Potassium |
Losartan Potassium 12.5mg Tablet Losartan Potassium 25mg Tablet Losartan Potassium 50mg Tablet Losartan Potassium 100mg Tablet
Restriction: For hypertension in line with NICE Guidance CG127 |
09.01.04 |
Lusutrombopag Mulpleo® |
Restriction: In line with NICE Guidance only |
08.03.04.03 |
Lutetium (177Lu) oxodotreotide |
Restriction: In line with NICE Guidance only
Lutathera 370 MBq/mL solution for infusion |
13.06.02 |
Lymecycline |
Lymecycline 408mg capsules
Alternative choice to patients experiencing side-effects with doxycycline. |
01.06.04 |
Macrogol oral paediatric powder |
CosmoCol Paediatric oral powder 6.9g sachets is the preferred brand (applies to primary care) |
01.06.04 |
Macrogol oral powder Laxido®or Movicol® |
Compound Oral Powder Sachet NPF S/F
Prescribe generically |
09.05.01.03 |
Magnesium aspartate Magnaspartate® |
Magnesium aspartate 243mg (magnesium 5mmol) oral powder 5g sachets (contains magnesium aspartate 6.5 g (10 mmol Mg2+)/sachet)
For the acute treatment of mild to moderate hypomagnesaemia. For chronic hypomagnesaemia and for maintenance therapy, specialist advice should be sought.
|
09.05.01.03 |
Magnesium sulfate |
Magnesium sulfate 50% (magnesium 2mmol/ml) solution for injection ampoules |
13.10.04 |
Malathion Derbac-M® |
Derbac-M® - Malathion 0.5% liquid 50ml,100ml
Self Care Medicine. Available OTC for self care
|
02.02.05 |
Mannitol |
Mannitol 10% infusion Mannitol 15% infusion Mannitol 20% infusion
For mannitol 20%, an in-line filter is recommended (15-micron filters have been used). |
03.07 |
Mannitol inhalation Bronchitol ® |
Inhalation powder capsules with device
Restriction: In line with NICE Guidance only
This is an NHS England Specialised Commissioning Drug for Cystic Fibrosis. |
07.03.01 |
Marvelon® |
Monophasic
Recommendation: - Second Line due to increased risk of thromboembolism
|
01.02 |
Mebeverine Hydrochloride |
Mebeverine Hydrochloride 135mg Tablet
Standard release preparations only |
06.07.04 |
Mecasermin Increlex® |
Mecasermin 40mg/4ml Solution for Injection Vials
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for Growth Failure.
MHRA advice: Mecasermin- risk of benign and malignant neoplasia (Jan 2020) |
06.04.01.02 |
Medroxyprogesterone Provera® |
Medroxyprogesterone Acetate Tablets 5mg (Climanor®) Medroxyprogesterone Acetate Tablets 2.5mg, 5mg, 10mg, 100mg, 200mg, 400mg (Provera®) |
07.03.02.02 |
Medroxyprogesterone acetate Depo-Provera® |
Medroxyprogesterone Acetate Injection 150mg/ml pre-filled syringe Medroxyprogesterone Acetate Injection 150mg/ml vial |
08.03.02 |
Medroxyprogesterone acetate |
Medroxyprogesterone acetate 2.5mg tablets Medroxyprogesterone acetate 5mg tablets Medroxyprogesterone acetate 10mg tablets Medroxyprogesterone acetate 100mg tablets Medroxyprogesterone acetate 200mg tablets Medroxyprogesterone acetate 400mg tablets |
08.03.02 |
Megestrol Acetate |
Imported - Megestrol acetate 40mg tablets (unlicensed) Megace® - Megestrol acetate 160mg tablets
Megace® tablets are scored, and can be split to make required doses. |
04.01.01 |
Melatonin Circadin® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
10.01.01 |
Meloxicam |
Meloxicam 7.5mg tablets Meloxicam 15mg tablets
If an NSAID is needed, use ibuprofen (1200mg a day or less) or naproxen (1000mg a day or less) |
04.11 |
Memantine Ebixa® |
Memantine HCl Tablet 10mg Memantine HCl Tablet 20mg |
09.06.06 |
Menadiol sodium phosphate |
Menadiol Diphosphate 10mg Tablets
Special order |
03.08 |
Menthol crystals |
Limited clincial value for these products and patients may rather purchase these as OTC products.
Self Care Medicine-Available OTC for self-care.
|
03.04.02 |
Mepolizumab Nucala® |
Restriction: In line with NICE Guidance only
Not approved for inclusion in the North Staffordshire Joint Formulary:
UHNM is not commissioned to provide this treatment. All appropriate patients should be referred to a tertiary specialist commissioned centre.
|
|
01.05.03 |
Mercaptopurine |
Mercaptopurine 50mg Tablet Xaluprine® 20mg/1ml Oral Suspension
For the treatment of Inflammatory Bowel Disease [unlicensed indication]
BNF States : Mercaptopurine tablets and Xaluprine® oral suspension are not bioequivalent, haematological monitoring is advised when switching formulations.
Link to ESCA |
07.03.01 |
Mercilon® |
Monophasic
Low strength ethinylestradiol pill
Recommendation: - Second Line due to increased risk of thromboembolism |
01.05.01 |
Mesalazine |
Octasa MR gastro-resistant 400mg and 800mg Tablet - preferred brand Pentasa MR 500mg Tablet
Prescribe by recommended BRAND.
Other brands – Pentasa, Asacol MR, Salofalk, Mezavant XL. |
01.05.01 |
Mesalazine Foam Enema |
Mesalazine 1g/actuation Foam Enema
|
06.01.02.02 |
Metformin hydrochloride |
Metformin hydrochloride Tablets 500mg Metformin hydrochloride Tablets 850mg Metformin hydrochloride Oral Solution 500mg/5ml SF
1st line |
06.01.02.02 |
Metformin hydrochloride |
Metformin hydrochloride SR 500mg tablets Metformin hydrochloride SR 750mg tablets Metformin hydrochloride SR 1000mg tablets
2nd line in-line with NICE Guidance
Patients taking up to 2 g daily of the standard-release metformin may start with the same daily dose of metformin modified release; not suitable if dose of standard-release tablets more than 2 g daily. |
04.10.03 |
Methadone |
Methadone HCl Mix 1mg/1ml
Restriction: Initiation by substance abuse specialist only |
03.09.01 |
Methadone Hydrochloride Methadone linctus® |
Methadone Linctus 2mg/5mL
Restriction: Palliative Care only
Note: Methadone oral solution 1 mg/mL is 2½ times the strength of Methadone Linctus (2 mg/5mL). |
04.07.02 |
Methadone Hydrochloride |
Methadone Hydrochloride Oral Solution 1mg/ml Methadone Hydrochloride Oral Solution 1mg/ml SF
Restriction: Use in palliative care and substance misuse only |
05.01.13 |
Methenamine Hippurate Hiprex® |
Methenamine Tablets 1gram
1st line therapy for patients presenting with recurrent UTIs to minimise the risk of antibiotic resistance and C. diff infection.
BNF (Less suitable for prescribing): Methenamine (hexamine) hippurate should not generally be used because it requires an acidic urine for its antimicrobial activity and it is ineffective for upper urinary-tract infections; it may, however, have a role in the prophylaxis and treatment of chronic or recurrent uncomplicated lower urinary-tract infections |
01.05.03 |
Methotrexate |
Methotrexate 2.5mg Tablet
For the treatment of Inflammatory Bowel Disease [unlicensed indication]
Prescribe WEEKLY on the same day each week, as 2.5mg strength tablets.
Link to ESCA |
10.01.03 |
Methotrexate |
Methotrexate 2.5mg tablets Methotrexate injection (as pre-filled syringes/ pens/ injectors)- brands include Nordimet®, Zlatal®, Methofill® and Metoject PEN®
Prescribe WEEKLY (on the same day each week); orally as multiples of 2.5mg strength tablets.
Link to ESCA |
13.05.03 |
Methotrexate |
For the treatment of Inflammatory Skin Disease (licensed for severe skin psoriasis)
[unlicensed use in other inflammatory and autoimmune skin conditions i.e. atopic eczema, sarcoidosis, bullous pemphigoid, morphoea etc]
Methotrexate 2.5mg tablets
Prescribe WEEKLY (on the same day each week); orally as multiples of 2.5mg strength tablets.
Link to ESCA |
13.05.03 |
Methotrexate injection |
Methotrexate injection (as pre-filled syringes/ pens/ injectors)- brands include Nordimet®, Zlatal®, Methofill® and Metoject PEN®
Prescribe WEEKLY (on the same day each week)
Restriction: Initiation on specialist dermatological advice
|
02.05.02 |
Methyldopa |
Methyldopa 125mg Tablet - Considerably more costly than others Methyldopa 250mg Tablet Methyldopa 500mg Tablet
If methyldopa was used during pregnancy, stop within 2 days of birth (NICE CG107). |
01.06.06 |
Methylnaltrexone |
Restriction: Palliative care use only |
04.04 |
Methylphenidate hydrochloride |
Restriction: Initiation and stabilisation by specialist
Note Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of methylphenidate, prescribers should specify the brand to be dispensed.
Medicines for children leaflet: Methylphenidate for ADHD
Link to ESCA |
06.03.02 |
Methylprednisolone |
Methylprednisolone Tablets 2mg (Medrone) Methylprednisolone Tablets 4mg (Medrone) Methylprednisolone Tablets 16mg (Medrone) Methylprednisolone Tablets 100mg (Medrone)
Methylprednisolone Sodium Succinate Injection 40mg/ml Vial (Solu-Medrone) Methylprednisolone Sodium Succinate Injection 500mg/8ml Vial (Solu-Medrone) Methylprednisolone Sodium Succinate Injection 1g/16ml Vial (Solu-Medrone)
Methylprednisolone Acetate Susp for Injection 40mg/ml Vial (Depo-Medrone) Methylprednisolone Acetate Susp for Injection 80mg/2ml Vial (Depo-Medrone)
MHRA/CHM advice: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration (August 2017)
MHRA/CHM advice: Methylprednisolone injectable medicine containing lactose (Solu-Medrone® 40 mg): do not use in patients with cows’ milk allergy (October 2017) |
10.01.02.02 |
Methylprednisolone acetate Depo-Medrone® |
Depo-Medrone®- Methylprednisolone acetate 40mg/1ml suspension for injection vials (1ml, 2ml AND 3ml vial)
MHRA/CHM advice: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration (August 2017) |
01.02 |
Metoclopramide |
Metoclopramide 10mg Tablet Metoclopramide 5mg/5ml Oral Solution Metoclopramide 5mg/1ml 2ml Amp
MHRA/CHM advice—Metoclopramide: risk of neurological adverse effects—restricted dose and duration of use (August 2013)
Caution for <20 year olds. MHRA advises that length of treatment should be no longer than 5 days |
04.06 |
Metoclopramide Hydrochloride |
Metoclopramide Hydrochloride Tablet 10mg Metoclopramide Hydrochloride Injection 10mg/2ml Amps
Standard release preparations only
MHRA/CHM advice—Metoclopramide: risk of neurological adverse effects—restricted dose and duration of use (August 2013)
Caution for <20 year olds. MHRA advises that length of treatment should be no longer than 5 days |
02.02.01 |
Metolazone |
Metolazone 2.5mg Tablet Metolazone 5mg Tablet
Restriction: Initiation under direction of secondary care
Available from "special-order" manufacturers or specialist-importing companies. |
02.04 |
Metoprolol Tartrate |
Metoprolol Tartrate 50mg Tablet Metoprolol Tartrate 100mg Tablet |
13.06 |
Metronidazole Rozex® |
1st line treatment for papulopustular rosacea
Metronidazole 0.75% cream or gel
Acea®, Anabact®, Rozex® brands are more cost-effective. |
13.10.01.02 |
Metronidazole gel/ cream |
Metronidazole 0.75% gel Metronidazole 0.75% cream (more cost effective)
Acea®, Anabact®, Rozex® brands are more cost-effective.
|
13.08.01 |
Metvix® Methyl-5-aminolevulinate cream |
Metvix 160mg/g cream |
06.07.03 |
Metyrapone Metopirone® |
Metyrapone Capsules 250mg
- Resistant oedema due to increased aldosterone secretion in cirrhosis, nephrotic syndrome, and congestive heart failure (with glucocorticoid replacement therapy)
|
02.03.02 |
Mexiletine |
Licensed preparation: Namuscla® 167mg hard capsules is reserved for non-dystrophic myotonia and it is not licensed for ventricular arrhythmia. This is an NHS England specialised commissioning medicine.
Unlicensed preparation: Mexiletine 50mg, 100mg and 200mg capsules are unlicensed and only available from ’special-order’ manufacturers or specialist importing companies. For treatment of life-threatening ventricular arrhythmias (using the unlicensed preparations ONLY).
Restriction: Initiation under direction of cardiologist for VT
APC decision (August 2019): RAG rating change- reclassified as a Red drug (secondary care prescribing only). |
12.03.02 |
Miconazole Daktarin® |
Daktarin®miconazole 20mg/g oromucosal gel
MHRA advice: Topical miconazole, including oral gel: reminder of potential for serious interactions with warfarin.
Self Care Medicine. Available to purchase over the counter for fungal and associated bacterial infections of the mouth and throat in adults and children 4 months and over.
1 measuring spoon (provided) is equivalent to 124 mg miconazole per 5mL gel. |
13.10.02 |
Miconazole Daktarin® |
Daktarin®- Miconazole 2% cream 30g
Self Care Medicine. Generic product is available to purchase from the pharmacy.
|
07.02.02 |
Miconazole nitrate Gyno-Daktarin® |
Miconazole vaginal cream 2% Miconazole vaginal capsule 1200mg
Second line option where clotrimazole not tolerated or ineffective |
07.03.01 |
Microgynon 30 ED® |
Monophasic |
07.03.01 |
Microgynon 30® |
Monophasic |
07.03.02 |
Micronor® Norethisterone |
DISCONTINUED
Administration can be delayed for 3 hours without loss of contraceptive effect. |
04.08.02 |
Midazolam buccal Buccolam® |
Buccolam Pre-filled Syringe 0.5ml(2.5mg) Buccolam Pre-filled Syringe 1ml(5mg) Buccolam Pre-filled Syringe 1.5ml(7.5mg) Buccolam Pre-filled Syringe 2ml(10mg)
Only Licensed for patients between 3 months and 18 years of age. For patients over 18 years of age, Buccolam may be used off-label.
|
08.01.05 |
Midostaurin Rydapt ® |
Restriction: In line with NICE Guidance only |
08.02.04 |
Mifamurtide Mepact® |
Restriction: In line with NICE Guidance only |
07.01.02 |
Mifepristone Mifegyne® |
Mifepristone 200mg tablets |
02.01.02 |
Milrinone |
Restriction: Anaesthetics and CICU only |
07.03.04 |
Mini TT 380®Slimline |
Banded coil (Copper sleeves).
For minimum uterine length 5cm; replacement every 5 years. |
07.04.02 |
Mirabegron Betmiga® |
Mirabegron MR 25mg tablets Mirabegron MR 50mg tablets
1st line where there is established cognitive impairment/risk factors for dementia, and 3rd line due to unacceptable anticholinergic side effects.
Restriction: In line with NICE Guidance only
Mirabegron is now contra-indicated in patients with severe uncontrolled hypertension (MHRA October 2015) |
04.03.04 |
Mirtazapine |
Mirtazapine Tablet 15mg Mirtazapine Tablet 30mg Mirtazapine Tablet 45mg Mirtazapine Orodispersible Tablet 15mg Mirtazapine Orodispersible Tablet 30mg Mirtazapine Orodispersible Tablet 45mg |
01.03.04 |
Misoprostol |
Misoprostol 200microgram Tablet
For specialist initiation only |
07.01.01 |
Misoprostol |
Mysodelle - Misprostol 200microgram vaginal delivery system (7mcg/hr) Misoprostol 200microgram vaginal tablets Topogyne - Misoprostol 400microgram tablets
MHRA/CHM advice: Misoprostol vaginal delivery system (Mysodelle®): reports of excessive uterine contractions (tachysystole) unresponsive to tocolytic treatment (February 2018) |
04.04 |
Modafinil Provigil® |
Modafinil Tablet 100mg Modafinil Tablet 200mg
Restriction: Initiation by specialist
MHRA/CHM advice: Modafinil: potential risk of congenital malformations during pregnancy (February 2020) |
12.02.01 |
Mometasone furoate |
Mometasone furoate 50microgram/dose nasal spray
2nd line for the treatment and prophylaxis of allergic perennial rhinitis. Recommendation: Licensed for the treatment of nasal polyps
|
03.03.02 |
Montelukast Singulair® |
Montelukast 10mg Tablets Montelukast 4mg Chewable Tablets SF Montelukast 5mg Chewable Tablets SF Montelukast 4mg Granules Sachets SF
MHRA advice (Sep 2019): Montelukast (Singulair): reminder of the risk of neuropsychiatric reactions |
04.07.02 |
Morphine |
Zomorph Capsule 10mg M/R Zomorph Capsule 30mg M/R Zomorph Capsule 60mg M/R Zomorph Capsule 100mg M/R Zomorph Capsule 200mg M/R
Prescribe by brand to avoid medication errors. Zomorph is the preferred cost-effective brand of MR Morphine [12 hourly formulation] (Applicable in Primary care only). |
03.09.01 |
Morphine Hydrochloride |
Restriction: Palliative Care only |
04.07.02 |
Morphine Sulfate - Oral Solution |
Morphine Sulfate Oral Solution 10mg/5ml (POM) Morphine Sulfate Oral Solution 20mg/1ml (Controlled Drug) |
01.06.05 |
Moviprep® |
2nd line |
13.10.01.01 |
Mupirocin 2% Bactroban® |
Bactroban®- Mupirocin 2% cream 15g Bactroban®- Mupirocin 2% ointment 15g
Restriction: On specialist advice for the treatment of MRSA minor skin infection
|
08.02.01 |
Mycophenolate Mofetil |
Mycophenolate mofetil 250mg capsules Mycophenolate mofetil 500mg tablets Mycophenolate mofetil 200mg per 1ml oral suspension
MHRA/CHM advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018)
Link to ESCA (for renal transplant pts) |
08.02.01 |
Mycophenolate Mofetil |
All post-transplant immunosuppressants are RED for patients newly prescribed these medicines from April 2013
Mycophenolate mofetil 250mg capsules Mycophenolate mofetil 500mg tablets Mycophenolate mofetil 200mg per 1ml oral suspension
MHRA/CHM advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018)
|
10.01.03 |
Mycophenolate mofetil |
Mycophenolate mofetil 250mg capsules Mycophenolate mofetil 500mg tablets Mycophenolate mofetil 200mg per 1ml oral suspension
MHRA/CHM advice: Mycophenolate mofetil, mycophenolic acid: updated contraception advice for male patients (February 2018)
Link to ESCA (for rheumatology pts) |
13.02.01 |
Myribase®gel |
Rich Cream (equivalent to Doublebase®)
2nd Line
Pack size 100g, 500g |
10.01.01 |
Nabumetone |
Nabumetone 500mg tablets
If an NSAID is needed, use ibuprofen (1200mg a day or less) or naproxen (1000mg a day or less). |
03.07 |
N-acetylcysteine NACSYS® |
1st Line
Brand specific prescribing only- as NACSYS®
Preferred choice of mucolytic liquid. Use in preference to carbocisteine liquid/carbocisteine sachets for patients with swallowing difficulty. |
06.07.02 |
Nafarelin Synarel® |
Nafarelin Nasal Spray 200mcg/dose
Restriction: Initiation under direction of a specialist
Fertility drugs should not be prescribed in Primary care. They are funded as part of the fertility treatment and will be provided from fertility clinic. |
02.06.04 |
Naftidrofuryl Oxalate |
Naftidrofuryl Oxalate 100mg Capsule
Restriction: In line with NICE Guidance
Cilostazol, pentoxifylline and inositol nicotinate are not recommended for the treatment of intermittent claudication in people with peripheral arterial disease. NICE TA 223 |
01.06.06 |
Naldemedine Rizmoic® |
Naldemedine 200microgram Tablet
Restriction: In line with NICE Guidance only
|
04.10.01 |
Nalmefene |
Restriction: In line with NICE Guidance only
Restriction: Initiation by substance abuse unit, no prescribing by General Practice
Note: Not to be prescribed in hospital
Patients with alcohol dependence should be referred using the GP surgeries clinical systems online referral form.
- Staffordshire CCG’s – Humankind - Staffordshire treatment and recovery service (STARS) – Link to website
- Stoke-on-Trent CCG – North Staffordshire Combined Healthcare – Community drug and alcohol service (CDAS) - Link to website
|
01.06.06 |
Naloxegol |
Naloxegol 12.5mg Tablet
Naloxegol 25mg Tablet
Restriction: In line with NICE Guidance only |
04.10.03 |
Naltrexone Nalorex® |
Naltrexone Tablets 50mg
Restriction: Initiation by substance abuse unit only |
10.01.01 |
Naproxen |
Naproxen 250mg tablets Naproxen 500mg tablets
Standard release preparations only
|
12.02.03 |
Naseptin® Chlorhexidine hydrochloride with neomycin sulfate |
Naseptin®- Chlorhexidine hydrochloride 0.1%/neomycin sulfate 0.5% nasal cream
Restriction: For eradication or suppression of nasal carriage of staphylococci, if staphylococcus is resistant to mupirocin or patient allergic to mupirocin
Contains arachis (peanut) oil so should not be used in patients with a peanut allergy. Patients with soya allergy should also avoid Naseptin® |
08.02.04 |
Natalizumab Tysabri® |
Restriction: In line with NICE Guidance only |
02.04 |
Nebivolol |
Nebivolol 2.5mg Tablet (more cost-effective to use half a 5mg tablet) Nebivolol 5mg Tablet
Restriction: For patients who cannot tolerate Bisoprolol for heart failure
Does not offer any additional benefit over established beta blockers that are available at a lower aquisition cost. |
04.07.01 |
Nefopam Hydrochloride Acupan® |
Nefopam Hydrochloride Tablets 30mg
Restriction: Initiation only if recommended by specialist |
11.03.01 |
Neomycin As Neosporin® |
Neosporin® contains gramicidin and polymyxin B
(Neomycin Sulfate, (equivalent to 1.75 mg neomycin base), Polymyxin B Sulfate equal to 10,000 Polymyxin B units, Gramicidin, 0.025 mg) |
10.02.01 |
Neostigmine |
Neostigmine bromide 15mg tablets Neostigmine metilsulfate 2.5mg/1ml solution for injection ampoules (Hospital only) |
11.08.02 |
Nepafenac Nevanac® |
Nepafenac 1mg/ml eye drops Nepafenac 3mg/ml eye drops
Restriction: Reduction of postoperative macular oedema associated with cataract surgery in diabetic patients, previous uveitis, vein occlusions and complicated surgery |
08.03.04.01 |
Neratinib Nerlynx® |
Restriction: In line with NICE Guidance only |
02.06.03 |
Nicorandil |
Nicorandil 10mg Tablet Nicorandil 20mg Tablet
MHRA advice on Nicorandil (Ikorel): now second-line treatment for angina- risk of ulcer complications (January 2016) |
09.06.02 |
Nicotinamide |
Nicotinamide 500mg Tablets (unlicensed) |
04.10.02 |
Nicotine replacement therapy |
1st line for smoking cessation.
Restriction: As part of a smoking cessation programme or during inpatient stay only.
Nicotine replacement therapy is funded by Public Health. GPs should not routinely prescribe; patients should be directed to a local provider of stop smoking services to access support and treatment.
Self Care Medicine-Available OTC for self-care.
|
02.06.02 |
Nifedipine |
Different versions of modified-release preparations may not have the same clinical effect. To avoid confusion between these different formulations of nifedipine, prescribers should specify the brand to be dispensed.
Modified-release formulations may not be suitable for dose titration in hepatic disease. As per BNF
Drug discontinuations Adalat 5mg immediate release capsules* –discontinued from February 2019. Adalat 10mg immediate release capsules* – discontinued after March 2019 Adalat Retard 10mg modified release tablets – discontinued after November 2018 Adalat Retard 20mg modified release tablets – discontinued August 2018 Adalat LA 20mg*, 30mg and 60mg prolonged release – discontinued
*Bayer is the main supplier of these products.
See UKMI memo below on treatment alternatives. |
08.01.05 |
Nilotinib Tasigna® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice (May 2016): Risk of hepatitis B virus reactivation with tyrosine kinase inhibitors |
02.06.02 |
Nimodipine Nimotop® |
Nimodipine 30mg Tablet
Restriction: For subarachnoid haemorrhage |
08.01.05 |
Nintedanib esilate |
Restriction: In line with NICE Guidance only |
08.01.05 |
Niraparib Zejula® |
Restriction: In line with NICE Guidance only |
05.01.13 |
Nitrofurantoin |
Nitrofurantoin Cap 50mg Nitrofurantoin Tab 100mg Nitrofurantoin Cap 100mg Nitrofurantoin Cap 100mg M/R Nitrofurantoin Oral Susp 25mg/5ml S/F- Significantly expensive item (Applicable in Primary care only)
We advise prescribing the 100mg MR twice daily as it is more cost effective, associated with better compliance and less gastric side effects than normal release preparations.
Nitrofurantoin is now recommended over trimethoprim as a first-line choice for uncomplicated urinary tract infections, where clinically appropriate (NICE NG109, Oct 2018). |
08.01.05 |
Nivolumab Opdivo® |
Restriction: In line with NICE Guidance only
MHRA advice (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation |
02.07.02 |
Noradrenaline / Norepinephrine |
Solution for infusion ampoules/ vials |
06.04.01.02 |
Norethisterone |
Norethisterone Tablets 5mg |
07.03.02 |
Norgeston® Levonorgestrel 30 microgam |
Administration can be delayed for 3 hours without loss of contraceptive effect. |
07.03.02 |
Noriday® Norethisterone 350 microgram |
Administration can be delayed for 3 hours without loss of contraceptive effect
Suitable alternative to discontinued Micronor |
07.03.01 |
Norimin® |
Monophasic
|
07.03.01 |
Norinyl-1® |
Monophasic
High strength oestrogen pill - suitable for women taking liver enzyme-inducing drugs.
Recommendation: - Second Line due to increased risk of thromboembolism.
|
07.03.04 |
Nova-T® 380 |
Not banded (copper in stem only) coil.
For uterine length 6.5-9cm; replacement every 5 years. |
04.07.04.01 |
NSAIDs |
Ibuprofen Tablets 200mg Ibuprofen Tablets 400mg Ibuprofen Tablets 600mg Ibuprofen 100mg/5ml Oral Solution SF
Naproxen Tablets 250mg Naproxen Tablets 500mg
Recommendation for NSAIDs: As per Anti-Migraine Prescribing Guide
If an NSAID is needed, use ibuprofen (1200mg a day or less) or naproxen (1000mg a day or less). Use lowest effective dose and the shortest duration of treatment necessary to control symptoms.
Self Care Medicine- Available OTC for Self-care (Ibuprofen only)
|
10.02 |
Nusinersen Spinraza ® |
Restriction: In line with NICE Guidance only
|
A2.05.02 |
Nutilis Clear Nutilis® |
175g tin (ACBS)
This is the North Staffordshire's preferred thickener of choice.
For thickening of liquids or foods in dysphagia. Not suitable for children under 3 years. Formulation: Powder , dried glucose syrup, xanthan gum, guar gum, gluten- and lactose-free.
Gum based products are generally preferred as they thicken to a more stable end point (unlike starch based products, they do not continue thickening over time) and provide a smoother texture, which improves acceptability and palatability for patients |
09.04 |
Nutilis® Complete Crème Level 3 |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Nutilis® Complete Drink Level 3 |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Nutilis® Fruit Level 4 |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Nutricrem |
Initiation by specialist dietician services prior to continuation within primary care. |
07.02.02 |
Nystatin |
CREAM DISCONTINUED
Currently available in combination as Nystatin 100,000 units/g with Chlorhexidine Hydrochloride 1% cream |
12.03.02 |
Nystatin oral suspension |
Nystatin 100,000unit/ml oral suspension |
13.10.02 |
Nystatin cream |
Nystatin cream discontinued in UK 2008
An alternative product is Nystatin 100,000 units/g with Chlorhexidine Hydrochloride 1%, 30g or a similar product within the drug class. |
01.09.01 |
Obeticholic acid |
Restriction: In line with NICE Guidance only Not approved for inclusion in the North Staffordshire Joint Formulary: UHNM is not commissioned to provide this treatment. All appropriate patients should be referred to a tertiary specialist commissioned centre.
|
|
08.02.03 |
Obinutuzumab Gazyvaro® |
Restriction: In line with NICE Guidance only |
08.02.03 |
Ocrelizumab Ocrevus® |
Restriction: In line with NICE Guidance only |
11.08.02 |
Ocriplasmin Jetrea® |
Restriction: In line with NICE Guidance only |
08.03.04.03 |
Octreotide acetate |
Restriction: In accordance with NHS England prescribing policy
- Acromegaly
- Cancer indication
- Congenital hyperinsulism
Octreotide acetate 50microgram per 1ml solution for injection ampoules
Octreotide acetate 50microgram per 1ml solution for injection ampoules Octreotide acetate 50microgram per 1ml solution for injection pre-filled syringes
Octreotide acetate 100microgram per 1ml solution for injection ampoules Octreotide acetate 100microgram per 1ml solution for injection pre-filled syringes
Octreotide acetate 500microgram per 1ml solution for injection ampoules Octreotide acetate 500microgram per 1ml solution for injection pre-filled syringes
Octreotide acetate 1mg per 5ml solution for injection vials
Sandostatin® LAR 10mg powder and solvent for injection vials Sandostatin® LAR 20mg powder and solvent for injection vials Sandostatin® LAR 30mg powder and solvent for injection vials |
08.03.04.03 |
Octreotide acetate |
- Non NHS England indications i.e. palliative care
Octreotide acetate 50microgram per 1ml solution for injection ampoules Octreotide acetate 50microgram per 1ml solution for injection pre-filled syringes
Octreotide acetate 100microgram per 1ml solution for injection ampoules Octreotide acetate 100microgram per 1ml solution for injection pre-filled syringes
Octreotide acetate 500microgram per 1ml solution for injection ampoules Octreotide acetate 500microgram per 1ml solution for injection pre-filled syringes
Octreotide acetate 1mg per 5ml solution for injection vials
Sandostatin® LAR 10mg powder and solvent for injection vials Sandostatin® LAR 20mg powder and solvent for injection vials Sandostatin® LAR 30mg powder and solvent for injection vials |
07.02.01 |
Oestrogens, Topical |
Ovestin® cream (Estriol 1mg/g) is the preferred choice. Estriol 0.01% cream Vagifem®- Estradiol Vaginal Tablet 10mcg
|
08.02.03 |
Ofatumumab Arzerra® |
Restriction: In line with NICE Guidance only |
11.03.01 |
Ofloxacin Exocin® |
Ofloxacin 0.3% eye drops |
04.02.01 |
Olanzapine |
Olanzapine Tablet 2.5mg Olanzapine Tablet 5mg Olanzapine Tablet 7.5mg Olanzapine Tablet 10mg Olanzapine Tablet 15mg Olanzapine Tablet 20mg Olanzapine Orodispersible Tablet 5mg Olanzapine Orodispersible Tablet 10mg Olanzapine Orodispersible Tablet 15mg
Do not prescribe Oral Lyophilisates preparations - Very Expensive-(Applicable in Primary care only) |
04.02.02 |
Olanzapine embonate ZypAdhera® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
08.01.05 |
Olaparib Lynparza® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Lynparza® (olaparib): Risk of medication errors with new pharmaceutical form (May 2018)
|
08.01.05 |
Olaratumab Lartruvo® |
Restriction: In line with NICE Guidance only
MHRA advice (June 2019): Lartruvo▼ (olaratumab)- withdrawal of the EU marketing authorisation due to lack of efficacy; No new patients should be started on olaratumab therapy. |
12.01.03 |
Olive Oil ear drops |
Olive Oil Ear Drops
Self Care Medicine-Available OTC for self-care. For the removal of earwax. Allow to warm to room temperature before use.
|
02.12 |
Omacor® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
NHS England Guidance for CCGs:
prescribers in primary care should not initiate omega-3 Fatty Acids for any new patient. prescribers should be supported in deprescribing omega-3 Fatty Acids in all patients and, where appropriate, ensure the availability of relevant services to facilitate this change. |
05.03.03.02 |
Ombitasvir, paritaprevir & ritonavir Viekirax® |
Ombitasvir, paritaprevir & ritonavir Tablets 12.5/75/50mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy This is an NHS England Specialised Commissioning Drug for Hepatitis C
|
01.03.05 |
Omeprazole |
Omeprazole 10mg G/R Capsule Omeprazole 20mg G/R Capsule Omeprazole 10mg G/R Tablet Dispersible Omeprazole 20mg G/R Tablet Dispersible
1st line PPI (except for MUPs) |
04.06 |
Ondansetron |
Ondansetron (as Ondansetron hydrochloride) Tablets 4mg Ondansetron (as Ondansetron hydrochloride) Tablets 8mg Ondansetron (as Ondansetron hydrochloride) Injection 4mg/2ml Amps Ondansetron Orodispersible film 4mg (Prescribe as Setofilm®) Ondansetron Orodispersible film 8mg (Prescribe as Setofilm®)
1st Line in secondary care
If patient has swallowing difficulties the most cost effective option for both 4mg and 8mg strength are the Setofilm® orodisperible films as the liquid and generically prescribed orodispersible tablets and melts are more expensive. These must be prescribed by brand Setofilm®.
MHRA advice: Ondansetron- small increased risk of oral clefts following use in the first 12 weeks of pregnancy (Jan 2020) |
04.09.01 |
Opicapone Ongentys® |
Opicapone Capsules 50mg
Restriction: To be used where entacapone is contraindicated, poorly tolerated or poorly effective.
To be initiated only by a Consultant Neurologist or Parkinson’s Disease Nurse. |
09.02.01.02 |
Oral Rehydration Salts Dioralyte® |
Dioralyte®oral powder sachets blackcurrant Dioralyte®oral powder sachets citrus Dioralyte®oral powder sachets plain
Reconstitute 1 sachet with 200mL of water (freshly boiled and cooled for infants); 5 sachets reconstituted with 1 litre of water provide Na+ 60 mmol, K+ 20 mmol, Cl–60 mmol, citrate 10 mmol, and glucose 90 mmol. |
04.05.01 |
Orlistat |
Orlistat Capsule 120mg
Restriction: As part of weight reduction programme only
Initiated ONLY after trial of weight loss. Should not prescribe outside its limited licensed indication. Treatment with orlistat should be discontinued after 12 weeks if less than 5% of the body weight has been lost since the start of therapy |
04.09.02 |
Orphenadrine |
Orphenadrine Oral Solution 50mg/5ml SF |
05.03.04 |
Oseltamivir Tamiflu® |
Oseltamivir Phosphate Capsules 30mg Oseltamivir Phosphate Capsules 45mg Oseltamivir Phosphate Capsules 75mg Oseltamivir Phosphate Oral Suspension 6mg/ml
Only to be prescribed on the recommendation of Public Health England
Restriction: In line with NICE Guidance
Recommended to only prescribe when official notification that influenza is circulating in the Community: to patients in "At Risk" groups, if they present within 36 hours of first symptoms and who can start treatment within 48 hours of the onset of symptoms. |
08.01.05 |
Osimertinib Tagrisso® |
Restriction: In line with NICE Guidance only |
11.04.02 |
Otrivine-Antistin® Antazoline 0.5% with Xylometazoline 0.05% |
Otrivine-Antistin®eye drops
Self Care Medicine-Available OTC for self-care.
|
07.03.01 |
Ovranette® |
Monophasic |
07.03.01 |
Ovysmen® |
Monophasic |
08.01.05 |
Oxaliplatin |
Restriction: In line with NICE Guidance only |
04.08.01 |
Oxcarbazepine Trileptal® |
Oxcarbazepine 150mg Film-coated Tablets Oxcarbazepine 300mg Film-coated Tablets Oxcarbazepine 600mg Film-coated Tablets Oxcarbazepine Oral Solution 60mg/ml
Restriction: Initiation and stabilisation by specialist Maintain patient on specific manufacturer's products. |
11.07 |
Oxybuprocaine hydrochloride Minims® |
Minims Oxybuprocaine hydrochloride 0.4% eye drops (0.5ml unit doses)
|
07.04.02 |
Oxybutynin hydrochloride Immediate release |
Oxybutynin hydrochloride Tablet 2.5mg Oxybutynin hydrochloride Tablet 5mg
Oxybutynin hydrochloride 2.5mg/5ml oral solution sugar free Oxybutynin hydrochloride 5mg/5ml oral solution sugar free
Reserve liquid preparation for patients with swallowing difficulty as expensive.(Applicable in Priamry care)
|
07.04.02 |
Oxybutynin Hydrochloride Kentera® |
Oxybutynin 3.9mg/24hours patch
Restriction: For women unable to tolerate oral medication |
07.04.02 |
Oxybutynin Hydrochloride Lyrinel XL® |
Lyrinel XL®5mg Tablet Lyrinel XL®10mg Tablet |
04.07.02 |
Oxycodone Hydrochloride Prescribe by brand |
Shortec Capsule 5mg Shortec Capsule 10mg Shortec Capsule 20mg
Longtec Tablet 5mg M/R Longtec Tablet 10mg M/R Longtec Tablet 15mg M/R Longtec Tablet 20mg M/R Longtec Tablet 30mg M/R Longtec Tablet 40mg M/R Longtec Tablet 60mg M/R Longtec Tablet 80mg M/R Longtec Tablet 120mg M/R
Oxycodone Hydrochloride Oral Solution 10mg/1ml S/F Oxycodone Hydrochloride Oral Solution 5mg/5ml S/F
Please prescribe the normal release as Shortec® and the modified release as Longtec® as this is more cost effective (Applicable in Primary care only).
Restriction: See NMC/APC Advice
APC/NMC Advice: Oxycodone February 2006 The NMC agreed that in patients who develop marked cognitive side effects from morphine, oxycodone is a useful alternative, and appears to be comparable in efficacy to morphine. Oxycodone should only be prescribed on the advice of the palliative care team, the chronic pain team, or via the UHNM Pain Clinic. |
13.06.02 |
Oxytetracycline |
Oxytetracycline 250mg tablets
Alternative to doxycycline. |
07.01.01 |
Oxytocin Syntocinon® |
Oxytocin 5units/1ml solution for injection ampoules Oxytocin 10units/1ml solution for injection ampoules |
08.01.05 |
Paclitaxel |
Restriction: In line with NICE Guidance only |
08.01.05 |
Palbociclib Ibrance® |
Restriction: In line with NICE Guidance only |
04.02.02 |
Paliperidone Xeplion® |
Paliperidone 50mg/0.5ml suspension for injection pre-filled syringes Paliperidone 75mg/0.75ml suspension for injection pre-filled syringes Paliperidone 100mg/1ml suspension for injection pre-filled syringes Paliperidone 150mg/1.5ml suspension for injection pre-filled syringes
Restriction: For use in secondary care or by community CPN teams under direction of a psychiatrist.
N.B: Xeplion is the monthly depot injection; Trevicta is the three monthly depot injection. |
04.06 |
Palonosetron & netupitant Akynzeo® |
Netupitant/ Palonosetron Capsules 300mg/0.5mg
Restriction: For the prevention of nausea and vomiting in highly emetogenic chemotherapy regimens |
01.09.04 |
Pancreatin Creon® Micro |
100 mg granules = one measured scoopful (scoop supplied with product).
For infants, Creon Micro® granules can be mixed with a small amount of milk on a spoon and administered immediately—granules should not be added to the baby's bottle. |
01.09.04 |
Pancreatin Pancrex® |
Powder
Counsel patient on need for adequate hydration |
01.09.04 |
Pancreatin Creon® 25000 |
Capsules
Counsel patient on need for adequate hydration |
01.09.04 |
Pancreatin Nutrizym® 22 |
Gastro-resistant capsules
Counsel patient on need for adequate hydration Should not be used in children aged 15 years or less with cystic fibrosis
Note: Nutrizym 10 has been discontinued, so can only prescribe Nutrizym 22. |
01.09.04 |
Pancreatin Creon® 10000 |
Capsules
Counsel patient on need for adequate hydration |
01.09.04 |
Pancreatin Pancrex® V |
Tablets Tablets Forte Capsules Powder
Counsel patient on need for adequate hydration Pancrex V powder may be administered via nasogastric tube or gastrostomy tube |
01.09.04 |
Pancreatin Creon® 40000 |
Capsules
Counsel patient on need for adequate hydration
Mylan confirm discontinuation of this strength from June 2019. |
01.09.04 |
Pancreatin Pancrease® HL |
Capsules
Counsel patient on need for adequate hydration Should not be used in children aged 15 years or less with cystic fibrosis |
08.01.05 |
Panitumumab Vectibix® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Severe skin reactions
MHRA/CHM advice: Epidermal growth factor receptor (EGFR) inhibitors: serious cases of keratitis and ulcerative keratitis (May 2012) |
08.01.05 |
Panobinostat Farydak® |
Restriction: In line with NICE Guidance only |
04.07.01 |
Paracetamol |
Paracetamol Tablet 500mg Paracetamol Capsule 500mg - More Expensive than Tablets (Applicable in Primary care only) Paracetamol Tablet Soluble 500mg - More Expensive than Tablets ( Applicable in Primary care only) Paracetamol Oral Solution Paediatric 120mg/5ml Paracetamol Oral Solution Paediatric 120mg/5ml S/F Paracetamol Oral Suspension 250mg/5ml Paracetamol Oral Suspension 250mg/5ml S/F Paracetamol Syrup 120mg/5ml
Oral & rectal preparations |
04.07.04.01 |
Paracetamol |
Paracetamol Tablet 500mg Paracetamol Capsule 500mg - More Expensive than Tablets Paracetamol Tablet Soluble 500mg - More Expensive than Tablets Paracetamol Oral Solution Paediatric 120mg/5ml Paracetamol Oral Solution Paediatric 120mg/5ml S/F Paracetamol Oral Suspension 250mg/5ml Paracetamol Oral Suspension 250mg/5ml S/F Paracetamol Syrup 120mg/5ml
Self Care Medicine - Available OTC for self-care.
|
04.07.01 |
Paracetamol & codeine Co-codamol 30/500 |
Co-Codamol Capsule 30mg/500mg Co-Codamol Tablet 30mg/500mg Co-Codamol Effervescent Tablet 30mg/500mg
Prescribing as separate components allows dosing flexibility and is more cost-effective (Applicable in Primary care only).
Avoid effervescent tablets in patients needing salt-restricted diet. Reserve for patients with swallowing difficulties. |
04.07.01 |
Paracetamol & codeine Co-codamol 8/500 |
Co-Codamol Tablet 8mg/500mg Co-Codamol Effervescent Tablet 8mg/500mg
Please note over the counter (OTC) sale is limited to MAX three days only. |
04.07.01 |
Paracetamol IV |
Paracetamol Solution for Infusion 1g/100ml vials
Restriction: Post-operative pain relief, paediatrics and ITU only |
04.08.02 |
Paraldehyde |
Paraldehyde Injection 5ml - May be given rectally, not for parenteral use. Paraldehyde Rectal solution (Pre-mixed 50:50 - 50% paraldehyde and 50% olive oil).
Unlicensed product.
|
09.06.07 |
Paravit-CF® |
Restriction: Supplementation of Vitamins A, D, E and K for paediatric and adult patients with cystic fibrosis.
Prescribing in primary care to commence once a letter from secondary care is received by the GP recommending that Paravit CF® is commenced, and also detailing which supplements Paravit CF® will be replacing.
Capsules or liquid available |
04.03.03 |
Paroxetine |
Paroxetine (as Paroxetine Hydrochloride) Tablet 20mg Paroxetine (as Paroxetine Hydrochloride) Tablet 30mg Paroxetine (as Paroxetine Hydrochloride) Oral Suspension 10mg/5ml SF
Concern noted due to problems with discontinuation- Associated with a higher risk of withdrawal reactions
|
09.02.01.01 |
Patiromer calcium Veltassa® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Pazopanib Votrient® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Pegaspargase Oncaspar® |
Restriction: In line with NICE Guidance only |
08.02.04 |
Peginterferon Alfa Pegasys® |
Restriction: In line with NICE Guidance only |
08.02.04 |
Peginterferon Beta-1a Plegridy® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Pembrolizumab Keytruda® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Pembrolizumab (Keytruda®): reports of organ transplant rejection (July 2017) |
08.01.03 |
Pemetrexed disodium Alimta® |
Restriction: In line with NICE Guidance only |
09.08.01 |
Penicillamine |
Penicillamine 125mg tablets Penicillamine 250mg tablets
For Wilson's disease only (see seperate entry for rheumatoid arthritis)
|
10.01.03 |
Penicillamine |
Penicillamine 125mg tablets Penicillamine 250mg tablets
For autoimmune rheumatic diseases
Link to ESCA |
07.04.03 |
Pentosan polysulfate sodium Elmiron® |
Elmiron 100mg capsules
Restriction: In line with NICE Guidance only |
01.02 |
Peppermint Oil |
Self Care Medicine-Available OTC for self-care
|
01.01.02 |
Peptac®Liquid Alternative to Gaviscon |
Self Care Medicine-Available OTC for self-care.
Na+ content 3.1 mmol/5ml
|
04.08.01 |
Perampanel Fycompa® |
Perampanel 2mg tablets Perampanel 4mg tablets Perampanel 6mg tablets Perampanel 8mg tablets Perampanel 10mg tablets Perampanel 12mg tablets
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products.
All strengths priced the same so optimise dose for cost effective prescribing.(Applicable in Primary care only) |
02.05.05.01 |
Perindopril erbumine |
Perindopril Erbumine 2mg Tablet Perindopril Erbumine 4mg Tablet Perindopril Erbumine 8mg Tablet
Do not prescribe Perindopril arginine - this is the branded Coversyl version- see NHS england advice below
NHS England Guidance for CCGs
- prescribers in primary care should not initiate perindopril arginine for any new patient.
- prescribers should be supported in deprescribing perindopril arginine in all patients and, where appropriate, ensure the availability of relevant services to facilitate this change.
2nd line ACE inhibitor |
13.10.04 |
Permethrin |
Permethrin 5% cream 30g
BNF designates Lyclear®1% creme rinse as less suitable for prescribing, thus do not prescribe.
Self Care Medicine. Available OTC for self care
|
08.01.05 |
Pertuzumab Perjeta® |
Restriction: In line with NICE Guidance only |
04.07.02 |
Pethidine Hydrochloride |
Pethidine Hydrochloride Tablets 50mg Pethidine Hydrochloride Injection 50mg/1ml Amps Pethidine Hydrochloride Injection 100mg/2ml Amps |
04.03.02 |
Phenelzine Nardil® |
Phenelzine Tablets 15mg
Restriction: Initiation by psychiatrist or GP with a special interest in Mental Health |
02.08.02 |
Phenindione |
Phenindione 10mg tablets Phenindione 25mg tablets
For patients intolerant of warfarin
MHRA/CHM advice: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR (January 2017)
 
|
04.08.01 |
Phenobarbital |
Phenobarbital Tablets 15mg Phenobarbital Tablets 30mg Phenobarbital Tablets 60mg Phenobarbital Elixir 15mg/5ml
Restriction: Initiation and stabilisation by specialist Maintain patient on specific manufacturer's products. |
13.10.04 |
Phenothrin |
Full Marks® - Phenothrin 0.2% lotion (alcohol) Full Marks® - Phenothrin 0.5% liquid (aqueous) Full Marks® - Phenothrin 0.5% mousse (alcohol)
Self Care Medicine-Available OTC for self-care
|
02.07.02 |
Phenylephrine |
Solution for injection ampoules/ pre-filled syringes |
11.05 |
Phenylephrine hydrochloride Minims ® |
Minims Phenylephrine hydrochloride 2.5% eye drops 0.5ml unit dose Minims Phenylephrine hydrochloride 10% eye drops 0.5ml unit dose |
04.08.01 |
Phenytoin |
Phenytoin Sodium Capsule 25mg Phenytoin Sodium Capsule 50mg Phenytoin Sodium Capsule 100mg Phenytoin Sodium Capsule 300mg Phenytoin Sodium Chewable Tablets 50mg Phenytoin Sodium Tablets 100mg Phenytoin Oral Liquid 30mg/5ml
Restriction: Initiation and stabilisation by specialist Maintain patient on specific manufacturer's products.
Additional Information June 2006: Phenytoin 90mg in 15mL suspension may be considered approximately equivalent to capsules containing phenytoin sodium 100mg.
Phenytoin interacts significantly with NG feeds- please contact pharmacy for more information where necessary. |
04.08.02 |
Phenytoin |
Phenytoin Injection 250mg/5ml Amps
NHS Improvement Patient Safety Alert: Risk of death and severe harm from error with injectable phenytoin (November 2016)
Use of injectable phenytoin is error-prone throughout the prescribing, preparation, administration and monitoring processes; all relevant staff should be made aware of appropriate guidance on the safe use of injectable phenytoin to reduce the risk of error.
|
03.09.01 |
Pholcodine Linctus, BP |
Limited clincial value for these products and patients may rather purchase these as OTC products.
Self Care Medicine- Available OTC for self-care
|
01.06.04 |
Phosphates Rectal |
Fleet®Ready-to-use Enema |
09.05.02.01 |
Phosphate-Sandoz® |
Phosphate-Sandoz® Sodium dihydrogen phosphate anydrous 1.936gram effervescent tablets (phosphate 16.1mmol/tablet) |
09.06.06 |
Phytomenadione Konakion®MM |
Konakion®MM Phytomenadione 10mg per 1ml solution for injection ampoules (10mg/1ml)
Konakion®MM Paediatric phytomenadione 10mg per 1ml solution for injection ampoules (2mg/0.2ml). This strength is also licensed for oral use.
Oral use: For oral administration, oral dispensers are provided in the Konakion MM® paediatric pack. After breaking the ampoule open, 0.2 ml of solution should be withdrawn into the oral dispenser until it reaches the mark on the dispenser (0.2 ml = 2 mg vitamin K). Drop the contents of the dispenser directly into the patient's mouth by pressing the plunger. |
13.08.01 |
Picato® Ingenol mebutate 150 or 500microgram/g gel |
Picato®150microgram/g gel 1.41g Picato®500microgram/g gel 0.94g
For the treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults
Restriction: Patients with actinic keratosis affecting an area of skin of up to 25cm2
MHRA advice (Oct 2019): Ingenol mebutate gel (Picato▼)- increased incidence of skin tumours seen in some clinical studies
MHRA advice (Feb 2020): Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Clinicians should stop prescribing Picato and consider other treatment options for actinic keratosis as appropriate. The licence of ingenol mebutate (Picato) has been suspended as a precautionary measure while the European Medicines Agency (EMA) continues to investigate concerns about a possible increased risk of skin malignancy. |
01.06.05 |
Picolax ® |
1st line |
12.03.05 |
Pilocarpine hydrochloride Salagen® |
Pilocarpine hydrochloride 5mg tablets
Restriction: Consultant use only following irradiation for head and neck cancer.
Licensed for treatment of xerostomia following irradiation for head and neck cancer; dry mouth and dry eyes in Sjögren's syndrome. Discontinue if no improvement after 2–3 months. |
11.06 |
Pilocarpine hydrochoride |
Pilocarpine hydrochoride 1% eye drops Pilocarpine hydrochoride 2% eye drops Pilocarpine hydrochoride 4% eye drops |
13.05.03 |
Pimecrolimus Elidel® |
Elidel®1% cream 30g, 60g, 100g
Restriction: Initiation only by physicians with a special interest and experience in dermatology
|
06.01.02.03 |
Pioglitazone Actos® |
Pioglitazone Tablets 15mg Pioglitazone Tablets 30mg Pioglitazone Tablets 45mg
1st line thiazolidinedione
MHRA/CHM advice: Pioglitazone cardiovascular safety (December 2007 and January 2011)
EMA: Pioglitazone: risk of bladder cancer (July 2011) |
03.11 |
Pirfenidone Esbriet® |
Pirfenidone 267mg capsules, tablets Pirfenidone 801mg tablets
Restriction: In line with NICE Guidance only
This is an NHS England Specialised Commissioning Drug for IDIOPATHIC PULMONARY FIBROSIS |
08.01.02 |
Pixantrone dimaleate Pixuvri® |
Restriction: In line with NICE Guidance only |
09.06.04 |
Plenachol® Colecalciferol |
HIGH DOSE BOOST
Plenachol®Colecalciferol 20,000unit capsules |
09.01.07 |
Plerixafor Mozobil® |
24mg/1.2ml solution for injection vials
Restriction: In accordance with NHS England prescribing policy |
13.07 |
Podophyllotoxin |
Warticon® 0.15% cream 5g Condyline® 0.5% solution 3.5ml Warticon® 0.5% solution 3ml
A total of four 3-day treatment courses for Warticon® cream and solution, or five 3-day treatment courses for Condyline®. Direct medical supervision is required for lesions greater than 4 cm2.
|
08.01.05 |
Polatuzumab vedotin Polivy® |
Restriction: In line with NICE Guidance only |
09.02.01.01 |
Polystyrene Sulphonate Resins Calcium Resonium® |
Calcium polystyrene sulfonate 999.34 mg per 1 gram |
13.09 |
Polytar® |
Polytar®scalp shampoo 150ml
Contains peanut oil.
Self Care Medicine. Available OTC for self care
|
08.02.04 |
Pomalidomide Imnovid® |
Restriction: In line with NICE Guidance only
Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a completed Prescription Authorisation Form.
MHRA/CHM advice (May 2016): Risk of hepatitis B reactivation |
08.01.05 |
Ponatinib Iclusig® |
Restriction: In line with NICE Guidance only
MHRA/CHM advice: Ponatinib: risk of vascular occlusive events—updated advice on possible dose reduction (updated April 2017)
MHRA/CHM advice: Risk of hepatitis B virus reactivation with BCR-ABL tyrosine kinase inhibitors (May 2016)
MHRA/CHM advice: Ponatinib (Iclusig®): reports of posterior reversible encephalopathy syndrome (October 2018) |
03.05.02 |
Poractant Alfa Curosurf® |
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised commissioning drug for RESPIRATORY DISTRESS SYNDROME. |
09.02.01.01 |
Potassium chloride |
Sando-K® (potassium chloride 600mg and potassium bicarbonate 400mg) effervescent tablets
Kay-Cee-L® (potassium chloride) 75mg per 1ml syrup
Potassium chloride MR 600mg tablets (Slow K has been discontinued and the imported products of potassium chloride are costly)
|
07.04.03 |
Potassium citrate |
Effercitrate® tablets - equivalent to 5ml Potassium Citrate Mixture BP
Self Care Medicine-Available OTC for self care
(Please note exceptions may apply) |
13.11.06 |
Potassium permanganate Permitabs® |
Potassium permanganate 400mg tablets for cutaneous solution 30 tablets
Caution - Not for Oral use and can be fatal if ingested orally.
1 tablet dissolved in 4 litres of water provides a 0.01% (1 in 10,000) solution for external use only. |
11.08.02 |
Povidone iodine Minims® |
Minims Povidone iodine 5% eye drops (0.4ml unit dose) |
04.09.01 |
Pramipexole Prescribe MR prep by brand |
Pramipexole 0.088 mg tablets Pramipexole 0.18 mg tablets Pramipexole 0.35 mg tablets Pramipexole 0.70 mg tablets
Pipexus 0.26 mg prolonged-release tablets Pipexus 0.52 mg prolonged-release tablets Pipexus 1.05 mg prolonged-release tablets Pipexus 1.57 mg prolonged-release tablets Pipexus 2.10 mg prolonged-release tablets Pipexus 2.62 mg prolonged-release tablets Pipexus 3.15 mg prolonged-release tablets
Restriction: Initiation by specialist
Pipexus© is the preferred cost-effective MR Brand (Applicable in primary care). |
07.02.01 |
Prasterone (intravaginal) Intrarosa® |
Not approved for inclusion in the North Staffordshire Joint Formulary |
|
02.09 |
Prasugrel Efient® |
Prasugrel Tablet 5mg Prasugrel Tablet 10mg
Restriction: For consultant cardiologist initiation only.
MHRA advice - Prasugrel (Efient): increased risk of bleeding (December 2014) |
01.05.02 |
Prednisolone |
Prednisolone 1mg Tablet
Prednisolone 5mg Tablet
Where possible, please refrain from prescribing E/C tablets |
06.03.02 |
Prednisolone |
Plain Tablets 1mg, 2.5mg and 5mg Soluble Tablets 5mg Oral Solution 5mg/5ml
Plain tablets preferable over E/C tablets. Reserve Oral solution for patients unable to swallow prednisolone tablets e.g. young children. Lower cost alternative to soluble tablets.
Glucocorticoid equivalent Prednisolone 5mg = Dexamethasone 0.75mg = Hydrocortisone 20mg |
08.02.02 |
Prednisolone |
All post-transplant immunosuppressants are RED for patients newly prescribed these medicines from April 2013
Prednisolone 1mg tablets Prednisolone 5mg tablets |
10.01.02.01 |
Prednisolone |
Prednisolone 1mg tablets Prednisolone 5mg tablets |
11.04.01 |
Prednisolone |
Predsol®- Prednisolone sodium phosphate 0.5% ear/eye drops Pred Forte®- Prednisolone acetate 1% eye drops Minims Prednisolone sodium phosphate 0.5% ear/eye drops (0.5ml unit dose) |
01.05.02 |
Prednisolone foam enema |
Restriction: For patients that cannot tolerate Colifoam®
Please note that is significantly more expensive than Colifoam® enema.
|
12.01.01 |
Prednisolone sodium phosphate Predsol® |
Predsol®- Prednisolone sodium phosphate 0.5% ear/eye drops |
04.07.03 |
Pregabalin |
Pregabalin Capsule 25mg Pregabalin Capsule 50mg Pregabalin Capsule 75mg Pregabalin Capsule 100mg Pregabalin Capsule 150mg Pregabalin Capsule 200mg Pregabalin Capsule 225mg Pregabalin Capsule 300mg
As of the 1st April 2019 Pregabalin is re-classified as a Schedule 3 Controlled Drug
Restriction: 3rd line for neuropathic pain in line with the Non-Malignant Chronic Pain Guide
Restriction: 4th line for diabetic neuropathy in line with the Non-Malignant Chronic Pain Guide
For cost effective prescribing choose generic in non epileptic indications. Reserve the oral solution (100mg/5ml SF) for patients with swallowing difficulties ONLY as very expensive.(Applicable in Primary care only) |
09.01.01.01 |
Pregaday® |
Ferrous fumarate 322mg/folic acid 350microgram tablets |
04.08.01 |
Primidone |
Primidone Tablets 50mg Primidone Tablets 250mg
Restriction: Initiation and stabilisation by specialist Maintain patient on specific manufacturer's products. |
04.09.03 |
Primidone |
Primidone Tablets 50mg Primidone Tablets 250mg
Restriction: Initiation by specialist |
09.04 |
Pro-Cal® Shot |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
Pro-Cal® Powder |
Initiation by specialist dietician services prior to continuation within primary care.
|
04.06 |
Prochlorperazine |
|
04.09.02 |
Procyclidine |
Procyclidine Tablets 5mg Procyclidine Oral Solution 5mg/5ml SF |
06.04.01.02 |
Progesterone |
Progesterone Capsule 100mg (For use in HRT)
 Other Progesterone presentations are Specialist Use Only for fertility treatments, and will be provided in Fertility Clinics i.e.
- Crinone 8% vaginal gel
- Cyclogest 200mg and 400mg pessaries
- Gestone 50mg/ml and 100mg/2ml solution for injection Amps
- Lutigest 100mg vaginal tablets
- Lubion 25mg/1.112ml solution for injection vials
- Utrogestan 200mg vaginal capsules
|
04.02.01 |
Promazine Hydrochloride |
Promazine tablet 25mg Promazine tablet 50mg Promazine Oral solution 25mg/5ml Promazine Oral solution 50mg/5ml |
03.04.01 |
Promethazine Hydrochloride Phenergan® |
Promethazine Hydrochloride 10mg tablet Promethazine Hydrochloride 25mg tablet Promethazine Hydrochloride 5mg/5ml Oral solution SF
Self Care Medicine-Available OTC for self-care. Please note exceptions may apply.
|
04.01.01 |
Promethazine Hydrochloride |
Promethazine Hydrochloride 10mg tablets Promethazine Hydrochloride 25mg tablets Promethazine Hydrochloride 5mg/5ml Elixir |
04.06 |
Promethazine hydrochloride |
Promethazine Hydrochloride Tablets 10mg Promethazine Hydrochloride Tablets 25mg Promethazine Hydrochloride Elixir 5mg/5ml Promethazine Hydrochloride Injection 25mg/ml 1ml Amp |
02.03.02 |
Propafenone Hydrochloride |
Propafenone Hydrochloride 150mg Tablet Propafenone Hydrochloride 300mg Tablet
Restriction: Initiation under direction of cardiologist |
04.09.03 |
Propranolol |
Propranolol HCl Tablet 10mg Propranolol HCl Tablet 40mg Propranolol HCl Tablet 80mg Propranolol HCl Tablet 160mg Propranolol MR Capsule 80mg Propranolol MR Capsule 160mg Propranolol Oral Solution 5mg/5ml Propranolol Oral Solution 10mg/5ml Propranolol Oral Solution 40mg/5ml Propranolol Oral Solution 50mg/5ml |
02.04 |
Propranolol Hydrochloride |
Propranolol Hydrochloride Tablet 10mg Propranolol Hydrochloride Tablet 40mg Propranolol Hydrochloride Tablet 80mg Propranolol Hydrochloride Tablet 160mg Propranolol Hydrochloride MR Capsule 80mg Propranolol Hydrochloride MR Capsule 160mg Propranolol Hydrochloride Oral Solution 5mg/5ml Propranolol Hydrochloride Oral Solution 10mg/5ml Propranolol Hydrochloride Oral Solution 40mg/5ml Propranolol Hydrochloride Oral Solution 50mg/5ml
Prescribe MR capsules generically as more cost-effective(Applicable in Primary care only) |
04.01.02 |
Propranolol Hydrochloride |
Propranolol Hydrochloride 10mg tablets Propranolol Hydrochloride 40mg tablets Propranolol Hydrochloride 80mg tablets Propranolol Hydrochloride 160mg tablets Propranolol Hydrochloride Oral solution SF |
04.07.04.02 |
Propranolol Hydrochloride |
Propranolol Hydrochloride Tablet 10mg Propranolol Hydrochloride Tablet 40mg Propranolol Hydrochloride Tablet 80mg Propranolol Hydrochloride Tablet 160mg Propranolol Hydrochloride MR Capsule 80mg Propranolol Hydrochloride MR Capsule 160mg Propranolol Hydrochloride Oral Solution 5mg/5ml Propranolol Hydrochloride Oral Solution 10mg/5ml Propranolol Hydrochloride Oral Solution 40mg/5ml Propranolol Hydrochloride Oral Solution 50mg/5ml
1st line (As per Anti-Migraine Prescribing Guide) |
06.02.02 |
Propylthiouracil |
Propylthiouracil Tablets 50mg
Hepatotoxicity - Severe hepatic reactions have been reported, including fatal cases and cases requiring liver transplant - discontinue if significant liver-enzyme abnormalities develop
Carbimazole and Propylthiouracil are associated with rare cases of neutropenia and agranulocytosis due to bone marrow suppression. • Patients should be advised to report symptoms suggestive of infection, especially sore throat. • Blood Count should be performed if there is clinical evidence of infection. • Carbimazole/Propylthiouracil should be stopped if there is clinical or lab evidence of neutropenia. |
09.04 |
ProSource ® TF |
Initiation by specialist dietician services prior to continuation within primary care.
|
09.04 |
ProSource® Jelly |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
ProSource® Liquid |
Initiation by specialist dietician services prior to continuation within primary care. |
09.04 |
ProSource® Plus |
Initiation by specialist dietician services prior to continuation within primary care. |
02.08.03 |
Protamine sulfate |
Protamine sulfate 50mg/5mL solution for injection ampoules |
11.07 |
Proxymetacaine hydrochloride Minims® |
Minims Proxymetacaine hydrochloride 0.5% eye drops (0.5ml unit doses) |
01.06.07 |
Prucalopride Resolor® |
Prucalopride 1mg Tablet Prucalopride 2mg Tablet
Restriction: In line with NICE guidance only
Review 4 weeks after initiation to assess efficacy and discontinue if ineffective |
10.02.01 |
Pyridostigmine bromide |
Pyridostigmine bromide 60mg tablets |
09.06.02 |
Pyridoxine hydrochloride |
Pyridoxine hydrochloride 10mg tablets Pyridoxine hydrochloride 20mg tablets Pyridoxine hydrochloride 50mg tablets
Prolonged use of pyridoxine in a dose of 10 mg daily is considered safe but the long-term use of pyridoxine in a dose of 200 mg or more daily has been associated with neuropathy. The safety of long-term pyridoxine supplementation with doses above 10 mg daily has not been established. |
04.02.01 |
Quetiapine |
FIRST CHOICE- normal release tablets Quetiapine Tablet 25mg Quetiapine Tablet 100mg Quetiapine Tablet 150mg Quetiapine Tablet 200mg Quetiapine Tablet 300mg
SECOND CHOICE - MR where there are compliance issues Sondate XL Tablet 50mg Sondate XL tablet 150mg Sondate XL Tablet 200mg Sondate XL Tablet 300mg Sondate XL Tablet 400mg
THIRD CHOICE - If Sondate XL is unavailable Biquelle XL Tablet 50mg Biquelle XL tablet 150mg Biquelle XL Tablet 200mg Biquelle XL Tablet 300mg Biquelle XL Tablet 400mg
Prescribers should choose the most cost-effective option (Applicable in Primary care only)
|
02.03.02 |
Quinidine |
Quinidine 200mg Tablet Quinidine 300mg Tablet Quinidine 250mg SR Tablet
Restriction: Initiation under direction of cardiologist |
10.02.02 |
Quinine sulfate |
Quinine sulfate 200mg tablets
In hospital, ONLY Quinine sulfate 300mg strength tablets is available
MHRA/CHM advice: reminder of dose-dependent QT-prolonging effects (November 2017) |
06.06 |
Raloxifene hydrochloride Evista® |
Raloxifene hydrochloride 60mg Tablets
3rd line for secondary prevention of osteoporotic fractures in postmenopausal women (Bisphosphonates are first line for osteoporosis).
|
02.05.05.01 |
Ramipril |
Ramipril 1.25mg Capsule Ramipril 2.5mg Capsule Ramipril 5mg Capsule Ramipril 10mg Capsule Ramipril 1.25mg Tablet Ramipril 2.5mg Tablet Ramipril 5mg Tablet Ramipril 10mg Tablet Ramipril 2.5mg/5ml S/F Oral Solution
1st line ACE inhibitor |
11.08.02 |
Ranibizumab Lucentis® |
Lucentis 1.65mg/0.165ml solution for injection pre-filled syringes Lucentis 2.3mg/0.23ml solution for injection vials
Restriction: In line with NICE Guidance only |
01.03.01 |
Ranitidine |
Ranitidine Hydrochloride 75mg/5ml S/F Oral Solution Ranitidine Hydrochloride 150mg Tablet Ranitidine Hydrochloride 300mg Tablet
|
02.06.03 |
Ranolazine Ranexa® |
Ranolazine 375mg M/R Tablet Ranolazine 500mg M/R Tablet Ranolazine 750mg M/R Tablet
Restriction: To be initiated, titrated, and stabilised by cardiologists only |
04.09.01 |
Rasagiline |
Rasagiline Tablets 1mg
Restriction: Initiation by specialist |
08.01.05 |
Regorafenib Stivarga® |
Restriction: In line with NICE Guidance only |
09.06.07 |
Renavit® |
Renavit®tablets
Restriction: Only for use in renal failure patients undergoing dialysis
ACBS indication: Dietary management of water-soluble vitamin deficiency in adults with renal failure on dialysis |
06.01.02.03 |
Repaglinide Prandin® |
Repaglinide Tablets 0.5mg Repaglinide Tablets 1mg Repaglinide Tablets 2mg
Alternative to a sulphonylurea when it is not tolerated or is inappropriate |
03.04.02 |
Reslizumab Cinquil® |
10mg/mL Solution for infusion vials
Restriction: In line with NICE Guidance only
This is an NHS England specialised commissioning drug for the treatment of severe eosinophilic asthma |
02.10.02 |
Reteplase Rapilysin® |
Injection
Restriction: Cardiology and Anaesthetics only |
04.08.01 |
Retigabine |
Retigabine Tablet 50mg Retigabine Tablet 100mg Retigabine Tablet 200mg Retigabine Tablet 300mg Retigabine Tablet 400mg
Discontinued June 2017. See manufacturer's note
Restriction: In line with NICE Guidance only |
05.03.03.02 |
Ribavirin |
Ribavirin Tablets 200mg Ribavirin Tablets 400mg Ribavirin Capsules 200mg Ribavirin Oral Solution 40mg/ml Ribavirin Injection 1.2g/12ml vials
Restriction: In line with NICE Guidance This is an NHS England Specialised Commissioning Drug for Hepatitis C
|
08.01.05 |
Ribociclib succinate Kisqali® |
Restriction: In line with NICE Guidance only |
05.01.07 |
Rifaximin Targaxan® |
Rifaximin Tablets 550mg
Restriction: In line with NICE Guidance. To be initiated by a gastroenterologist only
Specialist use only for reduction in recurrence of hepatic encephalopathy |
04.09.03 |
Riluzole Rilutek® |
Riluzole Tablets 50mg
Restriction: Initiation by specialist
Neutropenia requires discontinuation of riluzole.
There is currently no ESCA developed for this drug |
11.04.01 |
Rimexolone Vexol® |
Rimexolone 1% opthalmic suspension
Restriction: 2nd line treatment when other topical corticosteroids have failed
Discontinued in 2016. Opthalmology to consider Lotoprednol 0.5% eyedrops post-op in patients who have previously developed a disproportionate increase in intra ocular pressure when treated with traditional corticosteroids |
13.05.03 |
Risankizumab Skyrizi® |
Restriction: In line with NICE guidance only |
06.06.02 |
Risedronate |
Risedronate Tablets 5mg Risedronate Tablets 30mg Risedronate Tablets 35mg
2nd line for Osteoporosis and Paget’s disease
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
04.02.01 |
Risperidone |
Risperidone Tablet 500mcg Risperidone Tablet 1mg Risperidone Tablet 2mg Risperidone Tablet 3mg Risperidone Tablet 4mg Risperidone Orodispersible Tablet 500mcg SF Risperidone Orodispersible Tablet 1mg SF Risperidone Orodispersible Tablet 2mg SF Risperidone Orodispersible Tablet 3mg SF Risperidone Orodispersible Tablet 4mg SF Risperidone Oral Solution 1mg/ml SF
Prescribe generically
See APC advice above (March 2010) |
04.02.02 |
Risperidone Risperdal Consta® |
Risperdal Consta® - Risperidone Powder for reconstitution 25mg vial Risperdal Consta® - Risperidone Powder for reconstitution 37.5mg vial Risperdal Consta® - Risperidone Powder for reconstitution 50mg vial
Restriction: Initiation under direction of a psychiatrist
Risperidone depot preparation should not be confused with oral preparations (which is 'Amber' on the formulary). |
08.02.03 |
Rituximab MabThera®, Rixathon®, Truxima® |
Restriction: In line with NICE Guidance only |
10.01.03 |
Rituximab MabThera®, Rixathon®, Truxima® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
Not routinely commissioned by NHS England for connective tissue disease (interstitial lung disease), primary Sjorgren's disease or chronic inflammatory demyelinating polyneuropathy except by prior IFR approval. |
02.08.02 |
Rivaroxaban Xarelto® |
Rivaroxaban Tablet 10mg Rivaroxaban Tablet 15mg Rivaroxaban Tablet 20mg
- Prevention of stroke and systemic embolism in AF
- Treatment of DVT and prevention of recurrent DVT & PE
- Treatment of PE and prevention of recurrent VTE
Restriction: In line with NICE Guidance and locally agreed guidelines
MHRA/CHM advice: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (June 2019)
MHRA/CHM advice: Rivaroxaban (Xarelto®): reminder that 15 mg and 20 mg tablets should be taken with food (July 2019) |
02.08.02 |
Rivaroxaban Xarelto® |
Rivaroxaban Tablet 2.5mg
- Prevention of adverse outcomes after acute management of acute coronary syndrome
Restriction: In line with NICE Guidance
MHRA/CHM advice: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (June 2019)
|
02.08.02 |
Rivaroxaban Xarelto® |
Rivaroxaban Tablet 10mg
Restriction: In line with NICE Guidance only. Orthopaedic consultant use only.
Complete course to be supplied by the hospital |
02.08.02 |
Rivaroxaban Xarelto® |
Rivaroxaban Tablet 2.5mg
Restriction: In line with NICE Guidance
MHRA/CHM advice: Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome (June 2019)
|
04.11 |
Rivastigmine |
Rivastigmine Cap 1.5mg Rivastigmine Cap 3mg Rivastigmine Cap 4.5mg Rivastigmine Cap 6mg Rivastigmine Oral Soln 2mg/1ml Rivastigmine Oral Soln 2mg/1ml S/F Rivastigmine Skin Patch 4.6mg/24hrs Rivastigmine Skin Patch 9.5mg/24hrs Rivastigmine Skin Patch 13.3mg/24hrs
Patches should only be used in patients with swallowing difficulties and should be prescribed as Alzest® which is more cost effective in primary care. |
04.07.04.01 |
Rizatriptan Maxalt® |
Rizatriptan (as Rizatriptan benzoate) Orodispersible Tablets 10mg Rizatriptan (as Rizatriptan benzoate) Tablets 5mg Rizatriptan (as Rizatriptan benzoate) Tablets 10mg Rizatriptan (as Rizatriptan benzoate) Oral Lyophilisates 10mg
4th line triptan (As per Anti-Migraine Prescribing Guide) |
13.08.01 |
RoC Sante Soleil® UVB |
Prescriptions in primary care must be endorsed ‘ACBS’
RoC Sante Soleil®sun lotion SPF50 125ml
Not recommended for prescribing as not listed in the ACBS section of NHS Drug Tariff.
Self Care Medicine. Available OTC for self care
|
03.03.03 |
Roflumilast Daxas® |
Roflumilast 250microgram tablets Roflumilast 500microgram tablets
Restriction: Initiation and stabilisation by specialist in Respiratory Medicine in line with NICE Guidance |
09.01.04 |
Romiplostim Nplate® |
Restriction: In line with NICE Guidance only |
04.09.01 |
Ropinirole |
Restriction: Initiation and stabilisation by specialist
Ropinirole Hydrochloride Tab 250mcg Ropinirole Hydrochloride Tab 500mcg Ropinirole Hydrochloride Tab 1mg Ropinirole Hydrochloride Tab 2mg Ropinirole Hydrochloride Tab 5mg
Ropinirole Hydrochloride Tab 2mg M/R Ropinirole Hydrochloride Tab 3mg M/R Ropinirole Hydrochloride Tab 4mg M/R Ropinirole Hydrochloride Tab 6mg M/R Ropinirole Hydrochloride Tab 8mg M/R
Ipinnia XL or Repinex XL are the preferred cost-effective MR brands (Applicable in primary care).
|
04.09.01 |
Rotigotine Neupro® |
Neupro Patch 1mg/24hours Neupro Patch 2mg/24hours Neupro Patch 3mg/24hours Neupro Patch 4mg/24hours Neupro Patch 6mg/24hours Neupro Patch 8mg/24hours
Restriction: Patients that are NBM or have swallowing difficulties.
Prescribing should be reviewed on discharge from secondary care |
08.02.04 |
Rucaparib Rubraca® |
Restriction: In line with NICE guidance only |
08.01.05 |
Ruxolitinib phosphate Jakavi® |
Restriction: In line with NICE Guidance only |
03.01.01.01 |
Salbutamol |
1st line: Generic Pressurised Metered Dose Inhaler (pMDI) 2nd line: Easyhaler Dry Powder Inhaler Salbutamol Inhalation Solution 2.5mg/2.5ml Unit Dose Vial Salbutamol Inhalation Solution 5mg/2.5ml Unit Dose Vial
Short Acting Beta2 Adrenoreceptor Agonist Indicated for Asthma and COPD. |
13.05.02 |
Salicylic acid |
Salicylic acid 2% ointment BP
For the treatment of hyperkeratotic and scaling conditions such as psoriasis. |
13.07 |
Salicylic acid |
Salatac® - Salicylic Acid 12% Gel Salactol® - Salicylic Acid 16.7% with Lactic Acid 16.7% Verrugon® complete - Salicylic Acid Ointment 50% ointment 6g Occlusal® - Salicylic Acid 26% solution 10ml
Self Care Medicine. Available OTC for self care
|
12.03.05 |
Salivix ®Pastilles |
Salivix®pastilles
May be prescribed under ACBS for patients suffering from dry mouth as a result of having (or having undergone) radiotherapy, or sicca syndrome.
Only useful in patients who have residual salivary gland function.
|
09.05.01.01 |
Sandocal®1000 |
Calcium carbonate 1.75gram/calcium lactate gluconate 2.263gram effervescent tablets (Each tablet contains 1 g calcium (Ca2+ 25 mmol)) |
10.01.03 |
Sarilumab Kevzara® |
Restriction: In line with NICE Guidance |
09.04 |
Scandishake® Mix |
Initiation by specialist dietician services prior to continuation within primary care. |
01.07.02 |
Scheriproct |
Scheriproct Suppository Scheriproct Ointment |
10.01.03 |
Secukinumab Cosentyx® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
Not routinely commissioned by NHS England for paediatric indications except by prior IFR approval. |
13.05.03 |
Secukinumab Cosentyx® |
Restriction: In line with NICE Guidance only |
04.09.01 |
Selegiline Hydrochloride |
Selegiline Tablets 5mg Selegiline Tablets 10mg Selegiline Oral Lyophilisates 1.25mg
Restriction: Initiation by specialist
Note: 1.25-mg oral lyophilisate is equivalent to 10-mg tablet. |
13.09 |
Selsun® Selenium sulfide 2.5% |
Selsun®- Selenium sulfide 2.5% shampoo 50ml,100ml,150ml
Self Care Medicine. Available OTC for self care
|
06.01.02.03 |
Semaglutide Ozempic® |
Ozempic 0.25mg/0.19mL Solution for injection 1.5mL pre-filled pens Ozempic 0.5mg/0.37mL Solution for injection 1.5mL pre-filled pens Ozempic 1mg/0.74mL Solution for injection 3mL pre-filled pens
Restriction: Treatment should be initiated by a diabetes specialist clinician and transferred to primary care after six months as long as the patient has had a beneficial metabolic process, i.e. at least a 1% HbA1c reduction AND at least a 3% reduction in weight. |
01.06.02 |
Senna |
Senna 7.5mg/5ml Oral Solution Senna 7.5mg Tablet
- Syrup is currently more cost effective than tablets - Time to effect approximately 8 to 12 hours
Available OTC and more expensive than Bisacodyl (Applicable in Primary care only) |
04.03.03 |
Sertraline |
Sertraline (as Sertraline hydrochloride) Tablet 50mg Sertraline (as Sertraline hydrochloride) Tablet 100mg |
09.05.02.02 |
Sevelamer |
For the treatment of Hyperphosphataemia
Sevelamer 800mg tablets Sevelamer 2.4g oral sachets - (reserve for patients with swallowing difficulties)
Commissioned by NHS England when used for adult renal dialysis
Link to ESCA
|
07.04.05 |
Sildenafil citrate |
Sildenafil citrate 25mg tablet Sildenafil citrate 50mg tablet Sildenafil citrate 100mg tablet
1st line for erectile dysfunction.
Generic sildenafil is no longer listed on the SLS restrictions list Please note that restriction to Sildenafil NHS prescribing has been lifted for generic form (does not apply to branded Viagra® which is non-formulary). Healthcare professionals should no longer offer generic Sildenafil on a private prescription. |
13.07 |
Silver nitrate Avoca® |
Avoca®Silver nitrate 40% pencils Avoca®Silver nitrate 75% applicators Avoca®Silver nitrate 95% pencils Avoca®Silver nitrate 95% applicators |
13.10.01.01 |
Silver sulfadiazine Flamazine® |
Flamazine®1% cream 20g,50g,250g,500g
This product is licensed for prophylaxis and treatment of Burn wounds. Also licensed for short-term treatment of infection in Pressure sores and Leg ulcers |
11.06 |
Simbrinza® Brinzolamide 10mg/ml & brimonidine 2mg/ml |
Simbrinza®- Brinzolamide 10mg/ml & brimonidine 2mg/ml eye drops |
05.03.03.02 |
Simeprevir Olysio® |
Simeprevir Capsules 150mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy NHS England commissioned
Simeprevir Discontinued |
01.01.01 |
Simeticone Infacol® |
Self Care Medicine-Available OTC for self-care.
|
03.09.02 |
Simple Linctus, BP |
Limited clincial value for these products and patients may rather purchase these as OTC products.
Self Care Medicine - Available OTC for self-care
|
02.12 |
Simvastatin |
Simvastatin 10mg tablet Simvastatin 20mg tablet Simvastatin 40mg tablet Simvastatin 80mg tablet
Use in accordance with locally agreed hyperlipidaemia guidelines |
06.01.02.03 |
Sitagliptin Januvia® |
Sitagliptin Tablets 25mg Sitagliptin Tablets 50mg Sitagliptin Tablets 100mg |
10.01.03 |
Sodium aurothiomalate Myocrisin® |
Myocrisin®Sodium aurothiomalate 20mg/1ml solution for injection ampoules Myocrisin®Sodium aurothiomalate 100mg/1ml solution for injection ampoules
DISCONTINUATION
Sanofi has confirmed the discontinuation of 10mg, 20mg and 50mg ampoules of Myocrisin from 30th June 2019 (being 3 months from the shortest expiry date). There are supplies within the supply chain, and will continue until current stock is depleted.
|
09.02.01.03 |
Sodium bicarbonate |
Sodium bicarbonate 500mg capsules |
12.01.03 |
Sodium bicarbonate ear drops |
Sodium bicarbonate 5% ear drops
Self Care Medicine-Available OTC for self-care. For the removal of ear wax.
|
07.04.04 |
Sodium chloride |
Sodium chloride 0.9% Irrigation solution |
09.02.01.02 |
Sodium chloride Slow Sodium® |
Slow Sodium® (sodium chloride) MR 600mg tablets
Each Slow Sodium® tablet contains approximately 10 mmol each of Na+and Cl-; tablets can be crushed before administration. |
13.11.01 |
Sodium chloride 0.9% |
Sodium chloride 0.9% 10mL Ampoules Sodium chloride 0.9% 20mL Ampoules Sodium chloride 0.9% 25mL Sachet (Normasol®) Sodium chloride 0.9% 100mL Sachet (Normasol®) Sodium chloride 0.9% Irrigation 1L
|
03.07 |
Sodium Chloride 3% and 6% nebuliser solution (Hypertonic) PulmoClear® |
Not approved for inclusion in the North Staffordshire Joint Formulary
|
|
03.07 |
Sodium chloride 7% (Hypertonic) PulmoClear® |
Nebulised solution
Restriction: For use in CF patients only, not in COPD. |
01.06.04 |
Sodium citrate Rectal |
Micro-enema Microlette®, Relaxit® and Micralax® |
06.06.02 |
Sodium Clodronate |
Sodium Clodronate Tablets 520mg Sodium Clodronate Tablets 800mg
Restriction: Initiation under direction of oncology/haematology only
For osteolytic lesions, hypercalcaemia and bone pain associated with skeletal metastases in breast cancer multiple myeloma.
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015)
|
11.04.02 |
Sodium cromoglicate |
Sodium cromoglicate 2% eye drops
Self Care Medicine - Available OTC for self-care, Patients should be advised to purchase a suitable product over the counter. First line for allergy symptoms.
|
12.02.01 |
Sodium cromoglicate Rynacrom® |
Sodium cromoglicate 4% nasal spray (Unlicensed product)
Self Care Medicine-Available OTC for self-care
|
09.05.03 |
Sodium fluoride |
Colgate Duraphat® 2800ppm Flouride toothpaste Colgate Duraphat® 5000ppm Flouride toothpaste Endekay® Sodium Fluoride Mouthwash 0.05% SF
Prescribing responsibility should be retained by dentists for most indications.
Rarely, prescription only tooth preparations may be prescribed in general practice on the recommendation of hospital specialists (e.g as part of a package of care for head and neck cancer) or following diagnosis of an oral condition that would benefit from this treatment
Self Care Medicine-Available OTC for self-care
|
07.04.04 |
Sodium hyaluronate,Chondroitin in water with Calcium Chloride iAluRil® |
Restriction: Not approved for inclusion in the North Staffordshire Joint Formulary. |
|
02.05.01 |
Sodium nitroprusside |
Seek specialist advice prior to initiation. |
02.13 |
Sodium tetradecyl sulfate |
Solution for Injection |
04.07.04.02 |
Sodium valproate |
Sodium Valproate Tablet 100mg Sodium Valproate Tablet 300mg M/R Sodium Valproate Tablet 500mg M/R Sodium Valproate Tablet E/C 200mg Sodium Valproate Tablet E/C 500mg Sodium Valproate Oral Solution 200mg/5ml S/F
2nd line (As per Anti-Migraine Prescribing Guide)
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme (MHRA, March 2018).
Patient Card – to be given by pharmacists to all female patients who are dispensed valproate medicines to inform them of the risks |
04.08.01 |
Sodium Valproate |
Sodium Valproate Tablet 100mg Sodium Valproate Tablet 300mg M/R Sodium Valproate Tablet 500mg M/R Sodium Valproate Tablet E/C 200mg Sodium Valproate Tablet E/C 500mg Sodium Valproate Oral Solution 200mg/5ml S/F
Restriction: Initiation and stabilisation by specialist Maintain patient on specific manufacturer's products.
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme (MHRA, March 2018).
Patient Card – to be given by pharmacists to all female patients who are dispensed valproate medicines to inform them of the risks
|
09.02.01.01 |
Sodium zirconium cyclosilicate Lokelma® |
Restriction: In line with NICE Guidance only |
05.03.03.02 |
Sofosbuvir Sovaldi® |
Sofosbuvir Tablets 400mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy NHS England commissioned |
05.03.03.02 |
Sofosbuvir & Velpatasvir Epclusa® |
Sofosbuvir & Velpatasvir Tablets 400/100mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy This is an NHS England Specialised Commissioning Drug for Hepatitis C
|
05.03.03.02 |
Sofosbuvir, velpatasvir & voxilaprevir Vosevi® |
Sofosbuvir, velpatasvir & voxilaprevir Tablets 400/100/100mg
Restriction: In line with NICE Guidance NHS England commissioned
|
13.08.01 |
Solaraze® Diclofenac sodium in sodium hyaluronate gel |
Solaraze®- Diclofenac 3% Gel 50g, 100g
For the treatment of actinic keratosis
Do not prescribe for longer than 3 months. Should not be confused with diclofenac 1% gel which is indicated for pain and inflammation. |
07.04.02 |
Solifenacin Vesicare® |
Solifenacin 5mg tablet Solifenacin 10mg tablet
Very expensive choice |
06.05.01 |
Somatropin |
All somatropin products are licensed for the treatment of short stature due to an inadequate secretion of growth hormone, for use in Turner Syndrome, chronic renal insufficiency and growth disturbance in short children born small for gestational age (SGA).
The exception is Zomacton® which is unlicensed for use in chronic renal insufficiency and SGA. Also Nutropin Aq® which is unlicensed for use in SGA.
Genotropin® and Omnitrope® are also licensed for use in Prader-Willi syndrome.
Humatrope® is the only product licensed for use in SHOX deficiency.
|
See BNF or manufacturer's SPC for appropriate device to be used with each preparation.
Restriction: Specialist use only. NICE approved patients only
Link to ESCA |
08.01.05 |
Sorafenib tosylate Nexavar® |
Restriction: In line with NICE Guidance only |
02.03.02 |
Sotalol Hydrochloride |
Sotalol Hydrochloride 40mg Tablet Sotalol Hydrochloride 80mg Tablet Sotalol Hydrochloride 160mg Tablet
Restriction: Initiation under direction of cardiologist |
13.08.01 |
SpectraBan® UVB |
Prescriptions in primary care must be endorsed ‘ACBS’
SpectraBan®sunscreen 20g
Not recommended for prescribing as not listed in the ACBS section of NHS Drug Tariff.
Self Care Medicine. Available OTC for self care
|
02.02.03 |
Spironolactone |
Spironolactone 25mg Tablet Spironolactone 50mg Tablet Spironolactone 100mg Tablet
Monitor electrolytes—discontinue if hyperkalaemia occurs |
09.06.04 |
Stexerol D3® Colecalciferol |
HIGH DOSE BOOST
Stexerol D3®Colecalciferol 25,000unit tablets |
02.10.02 |
Streptokinase Streptase® |
Injection |
01.03.03 |
Sucralfate |
Sucralfate 1g Tablet Sucralfate 1g/5mL S/F Oral Suspension
For Specialist Initiation Only |
01.05.01 |
Sulfasalazine |
Sulfasalazine 500mg Tablet (plain) Sufasalzine 500mg enteric coated Tablet Sulfasalazine 500mg Suppositories Sulfasalazine 250mg/5ml S/F Oral Suspension (ONLY for patients with swallowing difficulties)
Please note the plain tablets are more cost effective than enteric coated ones- (Applicable in Primary care only)
Link to ESCA
|
10.01.03 |
Sulfasalazine Salazopyrin EN-Tabs |
Sulfasalazine gastro resistant 500mg tablets
Please note only the gastro resistant tablets are licensed for treatment of active rheumatoid arthritis.
Link to ESCA
|
04.02.01 |
Sulpiride Sulpor® |
Sulpiride Tablets 200mg Sulpiride Tablets 400mg |
04.07.04.01 |
Sumatriptan |
Sumatriptan (as Sumatriptan succinate) Tablet 100mg Sumatriptan (as Sumatriptan succinate) Tablet 50mg
1st line triptan. (As per Anti-Migraine Prescribing Guide)
|
04.07.04.01 |
Sumatriptan nasal spray |
Sumatriptan Aq Nasal Spray 10mg/0.1ml Unit dose Sumatriptan Aq Nasal Spray 20mg/0.1ml Unit dose
1st line triptan for young people 12-17 years (As per Anti-Migraine Prescribing Guide) |
08.01.05 |
Sunitinib Sutent® |
Restriction: In line with NICE Guidance only |
07.03.01 |
Sunya 20/75® |
Monophasic
Low strength ethinylestradiol pill
Recommendation: - Second Line due to increased risk of thromboembolism |
08.02.02 |
Tacrolimus |
All post-transplant immunosuppressants are RED for patients newly prescribed these medicines from April 2013
- Prograf ®: immediate release capsule, twice daily dosage
- Modigraf ®: immediate release formulation, twice daily dosage
- Advagraf ®: prolonged release capsule, once daily dosage
Brands of other immediate release capsules taken twice daily include Adoport®, Capexion®, Tacni® and Vivadex®.
Switching between tacrolimus brands requires careful supervision and therapeutic monitoring by an appropriate specialist. Envarsus® is not interchangable with other oral Tacrolimus containing products.
MHRA/CHM advice: Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012) |
08.02.02 |
Tacrolimus |
- Prograf ®: immediate release capsule, twice daily dosage
- Modigraf ®: immediate release formulation, twice daily dosage
- Advagraf ®: prolonged release capsule, once daily dosage
Brands of other immediate release capsules taken twice daily include Adoport®, Capexion®, Tacni® and Vivadex®.
Switching between tacrolimus brands requires careful supervision and therapeutic monitoring by an appropriate specialist. Envarsus® is not interchangable with other oral Tacrolimus containing products.
MHRA/CHM advice: Oral tacrolimus products: prescribe and dispense by brand name only, to minimise the risk of inadvertent switching between products, which has been associated with reports of toxicity and graft rejection (June 2012)
Link to ESCA |
13.05.03 |
Tacrolimus Protopic® |
Protopic®0.03% ointment 30g,60g Protopic®0.1% ointment 30g,60g
Restriction: Initiation only by physicians with a special interest and experience in dermatology
|
11.06 |
Tafluprost with timolol Taptiqom® |
1st line in patients who cannot tolerate a preservative-containing prostaglandin analogue/beta-blocker combination product
Taptiqom®- Tafluprost 15microgram/ml & Timolol 5mg/ml eye drops (0.3ml unit dose) - P/free |
08.01.05 |
Talimogene laherparepvac Imlygic® |
Restriction: In line with NICE Guidance only |
08.03.04.01 |
Tamoxifen citrate |
Tamoxifen citrate 10mg tablets (rarely required and more expensive) Tamoxifen citrate 20mg tablets Tamoxifen citrate 10mg/5ml oral solution SF (reserve for patients with swallowing difficulties)
|
07.04.01 |
Tamsulosin hydrochoride |
Tamsulosin Hydrochloride MR 400microgram capsules
Prescribe as capsule formulation as more cost effective than tablets |
04.07.02 |
Tapentadol Palexia® |
PALEXIA® SR 50 mg prolonged-release tablets PALEXIA® SR 100 mg prolonged-release tablets PALEXIA® SR 150 mg prolonged-release tablets PALEXIA® SR 200 mg prolonged-release tablets PALEXIA® SR 250 mg prolonged-release tablets
Restriction: Only to be used in line with the Non-Malignant Chronic Pain Guide
MHRA advice: Tapentadol (Palexia)- risk of seizures and reports of serotonin syndrome when co-administered with other medicines (Jan 2019) |
08.01.03 |
Tegafur with Uracil Uftoral® |
Restriction: In line with NICE Guidance only
Uftoral was discontinued by manufacturer (March 2013) |
05.03.03.02 |
Telaprevir Incivo® |
Telaprevir Tablets 375mg
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policy This is an NHS England Specialised Commissioning Drug for Hepatitis C
Telaprevir no longer has a marketing authorisation in the UK |
04.01.01 |
Temazepam |
Temazepam 10mg tablets Temazepam 20mg tablets
1st line benzodiazepine for short term treatment of insomnia
CSM Advice: Hypnotics and Anxiolytics are indicated for the short-term relief of sleep disturbance and/or anxiety. (For continuous use up to a maximum of 14 days). |
08.01.05 |
Temozolomide |
Restriction: In line with NICE Guidance only
This is a Specialised Drug which would not be routinely commissioned by CCGs for Endocrinology: non-malignant conditions. This would go through CCGs Individual Funding Request (IFR). |
05.03.03.01 |
Tenofovir Disproxil Viread® |
Tenofovir Disproxil Tablets 123mg Tenofovir Disproxil Tablets 163mg Tenofovir Disproxil Tablets 204mg Tenofovir Disproxil Tablets 245mg Tenofovir Disproxil Granules 33mg/g
Restriction: In line with NICE Guidance This is an NHS England Specialised Commissioning Drug for Hepatitis B +/- other anti-retroviral drugs.
7.5 scoops of granules contains approx. 245 mg tenofovir disoproxil (as fumarate).
|
05.03.01 |
Tenofovir, cobicistat, elvitegravir & emtricitabine Stribild® |
Stribild Tablets 150mg/150mg/200mg/245mg
Restriction: In accordance with NHS England prescribing policy
This is an NHS England Specialised Commissioning Drug for HIV in combination with other anti-retroviral drugs. |
03.01.01.01 |
Terbutaline Sulfate |
Terbutaline Sulfate breath actuated Inhalation 500 micrograms/dose (100 dose) Terbutaline turbohaler
Short Acting Beta2 Adrenoreceptor Agonist Indicated for Asthma and COPD. |
08.02.04 |
Teriflunomide Aubagio® |
Restriction: In line with NICE Guidance only |
06.06.01 |
Teriparatide Forsteo® |
20mcg/80microlitres Solution for Injection 2.4ml pre-filled pen
Restriction: In line with NICE Guidance only
This is a Specialised Drug which would not be routinely commissioned by CCGs for Male and Juvenile Osteoporosis. This would go through the CCGs Individual Funding Request (IFR) |
06.05.02 |
Terlipressin Glypressin® |
1mg/8.5ml Solution for Injection Amps 1mg Powder and solvent for solution for injection vials |
06.04.02 |
Testosterone |
Testosterone Implant 100mg (Organon) - unlicensed Testosterone Undecanoate Injection 1g/4ml vial (Nebido) Testosterone Injection 250mg/1ml Amp (Sustanon 250)
Restriction: Initiation under direction of a specialist (Injection and implants only) |
04.09.03 |
Tetrabenazine Xenazine® 25 |
Tetrabenazine Tablets 12.5mg Tetrabenazine Tablets 25mg
Restriction: Initiation by specialist |
11.07 |
Tetracaine hydrochloride Minims® |
Minims Tetracaine hydrochloride 0.5% eye drops (0.5ml unit doses) - P/free Minims Tetracaine hydrochloride 1% eye drops (0.5ml unit doses) - P/free |
06.05.01 |
Tetracosactide Synacthen® |
Tetracosactide Acetate 250mcg/ml Solution for Injection Amp Tetracosactide Acetate 1mg/ml Suspension for Injection Amp |
08.02.04 |
Thalidomide Celgene® |
Restriction: In line with NICE Guidance only
Patient, prescriber, and supplying pharmacy must comply with a pregnancy prevention programme. Every prescription must be accompanied by a complete Prescription Authorisation Form. |
03.01.03 |
Theophylline |
Brand must be stated
Note: The rate of absorption from modified-release preparations can vary between brands. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as an in-patient. (As per BNF) |
09.06.02 |
Thiamine |
Thiamine 50mg tablets Thiamine 100mg tablets
|
09.06.04 |
Thorens® Colecalciferol |
Maintenance dose (without calcium)
Thorens®Colecalciferol 10,000unit/ml drops (1 drop ≡ 200unit Colecalciferol)
|
02.09 |
Ticagrelor Brilique® |
Ticagrelor Tablet 60mg Ticagrelor Tablet 90mg Ticagrelor Orodispersible tablets 90mg
Restriction: In line with NICE Guidance only
Ticagrelor can now be used up to a maximum of 3 years as per NICE TA420. Duration needs to be specified by initiating specialist. |
13.05.03 |
Tildrakizumab Ilumetri® |
Restriction: In line with NICE Guidance only |
11.06 |
Timolol maleate |
Timolol maleate 0.25% eye drops Timolol maleate 0.5% eye drops Timolol maleate 0.1% eye gel Timolol maleate 0.5% eye gel (Timoptol-LA) Timolol maleate 0.25% and 0.5% eye drops (0.2ml unit doses)- P/free
|
03.01.02 |
Tiotropium Spiriva®Respimat |
Tiotropium 2.5 mcg/dose Respimat® device only
Long-Acting Antimuscarinic For use in Asthma only |
03.01.02 |
Tiotropium Braltus®Zonda |
Tiotropium 10 microgram per delivered dose (with Zonda Inhaler)
For use in COPD only
The delivered dose of Spiriva® and Braltus® inhalation powder products are the same (10 micrograms); no dose adjustment is necessary when switching between brands.
MHRA/CHM advice: Braltus® (tiotropium): risk of inhalation of capsule if placed in the mouthpiece of the inhaler (May 2018) |
03.01.04 |
Tiotropium & olodaterol Spiolto®Respimat |
Olodaterol (as Olodaterol hydrochloride 2.5microgram per 1 dose, Tiotropium (as Tiotropium bromide) 2.5 microgram per 1 dose Solution for inhalation cartridge with device (60 dose)
Long-Acting Antimuscarinic + Long-Acting Beta2 Adrenorecepter Agonist combination.
For use in COPD only
The combination product offers cost & compliance advantages compared to prescribing LAMA and LABA drugs as separate devices. |
08.01.05 |
Tisagenlecleucel Kymriah® |
Restriction: In line with NICE guideline only |
08.01.05 |
Tivozanib Fotivda® |
Restriction: In line with NICE Guidance only |
10.02.02 |
Tizanidine hydrochloride |
Tizanidine hydrochloride 2mg tablets Tizanidine hydrochloride 4mg tablets - EXPENSIVE
Monitor liver function monthly for first 4 months and in those who develop unexplained nausea, anorexia or fatigue.
Link to the ESCA
|
05.01.04 |
Tobramycin dry powder for inhalation Tobi® Podhaler |
28mg Inhalation Powder Capsules with device
Restriction:
- CF - In line with NICE Guidance. This is an NHS England Specialised Commissioning Drug for Cystic Fibrosis.
- Non-CF Bronchiectasis - 2nd line only. Prior approval is required from CCG. Respiratory consultant prescription only
|
05.01.04 |
Tobramycin nebuliser solution |
300mg/5ml nebuliser liquid Amps
Restriction: Non-CF Bronchiectasis. 1st line |
10.01.03 |
Tocilizumab RoActemra® |
Restriction: In line with NICE Guidance
Restriction: In accordance with NHS England prescribing policies
MHRA advice(July 2019): Rare risk of serious liver injury including cases requiring transplantation. |
01.05.03 |
Tofacitinib Xeljanz® |
Restriction: In line with NICE Guidance only |
10.01.03 |
Tofacitinib Xeljanz® |
Restriction: In line with NICE Guidance |
06.01.02.01 |
Tolbutamide |
Tolbutamide Tablets 500mg |
07.04.02 |
Tolterodine |
Tolterodine 1mg Tablet Tolterodine 2mg Tablet
|
07.04.02 |
Tolterodine tartrate Modified release |
Tolterodine MR 2mg capsule Tolterodine MR 4mg capsule
(prescribe as Neditol XL)
|
06.05.02 |
Tolvaptan Jinarc® |
Tablets 15mg Tablets 30mg Tablets 45mg Tablets 60mg Tablets 90mg
Restriction: In line with NICE guidelines (For treating autosomal dominant polycystic kidney disease- Blueteq form needed for this indication only as CCG Commissioned)
This is an NHS England Specialised Commissioning Drug for Hyponatremia in Cancer. |
04.07.04.02 |
Topiramate |
Topiramate Tabs 25mg Topiramate Tabs 50mg Topiramate Tabs 100mg Topiramate Tabs 200mg
1st line (As per Anti-Migraine Prescribing Guide)
|
04.08.01 |
Topiramate |
Topiramate Tablet 25mg Topiramate Tablet 50mg Topiramate Tablet 100mg Topiramate Tablet 200mg
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
08.01.05 |
Topotecan Hycamtin® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Trabectedin Yondelis® |
Restriction: In line with NICE Guidance only |
04.07.02 |
Tramadol Hydrochloride |
Tramadol Capsules 50mg
Restriction: Only to be used in line with the Non-Malignant Chronic Pain Guide
More costly than other weak opioids(Applicable in Primary care only) |
04.07.03 |
Tramadol Hydrochloride immediate release |
Tramadol Capsules 50mg
Restriction: Only to be used in line with the Non-Malignant Chronic Pain Guide
More costly than other weak opioids (Applicable in Primary care only) |
08.01.05 |
Trametinib Mekinist® |
Restriction: In line with NICE Guidance only |
02.11 |
Tranexamic Acid |
Tranexamic Acid 500mg tablet Tranexamic Acid 500mg/5mL solution for injection ampoules |
08.01.05 |
Trastuzumab |
Restriction: In line with NICE Guidance only
|
08.01.05 |
Trastuzumab emtansine |
Restriction: In line with NICE Guidance only
|
11.06 |
Travoprost |
Travoprost 40microgram/ml eye drops |
04.03.01 |
Trazodone Hydrochloride |
Trazodone Capsules 50mg Trazodone Capsules 100mg Trazodone Tablets 150mg
Note liquid preparation is expensive (Applicable in Priamary care only)
|
08.01.01 |
Treosulfan Trecondi® |
Restriction: In line with NICE Guidance only |
13.06.01 |
Tretinoin with clindamycin phosphate Treclin® |
Topical retinoids and related preparations with antibacterial
Treclin®- Clindamycin phosphate 1% and tretinoin 0.025% gel 30g |
13.06.01 |
Tretinoin with erythromycin Aknemycin® Plus |
Topical retinoids and related preparations with antibacterial
Aknemycin®Plus - Tretinoin 0.025% and erythromycin 4.0% solution, 25ml |
06.03.02 |
Triamcinolone Kenalog® |
Triamcinolone Acetonide Susp for Injection 40mg/ml Vial Triamcinolone Acetonide Susp for Injection 80mg/2ml Vial |
10.01.02.02 |
Triamcinolone acetonide Adcortyl® |
Adcortyl® - Intra-articular/Intradermal triamcinolone acetonide 10mg/1ml suspension for injection ampoules Kenalog® - Intra-articular/Intradermal triamcinolone acetonide 10mg/1ml suspension for injection vials
For doses below 5 mg use Adcortyl®; for larger doses greater than 15mg, use Kenalog®.
MHRA/CHM advice: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration (August 2017) |
12.03.01 |
Triamcinolone Acetonide 0.1% in Adhesive Basis Adcortyl in Orabase® |
DISCONTINUED
If prescribed, an unlicensed special will be dispensed at a high cost. Consider Hydrocortisone Buccal Tablets or Orabase protective paste 30g (which can be used in the mouth to provide a protective film over sore areas and ulcers). |
13.11.05 |
Triclosan |
Triclosan 1% surgical scrub Triclosan 2% (Ster-Zac Bath Concentrate®), 500ml
AQUASEPT DISCONTINUED |
04.02.01 |
Trifluoperazine |
Trifluoperazine Tablets 1mg Trifluoperazine Tablets 5mg Trifluoperazine Oral solution 5mg/5ml SF
Standard release preparations only |
08.01.05 |
Trifluridine-tipiracil Lonsurf® |
Restriction: In line with NICE Guidance only |
04.09.02 |
Trihexyphenidyl |
Trihexyphenidyl Tablets 2mg Trihexyphenidyl Tablets 5mg
Not recommended for use in Parkinson’s disease because of toxicity in the elderly and the risk of aggravating dementia. |
08.03.04.02 |
Triptorelin |
1st line
Decapeptyl SR (triptorelin acetate) 3mg vials - monthly Decapeptyl SR (triptorelin) 11.25mg vials - three monthly Decapeptyl SR (triptorelin embonate) 22.5mg vials - six monthly Gonapeptyl Depot (triptorelin acetate) 3.75mg pre-filled syringes - monthly
In endometriosis do not use for longer than 6 months (do not repeat)
|
11.05 |
Tropicamide |
Mydriacyl®- Tropicamide 1% eye drops Minims Tropicamide 0.5% eye drops 0.5ml unit dose Minims Tropicamide 1% eye drops 0.5ml unit dose |
07.04.02 |
Trospium chloride |
Trospium 20mg tablet
Good choice in patients taking other medicines, as does not affect CYP450 liver enzymes.
|
07.03.04 |
T-Safe® Cu 380A Quickload |
Recommendation: First line use
Banded coil (Copper sleeves)
For uterine length 6.5cm - 9cm; replacement every 10 years. |
07.03.04 |
TT 380® Slimline |
Recommendation: First line use
Banded coil (Copper sleeves).
For uterine length 6.5cm – 9cm; replacement every 10 years. |
07.03.05 |
Ulipristal EllaOne® |
Ulipristal Acetate 30mg tablets
See APC/NMC recommendation |
06.04.01.02 |
Ulipristal acetate Esmya® |
Ulipristal acetate Tablets 5mg
MHRA/CHM advice: Esmya® (ulipristal acetate) for symptoms of uterine fibroids: restrictions to use and requirement to check liver function before, during and after treatment (August 2018)
Manufacturer advises perform liver function tests before treatment initiation—do not initiate if transaminases exceed 2 times the upper limit of normal. During the first 2 treatment courses, monitor liver function monthly; for further treatment courses, perform liver function tests once before each new treatment course and when clinically indicated. At the end of each treatment course, perform liver function tests after 2–4 weeks. Discontinue treatment if serum transaminases exceed 3 times the upper limit of normal and closely monitor patient.
18/03/2020: MHRA Central alerting system
Esmya: Urgent patient level recall
All unexpired stock of Ulipristal acetate (Esmya) from patients, pharmacies and wholesalers are hereby recalled following a new case of liver failure requiring liver transplant in a patient taking the medicine.
- To protect patients while a safety review is conducted, the European Medicines Agency's safety committee, Pharmacovigilance Risk Assessment Committee, (PRAC) has recommended that women stop taking 5mg ulipristal acetate (Esmya and generic medicines) for uterine fibroids.
- Clinicians must contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy.
- All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should be provided advice about other possible treatments for uterine fibroids.
- Further information can be accessed via the hyperlink on the MHRA website: EL (20)A 16 Final.pdf
The formulary status of Esmya is now re-classified from 'Amber' to 'Red'. |
03.01.02 |
Umeclidinium Incruse®Ellipta |
Umeclidinium Bromide 65mcg/dose DPI Incruse Ellipta 55mcg/dose DPI
Long-Acting Antimuscarinic For use in COPD ONLY. |
03.01.04 |
Umeclidinium & vilanterol Anoro®Ellipta |
Umeclidinium Bromide 65mcg/dose/Vilanterol 22mcg/dose DPI Anoro Ellipta® 55mcg/22mcg DPI
Long-Acting Antimuscarinic + Long-Acting Beta2 Adrenorecepter Agonist combination.
For use in COPD only
The combination product offers cost & compliance advantages compared to prescribing LAMA and LABA drugs as separate devices. |
01.07.02 |
Uniroid HC |
Uniroid HC Ointment Uniroid HC Suppository Uniroid HC same formulation as Proctosedyl and considerably less expensive |
02.10.02 |
Urokinase |
Injection
Can be used for the unblocking of central venous lines (See BNF/ SPC) |
01.09.01 |
Ursodeoxycholic acid |
Ursodeoxycholic Acid 250mg Tablet- preferred option
Ursodeoxycholic Acid 250mg Capsule Ursodeoxycholic Acid 250mg/5ml Oral Suspension Ursodeoxycholic Acid 150mg Tablet Ursodeoxycholic Acid 300mg Tablet
500mg tablets are VERY EXPENSIVE - 250mg tablets are the preferred option as more cost effective( Applicable in Primary care only) |
01.05.03 |
Ustekinumab Stelara® |
Restriction: In line with NICE Guidance only |
13.05.03 |
Ustekinumab Stelara® |
Restriction: In line with NICE Guidance only
|
07.03.04 |
UT 380 Standard® |
Not banded (copper in stem only) coil.
For uterine length 6.5-9cm; replacement every 5 years. |
13.08.01 |
Uvistat ® UVB |
Prescriptions in primary care must be endorsed ‘ACBS’
Uvistat® suncream SPF 30 and 50 125ml Uvistat® lipscreen SPF 50
Self Care Medicine. Available OTC for self care
|
04.02.03 |
Valproic Acid Depakote® |
Valproic Acid Tablet EC 250mg (As Semisodium Valproate) Valproic Acid Tablet EC 500mg (As Semisodium Valproate)
Restriction: Initiation by psychiatrist
Contraindicated in women of childbearing potential unless part of the Pregnancy Prevention Programme (MHRA, March 2018).
Patient Card – to be given by pharmacists to all female patients who are dispensed valproate medicines to inform them of the risks |
04.10.02 |
Varenicline Champix® |
Varenicline Tartrate Tablet 0.5mg Varenicline Tartrate Tablet 1mg Varenicline Starter Pack (11 x 500mcg Tabs + 14 x 1mg Tabs)
2nd line for smoking cessation.
Restriction: As part of a smoking cessation programme only.
APC Advice: Varenicline (Champix®), revised May 2008.
- Nicotine Replacement Therapy remains the pharmacological agent of choice for smoking cessation.
- Consider varenicline or bupropion if NRT ineffective, not tolerated or inappropriate.
- Only use as a component of a smoking cessation programme.
- Current evidence is insufficient to recommend an additional treatment course in those who have stopped smoking after the initial 12 weeks of therapy
|
06.05.02 |
Vasopressin Pitressin® |
20units/ml Solution for Injection Amps |
01.05.03 |
Vedolizumab Entyvio® |
Restriction: In line with NICE Guidance only |
08.01.05 |
Vemurafenib Zelboraf® |
Restriction: In line with NICE Guidance only
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome)
MHRA/CHM advice (November 2015): Risk of potentiation of radiation toxicity |
08.01.05 |
Venetoclax Venclyxto® |
Restriction: In line with NICE Guidance only |
04.03.04 |
Venlafaxine |
Venlafaxine Capsules 75mg Venlafaxine Capsules 75mg M/R Venlafaxine Capsules 150mg M/R Venlafaxine Capsules 225mg M/R Venlafaxine tablets 75mg M/R Venlafaxine tablets 150mg M/R Venlafaxine tablets 225mg M/R
Restriction: 2nd line option after prior SSRI treatment
Vencarm XL is a cost-effective branded alternative to generic venlafaxine capsules. Venlalic XL is a cost-effective branded alternative to generic venlafaxine tablets (Applicable in primary care only).
|
02.03.02 |
Verapamil Hydrochloride |
Verapamil Hydrochloride 120mg M/R Capsule Verapamil Hydrochloride 180mg M/R Capsule Verapamil Hydrochloride 240mg M/R Capsule Verapamil Hydrochloride 40mg Tablet Verapamil Hydrochloride 80mg Tablet Verapamil Hydrochloride 120mg Tablet Verapamil Hydrochloride 120mg M/R Tablet - Prescribe brand Verapamil Hydrochloride 160mg Tablet Verapamil Hydrochloride 240mg M/R Tablet - Prescribe brand
Restriction: Initiation under direction of cardiologist |
02.06.02 |
Verapamil Hydrochloride |
Standard release tablets Modified release formulations.
Securon SR tablets are cost-effective brands. |
11.08.02 |
Verteporfin Visudyne® |
15mg powder for solution for infusion vials
Restriction: In line with NICE Guidance only
|
04.08.01 |
Vigabatrin Sabril® |
Vigabatrin Tablet 500mg Vigabatrin Powder Sachet 500mg S/F
Restriction: By specialist only Unnecessary to maintain patient on specific manufacturer's products. |
09.06.07 |
Vitamin |
Vitamin capsules BPC (or equivalent)
Multivitamins may be prescribed in the NHS to prevent or treat deficiency but not as dietary supplements. |
09.06.01 |
Vitamin A palmitate |
Retinol 50,000units/ml solution for injection vials (Unlicensed, Imported) |
09.06.02 |
Vitamin B and C Pabrinex® |
Pabrinex® Intramuscular High Potency solution for injection 5ml and 2ml ampoules Pabrinex® Intravenous High Potency solution for injection 5ml and 5ml ampoules
MHRA advice: Pabrinex- allergic reactions (Dec 2014) |
09.06.02 |
Vitamin B compound |
Vitamin B compound (nicotinamide 15mg/riboflavin 1mg/thiamine hydrochloride 1mg) tablets
- Designated less suitable for prescribing in BNF and high cost. If indicated, consider Vitamin B Compound Strong tablets instead.(Applicable in Primary care only)
|
09.06.02 |
Vitamin B compound strong |
Vitamin B compound strong (nicotinamide 20mg/pyridoxine hydrochloride 2mg/riboflavin 2mg/thiamine hydrochloride 5mg) tablets
NICE no longer recommends vitamin B Co (strong) for patients with alcohol use disorders (NICE CG100). Clinicians should review use accordingly. |
09.06.01 |
Vitamins A and D |
Vitamins A and D (vitamin A 4000unit/vitamin D 400unit) capsules BPC 1973 |
09.04 |
Vitasavoury® Soup |
Initiation by specialist dietician services prior to continuation within primary care. |
04.03.03 |
Vortioxetine |
Vortioxetine 5mg Tablets Vortioxetine 10mg Tablets Vortioxetine 20mg Tablets
Restriction: In line with NICE Guidance
Vortioxetine is recommended as an option for treating major depressive episodes in adults whose condition has responded inadequately to 2 antidepressants within the current episode. |
02.08.02 |
Warfarin Sodium |
Warfarin Sodium Tablet 1mg Warfarin Sodium Tablet 3mg Warfarin Sodium Tablet 5mg |
12.02.02 |
Xylometazoline hydrochloride |
Otrivine®- Xylometazoline hydrochloride 0.5% child nasal drops Otrivine®- Xylometazoline hydrochloride 1% adult nasal drops Xylometazoline hydrochloride 0.5% child nasal spray Xylometazoline hydrochloride 1% adult nasal spray
CHM/MHRA advice: With intranasal use in children
The CHM/MHRA has stated that non-prescription cough and cold medicines containing xylometazoline can be considered for up to 5 days’ treatment in children aged 6–12 years after basic principles of best care have been tried; these medicines should not be used in children under 6 years of age.
Maximum duration of 7 days to avoid rebound congestion.
Self Care Medicine- Available OTC for self-care as nasal spray 0.1%,nasal drops 0.05%(paediatric) and nasal drops 0.1%(adult).
|
01.07.02 |
Xyloproct ® |
Xyloproct Ointment |
05.03.04 |
Zanamivir inhalation Relenza® |
Zanamivir Powder For Inhalation 5mg blister + Diskhaler device
Only to be prescribed on the recommendation of Public Health England
Restriction: In line with NICE Guidance
Recommended to only prescribe when official notification that influenza is circulating in the Community: to patients in "At Risk" groups, if they present within 36 hours of first symptoms and who can start treatment within 48 hours of the onset of symptoms. |
13.02.01 |
ZeroAQS®cream |
Light (low paraffin)
Can also be used as a soap substitute
Pack size 500g |
09.05.04 |
Zinc sulfate Solvazinc® |
Solvazinc®Zinc sulfate monohydrate 125mg effervescent tablets (contains zinc sulfate monohydrate 125 mg (45 mg zinc))
Please note Valupak Zinc tablets 10mg are available as a food supplement and they are more cost effective but a much lower dose.
Self Care Medicine-Available OTC for self-care.
|
06.06.02 |
Zoledronic acid Aclasta® |
5mg/100ml solution for infusion
Restriction: In line with NICE Guidance only
- For Treatment of postmenopausal osteoporosis and osteoporosis in men (including corticosteroid-induced osteoporosis) in those for whom oral treatment options for osteoporosis are inappropriate and when initiated by a specialist. ONCE yearly administration. Before first infusion give 50 000–125 000 units of vitamin D.
- Also in treatment of Paget's disease of bone (at least 500 mg elemental calcium twice daily (with vitamin D) for at least 10 days is recommended following infusion).
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
06.06.02 |
Zoledronic acid Zometa® |
4mg/100ml Solution for infusion Vials
Restriction: For prevention of skeletal related events in adult patients with Myeloma
- Reduction of bone damage in advanced malignancies involving bone (calcium 500 mg daily and vitamin D 400 units daily should also be taken).
- Hypercalcaemia of malignancy
MHRA/CHM advice: Bisphosphonates: atypical femoral fractures (June 2011)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the jaw (November 2009) and Intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk (July 2015)
MHRA/CHM advice: Bisphosphonates: osteonecrosis of the external auditory canal (December 2015) |
04.07.04.01 |
Zolmitriptan |
Zolmitriptan Orodispersible Tablets 2.5mg Zolmitriptan Orodispersible Tablets 5mg Zolmitriptan Tablets 2.5mg Zolmitriptan Tablets 5mg
2nd line triptan. (As per Anti-Migraine Prescribing Guide)
NICE (CG150) recommends this for Menstrual-related Migraine. If this is not tolerated then consider Frovatriptan 2.5mg tablets instead (Unlicensed indication). |
04.07.04.01 |
Zolmitriptan nasal spray Zomig® |
Zolmitriptan 5mg/0.1ml Nasal Spray 0.1mg unit dose
Not for children under 18 years (As per Anti-Migraine Prescribing Guide)
1 spray of Zomig® nasal spray = 5 mg zolmitriptan. |
04.08.01 |
Zonisamide Zonegran® |
Zonisamide 25mg capsules Zonisamide 50mg capsules Zonisamide 100mg capsules
Restriction: Initiation and stabilisation by specialist Unnecessary to maintain patient on specific manufacturer's products. |
04.01.01 |
Zopiclone Zimovane® |
Zopiclone 3.75mg tablets Zopiclone 7.5mg tablets
CSM Advice: Hypnotics and Anxiolytics are indicated for the short-term relief of sleep disturbance and/or anxiety. (For continuous use up to a maximum of 14 days). |
04.02.01 |
Zuclopenthixol Clopixol® |
Zuclopentixol Tablets 2mg Zuclopentixol Tablets 10mg Zuclopentixol Tablets 25mg |
04.02.02 |
Zuclopenthixol acetate Clopixol-Acuphase® |
Zuclopentixol Acetate injection 50mg/ml 1ml Amp
Restriction: Initiation under direction of a psychiatrist
Used for an acute episode only. Not to be confused with decanoate depot preparation. |
04.02.02 |
Zuclopenthixol decanoate Clopixol® |
Zuclopenthixol Decanoate Injection 200mg/ml 1ml Amp Zuclopenthixol Decanoate Injection 500mg/ml 1ml Amp
Restriction: Initiation under direction of a psychiatrist
Used for maintenance treatments only. Not to be confused with acetate preparation used in the acute phase. |